β-d-2'-deoxy-2'-α-fluoro-2'-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment
Patent Information
- Application Number
- JP2024124117
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-01-08
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2036-03-07
AI Technical Summary
に対する本発明の化合物の薬物動態を管理するため、特定の化合物の投与経路及び投薬計画を修正することも、当業者の通常の作業に含まれる。
Smart Images

Figure 2024160265000001_ABST
Abstract
Description
[Technical field]
[0001] Priority This application claims priority to U.S. application Ser. No. 62 / 129,319, filed March 6, 2015, U.S. application Ser. No. 62 / 253,958, filed November 11, 2015, and U.S. application Ser. No. 62 / 276,597, filed January 8, 2016, each of which is incorporated herein by reference in its entirety.
[0002] The present invention relates to nucleotide compounds and compositions, and their uses for treating Hepatitis C Virus ("HCV"). [Background technology]
[0003] Hepatitis C virus (HCV) is a single-stranded RNA virus and a member of the Hepacivirus genus. It is estimated that 75% of all cases of liver disease are caused by HCV. HCV infection can lead to cirrhosis and liver cancer, and if untreated, can result in liver failure that may require a liver transplant. Approximately 170-200 million people are infected worldwide, with an estimated 3-4 million infected in the United States.
[0004] RNA polymerase is a key component in targeting RNA single-stranded viruses. The nonstructural protein NS5B RNA-dependent RNA polymerase of HCV is the main enzyme responsible for initiating and catalyzing viral RNA synthesis. As a result, HCV NS5B is currently an attractive target for anti-HCV drug discovery and development. There are two main subclasses of NS5B inhibitors: nucleoside analogs that are anabolized to the active triphosphate, which acts as an alternative substrate for the polymerase, and non-nucleoside inhibitors (NNIs) that bind to an allosteric region on the protein. Nucleoside or nucleotide inhibitors mimic the natural polymerase substrate and act as chain terminators. They inhibit the initiation of RNA transcription and the elongation of the nascent RNA strand.
[0005] In addition to targeting RNA polymerase, other RNA viral proteins may be targeted in combination therapies. For example, HCV proteins that are additional targets for therapeutic approaches are NS3 / 4A (a serine protease) and NS5A (a nonstructural protein that is an essential component of the HCV replicase and exerts a range of effects on cellular pathways).
[0006] The first nucleoside NS5B polymerase inhibitor, sovosbuvir (Sovaldi, Gilead Sciences), was approved in December 2013. Sovaldi is , a uridine phosphoramidate prodrug that is taken up by hepatocytes and undergoes intracellular activation to provide the active metabolite 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate, see structure below. [ka]
[0007] Sovaldi™ is the first drug with demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration with interferon. Sovaldi™ is the third drug to receive Breakthrough Therapy Designation from the FDA.
[0008] In 2014, the US FDA approved Harvoni™ (ledipasvir, an NS5A inhibitor, and sovosbuvir) for the treatment of chronic Hepatitis C virus genotype 1 infection. Harvoni™ is the first combination pill approved for the treatment of chronic HCV genotype 1 infection. It is also the first approved dosing regimen that does not require administration with interferon or ribavirin. Additionally, the FDA approved simeprevir (Olysio™) in combination with sovosbuvir (Sovaldi™) as an all-oral, once-daily, interferon- and ribavirin-free treatment for adults with genotype 1 HCV infection.
[0009] Also in 2014, the US FDA approved AbbVie's Vikira Pak™, a combination pack containing dasabuvir (a non-nucleoside NS5B polymerase inhibitor), ombitasvir (an NS5A inhibitor), paritaprevir (an NS3 / 4A inhibitor), and ritonavir. Vikira Pak™ can be used with or without ribavirin to treat patients with genotype 1 HCV infection, including those with compensated cirrhosis. Vikira Pak™ does not require co-therapy with interferon.
[0010] In July 2015, the US FDA approved Technivi™ and Daklinza™ for the treatment of HCV genotype 4 and HCV genotype 3, respectively. Technivi™ (ombitasvir / paritaprevir / ritonavir) is approved for use in combination with ribavirin for the treatment of HCV genotype 4 in patients without scarring or cirrhosis and is the first-line treatment for HCV-4 infected patients who do not require co-administration of interferon. Daklinza™ is approved for use with Sovaldi™ to treat HCV genotype 3 infection. Daklinza™ has demonstrated safety and efficacy in the treatment of HCV genotype 3 without the need for co-administration of interferon or ribavirin. It was the first drug to be developed.
[0011] In October 2015, the U.S. FDA warned that the HCV treatments Viikira Pak and Technivi can cause serious liver damage, primarily in patients with underlying advanced liver disease, and requested that additional safety information be added to the labels.
[0012] Other currently approved treatments for HCV include interferon alfa-2b or pegylated interferon alfa-2b (PegIntron™), which may be given with ribavirin (Rebetol™), NS3 / 4A telaprevir (Incivec™, Vertex and Johnson & Johnson), boceprevir (Victoris™), , Merck), simeprevir (Olysio™, Johnson & Johnson), paritaprevir (AbbVie), ombitasvir (AbbVie), (NNI) dasabuvir (ABT-333) and Merck's Zepatia™ (a single-tablet combination of two drugs, grazoprevir and elbasvir). Combination) can be mentioned.
[0013] Further NS5B polymerase inhibitors are currently in development. Merck is a uridine nucleoside analogue. Idenix is developing a tidoprodrug, MK-3682 (formerly IDX21437), which is currently in Phase II combination trials.
[0014] U.S. patents and WO applications describing nucleoside polymerase inhibitors for the treatment of Flaviviridae, including HCV, include those filed by Idenix Pharmaceuticals (U.S. Pat. Nos. 6,812,219, 6,914,054, 7,105,493, 7,138,376, 7,148,206, 7,157,441, 7,163,929, 7,169,766, 7,192,936, 7,365,057, 7,384,924, 7,456, ,155, No. 7,547,704, No. 7,582,618, No. 7,608,597, No. 7,608,600, No. 7,625,875, No. 7,635,689, No. 7, 662,798, 7,824,851, 7,902,202, 7,932,240, 7,951,789, 8,193,372, 8,299,038, Nos. 8,343,937, 8,362,068, 8,507,460, 8,637,475, 8,674,085, 8,680,071, 8,691,788, 8,742,101, 8,951,985, 9,109,001, 9,243,025, U.S. Patent Application Publication No. 2016 / 0002281, U.S. Patent Application Publication No. 201 Nos. WO 3 / 0064794, WO 2015 / 095305, WO 2015 / 081133, WO 2015 / 061683, WO 2013 / 177219, WO 2013 / 039920, WO 2014 / 137930, WO 2014 / 052638, WO 2012 / 154321; those filed by Merck (U.S. Patent Nos. 6,7 No. 77,395, No. 7,105,499, No. 7,125,855, No. 7,202,224, No. 7,323,449, No. 7 , 339,054, 7,534,767, 7,632,821, 7,879,815, 8,071,568, Nos. 8,148,349, 8,470,834, 8,481,712, 8,541,434, 8,697,694, 8,715,638, 9,061,041, 9,156,872, and International Publication No. WO 2013 / 009737); Emory and those filed by Gilead Sciences / Pharmasset Inc. (U.S. Patent Nos. 6,348,587, 6,911,424, 7,307,065, 7,495,006, 7,662,938, 7,772,208, 8,114,994, 8,168,583, 8,609,627, U.S. Patent Application Publication No. 2014 / 0212382, and WO 2014 / 1244430); No. 13, No. 8,008,264, No. 8,012,941, No. 8,012,942, No. 8,318,682, No. 8,324,179, No. 8,415,308, No. 8,45 No. 5,451, No. 8,563,530, No. 8,841,275, No. 8,853,171, No. 8,871,785, No. 8,877,733, No. 8,889,159, No. 8, Nos. 906,880, 8,912,321, 8,957,045, 8,957,046, 9,045,520, 9,085,573, 9,090,642 and 9,139,604) and (U.S. Pat. Nos. 6,908,924, 6,949,522, 7,094,770, 7,211,570, 7,429,572, 7, RE No. 601,820, RE No. 7,638,502, RE No. 7,718,790, RE No. 7,772,208, RE No. 42,015, RE No. 7,919,247, RE No. 7,964,580, RE No. No. 8,093,380, No. 8,114,997, No. 8,173,621, No. 8,334,270, No. 8,415,322, No. 8,481,713, No. 8,492,539, Nos. 8,551,973, 8,580,765, 8,618,076, 8,629,263, 8,633,309, 8,642,756, 8,716,262, 8,716,263, 8,735,345, 8,735,372, 8,735,569, 8,759,510 and 8,765,710; those filed by Hoffman La-Roche (U.S. Patent No. 6,660,721); those filed by Roche (U.S. Patent No. 6,784,166 Nos. 7,608,599, 7,608,601, and 8,071,567; those filed by Alios BioPharma Inc. (U.S. Patents Nos. 8,895,723, 8,877,731, 8,871,737, 8,846,896, 8,772,474, 8,980,865, 9,012,427, U.S. Patent Application Publication No. 2015 / 0105341, U.S. Patent Application Publication No. 2015 / 0011497, U.S. Patent Application Publication No. 2010 / 0249068 ... WO 2012 / 0070411, WO 2015 / 054465, WO 2014 / 209979, WO 2014 / 100505, WO 2014 / 100498, WO 2013 / 142159, WO 2013 / 142157, WO 2013 / 096680, WO 2013 / 088155, WO 2010 / 108135); Enanta those filed by Biopharmaceuticals (U.S. Patent Nos. 8,575,119, 8,846,638, 9,085,599, WO 2013 / 044030, WO 2012 / 125900); US Patent Nos. 7,268,119, 7,285,658, 7,713,941, 8,119,607, 8,415,309, 8,501,699 and 8,802,840; those filed by Biocryst Pharmaceuticals (U.S. Patent Nos. 7,388,002, 7,429,571, 7,514,410, 7,560,434, 7,994,139, 8,133,870, 8,163,703, 8,242,085 and 8,440,813); Alla Chem, Those filed by Inhibitex (U.S. Patent No. 8,759,318 and International Publication No. WO 2015 / 053662); Publication No. 2012 / 092484; those filed by Janssen Products (U.S. Patent Nos. 8,399,429, 8,431,588, 8,481,510, 8,552,021, 8,933,052, 9,006,29, and 9,012,428); those filed by the University of Georgia Foundation (U.S. Patent Nos. 6,348,587, 7,307,065, 7,662,938, 8,168,583, 8,673,926, 8,816,074, 8,921,384, and 8,946,244); those filed by RFS Pharma, LLC (U.S. Patent Nos. 6,348,587, 7,307,065, 7,662,938, 8,168,583, 8,673,926, 8,816,074, 8,921,384, and 8,946,244); US Patent Nos. 8,895,531, 8,859,595, 8,815,829, 8,609,627, 7,560,550, US Patent No. 2014 / 0066395, US Patent Application Publication No. 2014 / 0235566, US Patent Application Publication No. 20 Patent applications filed by University College Cardiff Consultants Limited (WO 2014 / 076490, WO 2010 / 081082, WO 2008 / 062206); applications filed by Achillion Pharmaceuticals, Inc. ( Nos. WO 2014 / 169278 and WO 2014 / 169280; Cocrystal Pharma, Inc. (U.S. Pat. No. 9,173,893); Katholieke Universiteit Leuven (WO 2015 / 158913); Catabasis (WO 2013 / 090420); and the Regents of the University of Minnesota (WO 2006 / 004637). can be done.
[0015] Nonetheless, there is a strong medical need for the development of safe, effective, and well-tolerated anti-HCV therapies, exacerbated by anticipated drug resistance. More potent direct-acting antiviral agents could significantly shorten treatment duration and improve compliance and SVR rates in patients infected with all HCV genotypes. Summary of the Invention [Problem to be solved by the invention]
[0016] It is therefore an object of the present invention to provide compounds, pharmaceutical compositions, and methods and uses for treating and / or preventing HCV infection. [Means for solving the problem]
[0017] Compounds of formula I, II, III, IV, V, VI, VII, and β-D-2'-deoxy-2'-α-fluoro-2'-β-C-substituted-N 6 It has been discovered that compounds containing -(mono- or di-methyl) purine nucleotides are highly active against the HCV virus when administered in effective amounts to a host in need thereof, which may be a human or any animal with a viral infection.
[0018] The disclosed nucleotides include those with nanomolar activity against HCV in vitro and therapeutic indices ranging from 25,000 or greater.
[0019] Surprisingly, the parent N 6 -(methyl)purine nucleosides had not been developed as drug candidates or specifically disclosed prior to the present invention. For example, in 2010, 3'-azido-N 6-Dimethyl-2,6-diaminopurine has been reported to be substantially undeaminated by adenosine deaminase over extended periods of time (120 minutes) and, for that reason, has been deemed an unsuitable compound for derivatization as a drug (see, e.g., WO 2010 / 091386, p. 86, and corresponding U.S. Pat. No. 8,609,627).
[0020] However, the compounds of the present invention are substantially N 6 N without deamination 6 It has now been discovered that 5-substituted-purine 5-monophosphates are synthesized at the 6-position to produce active guanine triphosphate compounds which then undergo synthesis at the 6-position resulting in superior activity and therapeutic indexes.
[0021] In particular, β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6 -Methyl-2,6-diaminopurine nucleotides, and β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6 -Dimethyl-2,6-diaminopurine nucleotides, and other β-D-2'-D-2'-α-fluoro-2'-β-C-substituted 2-modified-N 6 It has been discovered that 5' stabilized phosphate prodrugs or derivatives of -substituted purine nucleotides are highly active against HCV. 50 = 15.7 μmol) of the parent nucleoside β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6 The activity of 1,2-dimethyl-2,6-diaminopurine (NMDP) is insufficient to be suitable for use as a human drug. 6(combination of WO 2010 / 091386 p. 86 and corresponding U.S. Patent No. 8,609,627 references, suggesting that .alpha.-methyl-2,6-diaminopurine is not deaminated in vivo), which is surprising, as the stabilized racemic phosphate prodrug (phosphoramidate) exhibits an EC50 value, which is at least a 600-fold increase in activity in the replicon assay. 50 = 26 nanomolar (nM). The corresponding (S)-phosphoramidates showed an EC 50 = 4 nM (see the structure below and compound 5-2 in Table 7). Thus, a TC of over 100 micromolar 50 Therefore, the compound has a therapeutic index of over 25,000. For comparison, sofosbuvir has an EC 50 = 53 nM, TC > 100 micromolar 50 , and has a therapeutic index of greater than 1920. [ka]
[0022] Similarly, the replicon assay (EC 50 = 10.7 micromolar, "μM") 6 The activity of -dimethyl-2,6-diaminopurine also indicates insufficient activity to render it suitable for use as a human drug, but the stabilized racemic phosphate prodrug (phosphoramidate) shows an EC of >890-fold increase in activity in the replicon assay. 50 The corresponding (S)-phosphoramidate (compound 25, Table 7) also showed an EC 50 = 4nM (see structure below). Furthermore, compound 25 also has a therapeutic index of over 25,000. [ka]
[0023] In another example, the compound isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(N-methyl-N-cyclopropyl) -amino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate is EC 50 = 7 nM, and the corresponding (S)-phosphoramidate has an EC 50 = 5 nM (see compound 27 in Table 7 and structure below). [ka]
[0024] As mentioned above, β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6 The metabolism of β-D-methyl-2,6-diaminopurine nucleosides involves the production of the 5'-monophosphate and the deoxyribonuclease N to generate β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-guanine nucleosides as the 5'-monophosphate. 6 The monophosphate is then further metabolized to the active species, i.e., the 5'-triphosphate. β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-guanine triphosphate has IC 50 = 0.15 μM.
[0025] Thus, in one embodiment, the present invention provides a method for producing a cellular membrane comprising: [ka] (In the formula, Y is NR 1 R 2 and R 1is C1-C5 alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and pentyl), C1-C5 haloalkyl (including CH2F, CHF2, CF3, CH2CF3, CF2CH3 and CF2CF3), C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(heterocyclic), -(C0-C2 alkyl)(aryl), -(C0-C2 alkyl)(heteroaryl), -OR 25 , -C(O)R 3C (-C(O)CH3, -C(O)CH2CH3, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)OC2H5, -C(O)OC3 H7, -C(O)OC4H9, and -C(O)OC5H 11 ), -C(S)R 3D , or -SO2R 28 each of which may be substituted; R 2 is hydrogen, C1-C5 alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, and pentyl), C1-C5 haloalkyl (including CHF2, CHF2, CF3, CH2CF3, and CF2CF3), -(C0-C2 alkyl)(C3-C6 cycloalkyl), -C(O)R 3C (-C(O)CH3, -C(O)CH2CH3, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)OC2H5, -C(O)OC3H7, -C(O)OC4H9, and -C(O)OC5H 11 -(C0-C2 alkyl)(aryl), -(C0-C2 alkyl)(heterocycle), -(C0-C2 alkyl)(heteroaryl), where R 1 and R 2 at least one of is methyl, CH2F, CHF2, or CF3; R 3 is hydrogen, [ka] , diphosphate, triphosphate, optionally substituted carbonyl-linked amino acid or -C(O)R 3C and R 3A O - , OH, -O-optionally substituted aryl, -O-optionally substituted heteroaryl, or optionally substituted heterocyclyl; R 3B O - , OH, an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester; R 3C is alkyl, alkenyl, alkynyl, -(C0-C2)(cycloalkyl), -(C0-C2)(heterocyclo), -(C0-C2)(aryl), -(C0-C2)(heteroaryl), -O-alkyl, -O-alkenyl, -O-alkynyl, -O-(C0-C2)(cycloalkyl), -O-(C0-C2)(heterocyclo), -O-(C0-C2)(aryl), or -O-(C0-C2)(heteroaryl), each of which may be substituted; R 4 is a stabilized phosphate prodrug, including but not limited to a monophosphate, diphosphate, triphosphate, or a phosphoramidate, thiophosphoramidate, or any other moiety that is metabolized in vivo in a human or animal host to a monophosphate, diphosphate, or triphosphate; Or R 3 and R 4 can form 3',5'-cyclic prodrugs, including but not limited to 3',5'-cyclic phosphate prodrugs, with the oxygen to which they are attached; R 12 is CH3, CH2F, CHF2, CF3 or ethynyl).
[0026] In one embodiment, the present invention provides a method for producing a method for treating a cancer cell comprising: [ka] (In the formula, Y is NR 1 R 2 and R 1 is C1-C5 alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, and pentyl), C1-C5 haloalkyl (including CH2F, CHF2, CF3, CH2CF3, CF2CH3, and CF2CF3), C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(heterocyclic), -(C0-C2 alkyl)(aryl), -(C0-C2 alkyl)(heteroaryl), -OR 25 , -C(O)R 3C (-C(O)CH3, -C(O)CH2CH3, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)OC2H5, -C(O)OC3H7, -C(O)OC4H9 and -C(O)OC5H 11 ), -C(S)R 3D , or -SO2R 28 each of which may be substituted; R 2 is hydrogen, optionally substituted C1-C5 alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and pentyl), C1-C5 haloalkyl (including CHF2, CHF2, CF3, CH2CF3 and CF2CF3), optionally substituted -(C0-C2 alkyl)(C3-C6 cycloalkyl), optionally substituted -(C0-C2 alkyl)(heterocycle), optionally substituted -(C0-C2 alkyl)(aryl), optionally substituted -(C0-C2 alkyl)(heteroaryl), -C(O)R 3C (-C(O)CH3, -C(O)CH2CH3, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)OC2H5, -C(O)OC3H7, -C(O)OC4H9 and -C(O)OC5H 11 ), -C(S)R 3D , or -SO2R 28 where R 1 and R 2at least one of is methyl, CH2F, CHF2 or CF3; R 3 is hydrogen, [ka] , diphosphate, triphosphate, an optionally substituted carbonyl-linked amino acid, or -C(O)R 3C and R 3A O - , OH, -O-optionally substituted aryl, -O-optionally substituted heteroaryl, or optionally substituted heterocyclyl; R 3B O - , OH, an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester; R 3C is an alkyl, alkenyl, alkynyl, -(C0-C2)(cycloalkyl), -(C0-C2)(heterocyclo), -(C0-C2)(aryl), -(C0-C2)(heteroaryl), -O-alkyl, -O-alkenyl, -O-alkynyl, -O- -(C0-C2)(cycloalkyl), -O-(C0-C2)(heterocyclo), -O-(C0-C2)(aryl), -O-(C0-C2)(heteroaryl), -S-alkyl, -S-alkenyl, -S-alkynyl, -S-(C0-C2)(cycloalkyl), -S-(C0-C2)(heterocyclo), -S-(C0-C2)(aryl) or -S-(C0-C2)(heteroaryl), each of which may be substituted; R 3D is alkyl, alkenyl, alkynyl, -(C0-C2)(cycloalkyl), -(C0-C2)(heterocyclo), -(C0-C2)(aryl), -(C0-C2)(heteroaryl), -O-alkyl, -O-alkenyl, -O-alkynyl, -O-(C0-C2)(cycloalkyl), -O-(C0-C2)(heterocyclo), -O-(C0-C2)(aryl), or -O-(C0-C2)(heteroaryl), each of which may be substituted; R4 is a stabilized phosphate prodrug, including but not limited to a monophosphate, diphosphate, triphosphate, or a phosphoramidate, thiophosphoramidate, or any other moiety that is metabolized in vivo in a human or animal host to a monophosphate, diphosphate, or triphosphate; Or R 3 and R 4 may, together with the oxygen to which they are attached, form a 3',5'-cyclic prodrug, including but not limited to a 3',5'-cyclic phosphate prodrug; R 5 is C1-C5 alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and pentyl), C1-C5 haloalkyl (including CHF2, CHF2, CF3, CH2CF3 and CF2CF3), C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(heterocyclic), -(C0-C2 alkyl)(aryl), -(C0-C2 alkyl)(heteroaryl), -OR 25 , -C(O)R 3C (-C(O)CH3, -C(O)CH2CH3, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)OC2H5, -C(O)OC3H7, -C(O)OC4H9 and -C(O)OC5H 11 ), -C(S)R 3D , or -SO2R 28 each of which may be substituted; R 6is hydrogen, optionally substituted C1-C5 alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and pentyl), C1-C5 haloalkyl (including CHF2, CHF2, CF3, CH2CF3 and CF2CF3), optionally substituted -(C0-C2 alkyl)(C3-C6 cycloalkyl), optionally substituted -(C0-C2 alkyl)(heterocycle), optionally substituted -(C0-C2 alkyl)(aryl), optionally substituted -(C0-C2 alkyl)(heteroaryl), -C(O)R 3C (-C(O)CH3, -C(O)CH2CH3, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)OC2H5, -C(O)OC3H7, -C(O)OC4H9 and -C(O)OC5H 11 ), -C(S)R 3D , or -SO2R 28 and Or R 5 and R 6 may form a heterocycle together with the nitrogen to which they are attached; R 12 is CH3, CH2F, CHF2, CF3, or ethynyl; R 22 is Cl, Br, F, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -(C1-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(C3-C6 heterocycle), -(C0-C2 alkyl)(aryl), -(C0-C2 alkyl)(heteroaryl), -ONHC(=O)OR 23 , -NHOR 24 , -OR 25 , -SR 25 , -NH(CH2) 1~4 N(R 26 )2, -NHNHR 26 , -N=NR 27 , -NHC(O)NHNHR 27 , -NHC(S)NHNHR 27 , -C(O)NHNHR 27 , -NR 27 SO2R 28 , -SO2NR27 R 29 , -C(O)NR 27 R 29 , -CO2R 29 , -SO2R 29 , [ka] , -P(O)H(OR 29 ), -P(O)(OR 29 )(OR 30 ), -P(O)(OR 29 )(NR 29 R 30 ), or -NR 5 R 6 and For example, but not limited to, the following embodiments: chloro, bromo, fluoro, cyano, azido, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, and n-pentyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, 1-methylbutyl, 1-ethylpropyl, vinyl, allyl, 1-butynyl, 2-butynyl, acetylenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(CH 2)-Cyclopropyl, -(CH2)-cyclobutyl, -(CH2)-cyclopentyl, -(CH2)-cyclohexyl, aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, tetrahydrofuran, thiolane, pyrazolidine, piperidine, oxane, thiane, -(CH2)-aziridine, -(CH2)-oxirane, -(CH2)-thiirane, -(CH2)-azetidine, -(CH2)-oxetane, -(CH2)-thietane, -(CH2)-pyrrolidine , -(CH2)-tetrahydrofuran, -(CH2)-thiolane, -(CH2)-pyrazolidine, -(CH2)-piperidine, -(CH2)-oxane, -(CH2)-thiane, phenyl, pyridyl, -ONHC(=O)OCH3, -ONHC(=O)OCH2CH3, -NHOH, NHOCH3, -OCH3, OC2H5, -OPh, OCH2Ph, -SCH3, -SC2H5, -SPh, SCH2Ph, -NH(CH2)2NH2, -NH(CH2)2N(CH3)2, -NHNH2, -NHNHCH3, -N=NH, -N=NCH3, -N=NCH2CH3, -NHC(O)NHNH2, -NHC(S)NHNH2, -C(O)NHNH2, -NHSO2CH3, -NHSO2CH2CH3, -SO2NHCH3, -SO2N( CH3)2, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2, -CO2CH3, -CO2CH2CH3, -CO2Ph, -CO2CH2Ph, -SO2CH3, -SO2CH2CH3, -SO2Ph, -SO2CH2Ph, [ka] , -P(O)H(OH), -P(O)H(OCH3), -P(O)(OH)(OH), -P(O)(OH)(OCH3), -P(O)(OCH3)(O CH3), -P(O)(OH)(NH2), -P(O)(OH)(NHCH3), -P(O)(OH)N(CH3)2, -NHC(O)CH3, -NHC (O)CH2CH3, -NHC(O)CH(CH3)2, -NHC(O)OCH3, -NHC(O)OCH2CH3, -NHC(O)OCH(CH3)2, -NHC(O)OCH2CH2CH3, -NHC(O)OCH2CH2CH2CH3, and -NHC(O)OCH2CH2CH2CH2CH3, R 23 is C1-C5 alkyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(heterocycle)-(C0-2 alkyl)(aryl), or -(C0-C2 alkyl)(heteroaryl), each of which may be substituted; R 24 is hydrogen, C1-C6 alkyl, -(C1-C2 alkyl)(C3-C6 cycloalkyl), -(C1-C2 alkyl)(C3-C6 heterocycle), -(C0-C2 alkyl)(aryl), or -(C0-C2 alkyl)(heteroaryl), each of which, except for hydrogen, may be substituted; R 25 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(C3-C6 heterocycle), -(C0-C2 alkyl)(aryl), or -(C0-C2 alkyl)(heteroaryl), each of which, except for hydrogen, may be substituted; R 26 are independently selected from hydrogen, C1-C6 alkyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(heterocycle), -(C0-C2 alkyl)(aryl), or -(C0-C2 alkyl)(heteroaryl), each of which, except for hydrogen, is optionally substituted; R 27 is hydrogen or optionally substituted C1-C6 alkyl, R28 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(C3-C6 heterocycle), (C0-C2 alkyl)(aryl), or (C0-C2 alkyl)(heteroaryl), each of which may be substituted; R 29 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(C3-C6 heterocycle), -(C0-C2 alkyl)(aryl), or -(C0-C2 alkyl)(heteroaryl), each of which, except for hydrogen, may be substituted; Or R 27 and R 29 may form a heterocycle together with the nitrogen to which they are attached; R 30 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(C3-C6 heterocycle), -(C0-C2 alkyl)(aryl), or -(C0-C2 alkyl)(heteroaryl), each of which, except for hydrogen, may be substituted; Or R 29 and R 30 may be bonded together to form a heterocycle; and x is 1, 2 or 3.
[0027] β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6 The metabolism of β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6 -dimethyl-2,6-diaminopurine nucleoside triphosphate as well as the production of the corresponding guanine nucleoside triphosphate. See Schemes 2 and 3.
[0028] 2'-Deoxy-2'-α-fluoro-2'-β-C-substituted-N6 N-substituted 2,6-diaminopurine nucleotides can be modified by alkylation or acylation, which can modify the lipophilicity, pharmacokinetics and / or targeting of the nucleotide to the liver. 2 Further substitutions can be made at the N position as described herein. 2 -2'-deoxy-2'-α-fluoro-2'-β-C-substituted-N modified at the 2-position of diaminopurine, unless the amino group is completely replaced by a different moiety such as fluoro 6 It has been discovered that 2'-substituted-2,6-diaminopurine nucleotides can be dealkylated or deacylated by hepatic enzymes to further increase the specificity of the nucleotide derivatives both in vitro and in vivo. For example, the nucleoside phosphoramidate 2'-deoxy-2'-α-fluoro-2'-β-methyl-N 2 -Methyl-N 6 2'-Deoxy-2'-α-fluoro-2'-β-methyl-N-methyl-2,6-diaminopurine nucleoside phosphoramidate was synthesized by incubating with human liver S9 fraction for up to 60 min in vitro. 6 3,4-diaminopurine nucleoside phosphoramidate, and these conditions mimic in vivo conditions. 2 The modifications increase cell permeability and hepatitis targeting.
[0029] Despite the many publications and patent applications for antiviral nucleosides, the 2'-deoxy-2'-α-fluoro-2'-β-methyl-N- 6 -Methyl-2,6-diaminopurine nucleoside, 2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6 5'-stabilized phosphate derivatives of 2'-dimethyl-2,6-diaminopurine nucleosides and other β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N 6 -substituted purine nucleoside derivatives are not specifically disclosed, nor are their beneficial activities described.
[0030] Unless otherwise specified, the compounds described herein are provided in the β-D configuration. Similarly, when in the form of phosphoramide or thiophosphoramidate, the amino acid moiety may be in the L or D configuration. In alternative embodiments, the compounds may be provided in the β-L configuration. Similarly, any substituent that exhibits chirality may be provided in racemic, enantiomeric, diastereomeric form or any mixture thereof. Phosphoramidates, thiophosphoramidates or other stabilized phosphorus prodrugs that exhibit chirality at phosphorus may be provided as R 4 When used as stabilized phosphate prodrugs, the phosphorus prodrugs can be provided as chiral phosphorus derivatives, R or S, including racemic mixtures, or mixtures thereof. All of these combinations of configurations are encompassed by the invention described herein.
[0031] Thus, the present invention includes compounds of Formula I-VII, or pharma- ceutically acceptable compositions, salts, or prodrugs thereof, as described herein. [ka]
[0032] In one particular embodiment, the parent nucleoside, i.e., R 4 is hydrogen, and thus a nucleoside having a hydroxyl group at the 5' position, is not deaminated by adenosine deaminase for 7 minutes, 10 minutes, 30 minutes, 60 minutes, or 120 minutes under conditions that substantially mimic the in vivo environment (e.g., ambient temperature and aqueous physiological pH). Unless otherwise stated, the time period is 30 minutes. In this embodiment, the term "not substantially deaminated" means that the parent compound is not converted to the corresponding guanine derivative, i.e., the 6-oxo derivative, in an amount sufficient to provide a therapeutic effect in vivo.
[0033] Compounds, methods and compositions are provided for the treatment of a host infected with the HCV virus by administration of an effective amount of the compound or a pharma- ceutically acceptable salt thereof.
[0034] The compounds and compositions can also be used to treat anti-HCV antibody-positive and antigen-positive states, chronic liver inflammation caused by the virus, liver cancer resulting from advanced hepatitis C, liver cirrhosis, chronic or acute hepatitis C, fulminant hepatitis C, chronic persistent hepatitis C, and associated conditions such as fatigue caused by anti-HCV, and to prevent or slow the progression of clinical disease in individuals who are anti-HCV antibody or antigen-positive or who have been exposed to hepatitis C. The compounds or formulations containing the compounds can be used prophylactically.
[0035] In another embodiment, the compound of formula Ia: [ka] (In the formula, Y, R 3 and R 4 is as defined above.
[0036] In one embodiment of Formula Ia, R 3 is hydrogen.
[0037] In one embodiment of Formula Ia, Y is NR 1 R 2 If R 1 is methyl, R 2 is hydrogen.
[0038] In one embodiment of Formula Ia, Y is NR 1 R 2 If R 1 and R 2 are all methyl.
[0039] In one embodiment of Formula Ia, Y is NR 1 R 2 If R 1 is methyl, R 2 is cyclopropyl.
[0040] In another embodiment, the compound of formula Ib: [ka] (In the formula, Y, R 3 and R 4 is as defined above.
[0041] In one embodiment of Formula Ib, R 3 is hydrogen.
[0042] In one embodiment of Formula Ib, Y is NR 1 R 2 If R 1 is methyl, R 2 is hydrogen.
[0043] In one embodiment of Formula Ib, Y is NR 1 R 2 If R 1 and R 2 are all methyl.
[0044] In one embodiment, the compound of formula II: [ka] (In the formula, Y, R 3 , R 4 , R 12 and R 22 is as defined above.
[0045] In another embodiment, the compound of formula IIa: [ka] (In the formula, Y, R 3 , R 4 and R 22 is as defined above.
[0046] In another embodiment, the compound of formula IIb: [ka] (In the formula, Y, R 3 , R 4 and R 22 is as defined above.
[0047] In one embodiment, the compound of formula III: [ka] (Wherein, the variables Y, R 3 , R 7 , R 8 , R 9a , R 9b , R 10 , R 12 and R 22 discloses compounds of the formula (described herein).
[0048] In one embodiment, the compound of formula IV: [ka] (Wherein, the variables Y, R 3 , R 7 , R 8 , R 9a , R 9b , R 10 and R 22 discloses compounds of the formula (described herein).
[0049] In one embodiment, the compound of formula V: [ka] (Wherein, the variables Y, R 3 , R 7 , R 8 , R 9a , R 9b , R 10 and R 22 is herein The present invention discloses a compound of formula (I) as described above.
[0050] In one embodiment, the compound of formula VI: [ka] (In the formula, R 41 is halogen (especially F or Cl), OR 3 , N3, NH2 or CN, and the variables Y, R 3 , R 4 and R 12 Disclosed is a compound of formula (described herein).
[0051] In one embodiment, the compound of formula VII: [ka] (Wherein, the variables Y, R 3 , R 4 , R 12 and R 41 discloses compounds of the formula (described herein).
[0052] Phosphorus in any of the above formulas may be chiral and therefore may be provided as either the R or S enantiomer, or mixtures thereof, including racemic mixtures.
[0053] Compound 5 was separated into enantiomers 5-1 and 5-2, which were also prepared by chiral synthesis and designated compound 24.
[0054] In one embodiment, compounds, methods and compositions are provided for the treatment of a host infected or exposed to Hepatitis C as described herein. The compounds of the present invention can be administered alone or in combination with another anti-HCV drug in an amount effective to treat the infected host. In certain embodiments, it is useful to administer a combination of drugs that modulate the same or different pathways or inhibit different targets in the virus. The disclosed β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N 6 -Substituted purine nucleotides are NS5B polymerase inhibitors, and therefore NS3 / 4A protease inhibitors. It may be useful to administer the compound to the host in combination with a protease inhibitor, such as an NS5B polymerase inhibitor (e.g., telaprevir (Incivec™), boceprevir (Victoris™), simeprevir (Olicio™) or paritaprevir), or an NS5A inhibitor (e.g., ombitasvir). The compounds of the invention may also be administered in combination with a structurally different NS5B polymerase inhibitor, such as another compound described herein or below, including Gilead's Sovaldi™. The compounds of the invention may also be administered in combination with interferon alpha-2a, which may be pegylated or otherwise modified, and / or ribavirin.
[0055] The present invention relates to β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified 6 -substituted purine nucleotides are typically administered orally, for example in pill or tablet form, but may also be administered by other routes as deemed appropriate by the attending physician, including intravenously, transdermally, subcutaneously, topically, parenterally, or other suitable routes. [Brief description of the drawings]
[0056] [Figure 1] 1 is a chromatogram of a sample semi-prep run illustrating the separation of stereoisomers of compound 5 using a Phenominex Luna column as disclosed in Example 9. The y-axis is shown in units of mAU and the x-axis is measured in minutes. [Diagram 2] Graph of HCV replication inhibition curve for compound 5-2 (Table 7) and sovosbuvir. Compound 5-2 has EC50=4nM, TC50>100 micromolar and therapeutic index>25000. Sovosbuvir has EC50=53nM, TC50>100 micromolar and therapeutic index>1920. The y-axis is percent of virus control and the x-axis is drug concentration in μM. [Diagram 3]Graph of HCV replication inhibition curve for compound 25 (Table 7) and sovosbuvir. As described in Example 27, compound 25 has EC50=4nM, TC50>100μM and therapeutic index>25000. Sovosbuvir has EC50=53nM, TC50>100μM and therapeutic index>1920. The y-axis is percent of virus control and the x-axis is drug concentration in μM. [Figure 4] Figure 13 shows an intra-assay comparison of anti-HCV activity for Compound 5-2, Compound 25, Compound 27 (Table 7) and Sofosbuvir. The y-axis is percent of virus control and the x-axis is drug concentration in μM. See Example 27. [Diagram 5] 1 is a graph showing the stability of compound 5-2, the N2-acetate salt of compound 5-2, the N2-butyrate salt of compound 5-2, the N2-methyl derivative of compound 5-2, and the N2-n-pentylcarbamate salt of compound 5-2 in human blood, where the x-axis is incubation time measured in minutes and the y-axis is a measurement of the percent of parent compound remaining. [Figure 6] 1 is a graph showing the in vitro time course dealkylation of 2'-deoxy-2'-α-fluoro-2'-β-methyl-N2-methyl-N6-methyl-2,6-diaminopurine nucleoside phosphoramidate to 2'-deoxy-2'-α-fluoro-2'-β-methyl-N6-methyl-2,6-diaminopurine nucleoside phosphoramidate in the presence of human liver S9 fraction, where the x-axis is measured in minutes and the y-axis is a measurement of the concentration of remaining compound in nM. [Figure 7] 1 is a graph showing the stability of compound 5-2, the N2-acetate salt of compound 5-2, the N2-butyrate salt of compound 5-2, the N2-methyl derivative of compound 5-2, and the N2-n-pentylcarbamate salt of compound 5-2 in the presence of human liver S9 fraction. The x-axis is measured in minutes and the y-axis is a measurement of the percent compound remaining. [Figure 8]Figure 1 shows the main metabolites of compound 25 produced in human hepatocytes. The x-axis is incubation time in hours. The y-axis is intracellular concentration in pmol / 106 cells. See Example 33. [Figure 9] Figure 1 shows the main metabolites of compound 27 produced in human hepatocytes. The x-axis is incubation time in hours. The y-axis is intracellular concentration in pmol / 106 cells. See Example 33. [Figure 10] Figure 1 shows the main metabolites of compound 5-2 produced in human hepatocytes. The x-axis is incubation time in hours. The y-axis is intracellular concentration in pmol / 106 cells. See Example 33. [Figure 11] 1 is a graph showing the activation pathway for compound 25, compound 27, and compound 5-2. As can be seen, compound 25, compound 27, and compound 5-2 are converted to their corresponding monophosphate analogs and then metabolized to the common MP analog, β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-guanine-monophosphate. The monophosphate is then phosphorylated stepwise to the active triphosphate, β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-guanine triphosphate. See Example 33. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0057] The invention disclosed herein are compounds, methods, and compositions for the treatment of HCV viral infection in or exposure to humans and other host animals, comprising the administration of an effective amount of a compound of Formula I-VII described herein, or a pharma- ceutically acceptable salt or prodrug thereof, optionally in a pharma- ceutically acceptable carrier. The compounds of the invention either possess antiviral activity or are metabolized to compounds that exhibit such activity.
[0058] The compounds and compositions can also be used to treat conditions associated with or resulting from exposure to HCV virus.For example, the active compounds can be used to treat HCV antibody positive and HCV antigen positive conditions, chronic liver inflammation caused by viruses, liver cancer resulting from severe hepatitis C, liver cirrhosis, acute hepatitis C, fulminant hepatitis C, chronic persistent hepatitis C, and fatigue caused by anti-HCV.In one embodiment, the compounds or formulations containing the compounds can also be used prophylactically to prevent or delay clinical disease in individuals who are HCV antibody or HCV antigen positive or who have been exposed to hepatitis C.
[0059] In particular, β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6 -Methyl-2,6-diaminopurine nucleotides, and β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6 -Dimethyl-2,6-diaminopurine nucleotides, and other β-D-2'-D-2'-α-fluoro-2'-β-C-substituted 2-modified-N 6 It has been discovered that 5'-stabilized phosphate prodrugs or derivatives of β-substituted purine nucleotides are highly active against HCV. 6 -Methyl-2,6-diaminopurine activity (EC 50 = 15.7 micromolar), indicating insufficient activity making it unsuitable for use as a human drug, whereas the stabilized phosphate prodrug (phosphoramidate) showed an EC 50 = 26 nmol. Similarly, the parent nucleoside in the replicon assay, β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6 -Dimethyl-2,6-diaminopurine activity (EC 50= 10.7 micromolar, "μM"), indicating that it too is unsuitable for use as a human drug due to insufficient activity, whereas the stabilized phosphate prodrug (phosphoramidate) showed an EC 50 = 12 nanomolar ("nM").
[0060] Despite the large number of publications and patent applications for antiviral nucleosides, 2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6 -Methyl-2,6-diaminopurine Reotide, 2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6 -Dimethyl-2,6-diaminopurine nucleotides and other β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N 6 5'-stabilized phosphate derivatives of -substituted purine nucleotides are not specifically disclosed.
[0061] Unless otherwise specified, the compounds described herein are provided in the β-D configuration. In alternative embodiments, the compounds may be provided in the β-L configuration. Similarly, any substituent that exhibits chirality may be provided in racemic, enantiomeric, diastereomeric form or any mixture thereof. Phosphoramidates, thiophosphoramidates or other stabilized phosphorus prodrugs that exhibit phosphorus chirality are R 4 When used as a stabilized phosphate prodrug, it can be provided as an R or S chiral phosphorus derivative, or mixtures thereof, including racemic mixtures. The amino acids of the phosphoramidate or thiophosphoramidate can be in the D or L configuration, or mixtures thereof, including racemic mixtures. Any combination of these stereo configurations is encompassed by the invention described herein.
[0062] The present invention includes the following features. (a) Compounds of Formula I-VII as described herein, and pharma- ceutically acceptable salts and prodrugs thereof; (b) Formulas I to VII as described herein, and pharma- ceutically acceptable salts and prodrugs thereof, for use in the treatment or prevention of Hepatitis C viral infection; (c) the use of Formula I to Formula VII, and pharma- ceutically acceptable salts and prodrugs thereof, in the manufacture of a medicament for the treatment of Hepatitis C virus infection; (d) a method for the manufacture of a medicament intended for therapeutic use for treating Hepatitis C viral infection, characterized in that a compound of formula I to formula VII as described herein is used in said manufacture; (e) a pharmaceutical formulation comprising a compound of Formula I-VII, or a pharma- ceutically acceptable salt or prodrug thereof, in an amount effective to treat a host, together with a pharma- ceutically acceptable carrier or diluent; (f) Formulas I-VII as described herein, substantially free of stereoisomers of the described compounds or substantially separated from other chemical components; (g) A method of making a therapeutic product comprising an effective amount of Formulas I-VII described herein.
[0063] I. 2'-Deoxy-2'-α-fluoro-2'-β-C-substituted-2-modified-N of the present invention 6 -Substituted purine nucleotides The active compounds of the present invention may be provided in the form of pharma- ceutically acceptable compositions, salts or prodrugs thereof, for example those represented by formula I: [ka] (In the formula, Y is NR 1 R 2 and R 1 is C1-C5 alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, and pentyl); C1-C5 haloalkyl (including CH2F, CH2F, CF3, CH2CF3, CF2CH3, and CF2CF3), C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(heterocycle), -(C0-C2 alkyl)(aryl), -(C0-C2 alkyl)(heteroaryl), -OR 25 , -C(O)R 3C (-C(O)CH3, -C(O)CH2CH3, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)OC2H5, -C(O)OC3H7, -C(O)OC4H9 and -C(O)OC5H 11 ), -C(S)R 3D , or -SO2R 28 each of which may be substituted; R 2 is hydrogen, optionally substituted C1-C5 alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, and pentyl), C1-C5 haloalkyl (including CHF2, CH2F, CF3, CH2CF3, and CF2CF3), optionally substituted -(C0-C2 alkyl)(C3-C6 cycloalkyl), optionally substituted -(C0-C2 alkyl)(heterocycle), optionally substituted -(C0-C2 alkyl)(aryl), optionally substituted -(C0-C2 alkyl)(heteroaryl), -C(O)R 3C (-C(O)CH3, -C(O)CH2CH3, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)OC2H5, -C(O)OC3H7, -C(O)OC4H9 and -C(O)OC5H 11 ), -C(S)R 3D or -SO2R 28 where R 1 and R 2 at least one of is methyl, CH2F, CHF2 or CF3; R 3 is hydrogen, [ka] , diphosphate, triphosphate, an optionally substituted carbonyl-linked amino acid, or -C(O)R 3C and R 3A O - , OH, -O-optionally substituted aryl, -O-optionally substituted heteroaryl, or optionally substituted heterocyclyl; R 3B O - , OH, an optionally substituted N-linked amino acid, or an optionally substituted N-linked amino acid ester; R 3C is alkyl, alkenyl, alkynyl, -(C0-C2)(cycloalkyl), -(C0-C2)(heterocyclo), -(C0-C2)(aryl), -(C0-C2)(heteroaryl), -O-alkyl, -O-alkenyl, -O-alkynyl, -O-(C0-C2)(cycloalkyl), -O-(C0-C2)(heterocyclo), -O-(C0-C2)(aryl), or -O-(C0-C2)(heteroaryl), each of which may be substituted; R 4 is a stabilized phosphate prodrug, including but not limited to a monophosphate, diphosphate, triphosphate, or a phosphoramidate, thiophosphoramidate, or any other moiety that is metabolized in vivo in a human or animal host to a monophosphate, diphosphate, or triphosphate; Or R 3 and R 4 may, together with the oxygen to which they are attached, form a 3',5'-cyclic prodrug, including but not limited to a 3',5'-cyclic phosphate prodrug; R 12 is CH3, CH2F, CHF2, CF3 or ethynyl).
[0064] A stabilized phosphate prodrug is any moiety capable of delivering a monophosphate, diphosphate, or triphosphate.
[0065] In another embodiment, the compound of formula Ia: [ka] (In the formula, Y, R 3 and R 4 is as defined above.
[0066] In another embodiment, the compound of formula Ib: [ka] (In the formula, Y, R 3 and R 4 is as defined above.
[0067] In another embodiment, the compound has formula Ic: [ka] (In the formula, R 7 is hydrogen, C 1~6 Alkyl, C 3~7 cycloalkyl, heteroaryl, heterocyclic, or aryl, including but not limited to, phenyl, or naphthyl, where phenyl or naphthyl is C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, F, Cl, Br, I, Nitro, Cyano, C 1~6 Haloalkyl, -N(R 7’ )2, C 1~6 Acylamino, NHSO2C 1~6 Alkyl, -SO2N(R 7’ ) 2, COR 7’’ , and -SO2C 1~6 may be substituted with alkyl (R 7’ are independently hydrogen or C 1~6 is alkyl, R 7’’ -OR 11 or N(R 7 )2), R 8is hydrogen, C 1~6 alkyl, or R 9a Or R 9b and R 8 are joined together to form a cyclic ring containing the adjacent N and C atoms (CH2) n where n is 2 to 4; R 9a and R 9b teeth, (i) Hydrogen, C 1~6 Alkyl, cycloalkyl, -(CH2) c (NR 9’ )2, C 1~6 Hydroxyalkyl, --CH2SH, --(CH2)2S(O)(Me, --(CH2)3NHC(=NH)NH2, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, --(CH2) c COR 9’’ , aryl and aryl(C 1~3 alkyl)-, and the aryl group is independently selected from hydroxyl, C 1~6 Alkyl, C 1~6 optionally substituted with a group selected from alkoxy, halogen, nitro and cyano; (ii)R 9a and R 9b are all C 1~6 is alkyl, (iii)R 9a and R 9b together form a spiro ring (CH2) r and (iv) R 9a is hydrogen, and R 9b and R 8 are joined together to form a cyclic ring containing the adjacent N and C atoms (CH2) n and (v)R 9b is hydrogen, and R 9a and R 8 are joined together to form a cyclic ring containing the adjacent N and C atoms (CH2) n where c is 1 to 6, n is 2 to 4, r is 2 to 5, and R 9’ are independently hydrogen or C 1~6is alkyl, R 9’’ -OR 11 Or -N(R 11’ )2) and (vi)R 9a is hydrogen, and R 9b is hydrogen, CH3, CH2CH3, CH(CH3)2, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2Ph, CH2-indol-3-yl, -CH2CH2SCH3, CH2CO2H, CH2C(O)NH2, CH2CH2COOH, CH2CH2C(O)NH2, CH2CH2CH2NH2, -CH2CH2CH2NHC(NH)NH2, CH2-imidazol-4-yl, CH2OH, CH(OH)CH3, CH2((4'-OH)-Ph), CH2SH, or lower cycloalkyl; or (vii) R. 9a is CH3, CH2CH3, CH(CH3)2, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2Ph, CH2-indol-3-yl, -CH2CH2SCH3, CH2CO2H, CH2C(O)NH2, CH2CH2COOH, CH2CH2C(O)NH2, CH2CH2CH2CH2NH2, -CH2CH2CH2NHC(NH)NH2, CH2-imidazol-4-yl, CH2OH, CH(OH)CH3, CH2((4'-OH)Ph), CH2SH or lower cycloalkyl; R 9b is hydrogen, R 10 is optionally substituted by hydrogen, alkoxy, di(lower alkyl)-amino, or halogen; 1~6 Alkyl, C 1~6 Haloalkyl, C 3~7 cycloalkyl, heterocycloalkyl, aminoacyl, aryl such as phenyl, heteroaryl such as pyridinyl, substituted aryl or substituted heteroaryl; R 11 may be replaced by C 1~6 Alkyl, optionally substituted cycloalkyl, optionally substituted C 2~6 Alkynyl, optionally substituted C 2~6 alkenyl, or optionally substituted acyl, including but not limited to C(O)(C1~6 alkyl), Y, R 3 and R 12 is as defined herein).
[0068] In one embodiment, the compound of formula II: [ka] (In the formula, Y is NR 1 R 2 and R 1 is C1-C5 alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, and pentyl), C1-C5 haloalkyl (including CH2F, CHF2, CF3, CH2CF3, CF2CH3, and CF2CF3), C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(heterocyclic), -(C0-C2 alkyl)(aryl), -(C0-C2 alkyl)(heteroaryl), -OR 25 , -C(O)R 3C (-C(O)CH3, -C(O)CH2CH3, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)OC2H5, -C(O)OC3H7, -C(O)OC4H9 and -C(O)OC5H 11 ), -C(S)R 3D , or -SO2R 28 each of which may be substituted; R 2is hydrogen, optionally substituted C1-C5 alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and pentyl), C1-C5 haloalkyl (including CHF2, CHF2, CF3, CH2CF3 and CF2CF3), optionally substituted -(C0-C2 alkyl)(C3-C6 cycloalkyl), optionally substituted -(C0-C2 alkyl)(heterocycle), optionally substituted -(C0-C2 alkyl)(aryl), optionally substituted -(C0-C2 alkyl)(heteroaryl), -C(O)R 3C (-C(O)CH3, -C(O)CH2CH3, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)OC2H5, -C(O)OC3H7, -C(O)OC4H9 and -C(O)OC5H 11 ), -C(S)R 3D , or -SO2R 28 where R 1 and R 2 at least one of is methyl, CH2F, CHF2 or CF3; R 3 is hydrogen, [ka] , diphosphate, triphosphate, an optionally substituted carbonyl-linked amino acid, or -C(O)R 3C and R 3A O - , OH, -O-optionally substituted aryl, -O-optionally substituted heteroaryl, or optionally substituted heterocyclyl; R 3B O - , OH, an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester; R 3Cis an alkyl, alkenyl, alkynyl, -(C0-C2)(cycloalkyl), -(C0-C2)(heterocyclo), -(C0-C2)(aryl), -(C0-C2)(heteroaryl), -O-alkyl, -O-alkenyl, -O-alkynyl, -O- -(C0-C2)(cycloalkyl), -O-(C0-C2)(heterocyclo), -O-(C0-C2)(aryl), -O-(C0-C2)(heteroaryl), -S-alkyl, -S-alkenyl, -S-alkynyl, -S-(C0-C2)(cycloalkyl), -S-(C0-C2)(heterocyclo), -S-(C0-C2)(aryl) or -S-(C0-C2)(heteroaryl), each of which may be substituted; R 3D is alkyl, alkenyl, alkynyl, -(C0-C2)(cycloalkyl), -(C0-C2)(heterocyclo), -(C0-C2)(aryl), -(C0-C2)(heteroaryl), -O-alkyl, -O-alkenyl, -O-alkynyl, -O-(C0-C2)(cycloalkyl), -O-(C0-C2)(heterocyclo), -O-(C0-C2)(aryl), or -O-(C0-C2)(heteroaryl), each of which may be substituted; R 4 is a stabilized phosphate prodrug, including but not limited to a monophosphate, diphosphate, triphosphate, or a phosphoramidate, thiophosphoramidate, or any other moiety that is metabolized in vivo in a human or animal host to a monophosphate, diphosphate, or triphosphate; Or R 3 and R 4 may, together with the oxygen to which they are attached, form a 3',5'-cyclic prodrug, including but not limited to a 3',5'-cyclic phosphate prodrug; R 5is C1-C5 alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and pentyl), C1-C5 haloalkyl (including CHF2, CHF2, CF3, CH2CF3 and CF2CF3), C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(heterocyclic), -(C0-C2 alkyl)(aryl), -(C0-C2 alkyl)(heteroaryl), -OR 25 , -C(O)R 3C (-C(O)CH3, -C(O)CH2CH3, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)OC2H5, -C(O)OC3H7, -C(O)OC4H9 and -C(O)OC5H 11 ), -C(S)R 3D , or -SO2R 28 each of which may be substituted; R 6 is hydrogen, optionally substituted C1-C5 alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and pentyl), C1-C5 haloalkyl (including CHF2, CH2F, CF3, CH2CF3 and CF2CF3), optionally substituted -(C0-C2 alkyl)(C3-C6 cycloalkyl), optionally substituted -(C0-C2 alkyl)(heterocycle), optionally substituted -(C0-C2 alkyl)(aryl), optionally substituted -(C0-C2 alkyl)(heteroaryl), -C(O)R 3C (-C(O)CH3, -C(O)CH2CH3, -C(O)CH(CH3)2, -C(O)OCH3, -C(O)OC2H5, -C(O)OC3H7, -C(O)OC4H9 and -C(O)OC5H 11 ), -C(S)R 3D , or -SO2R 28 and Or R 5 and R 6 may form a heterocycle together with the nitrogen to which they are attached; R 12is CH3, CH2F, CHF2, CF3, or ethynyl; R 22 is Cl, Br, F, CN, N3, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -(C1-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(C3-C6 heterocycle), -(C0-C2 alkyl)(aryl), -(C0-C2 alkyl)(heteroaryl), -ONHC(=O)OR 23 , -NHOR 24 , -OR 25 , -SR 25 , -NH(CH2) 1~4 N(R 26 )2, -NHNHR 26 , -N=NR 27 , -NHC(O)NHNHR 27 , -NHC(S)NHNHR 27 , -C(O)NHNHR 27 , -NR 27 SO2R 28 , -SO2NR 27 R 29 , -C(O)NR 27 R 29 , -CO2R 29 , -SO2R 29 , [ka] , -P(O)H(OR 29 ), -P(O)(OR 29 )(OR 30 ), -P(O)(OR 29 )(NR 29 R 30 ), or -NR 5 R 6 and For example, but not limited to, the following embodiments: chloro, bromo, fluoro, cyano, azido, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, and n-pentyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, 1-methylbutyl, 1-ethylpropyl, vinyl, allyl, 1-butynyl, 2-butynyl, acetylenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(CH 2)-Cyclopropyl, -(CH2)-cyclobutyl, -(CH2)-cyclopentyl, -(CH2)-cyclohexyl, aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, tetrahydrofuran, thiolane, pyrazolidine, piperidine, oxane, thiane, -(CH2)-aziridine, -(CH2)-oxirane, -(CH2)-thiirane, -(CH2)-azetidine, -(CH2)-oxetane, -(CH2)-thietane, -(CH2)-pyrrolidine , -(CH2)-tetrahydrofuran, -(CH2)-thiolane, -(CH2)-pyrazolidine, -(CH2)-piperidine, -(CH2)-oxane, -(CH2)-thiane, phenyl, pyridyl, -ONHC(=O)OCH3, -ONHC(=O)OCH2CH3, -NHOH, NHOCH3, -OCH3, OC2H5, -OPh, OCH2Ph, -SCH3, -SC2H5, -SPh, SCH2Ph, -NH(CH2)2NH2, -NH(CH2)2N(CH3)2, -NHNH2, -NHNHCH3, -N=NH, -N=NCH3, -N=NCH2CH3, -NHC(O)NHNH2, -NHC(S)NHNH2, -C(O)NHNH2, -NHSO2CH3, -NHSO2CH2CH3, -SO2NHCH3, -SO2N( CH3)2, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2, -CO2CH3, -CO2CH2CH3, -CO2Ph, -CO2CH2Ph, -SO2CH3, -SO2CH2CH3, -SO2Ph, -SO2CH2Ph, [ka] , -P(O)H(OH), -P(O)H(OCH3), -P(O)(OH)(OH), -P(O)(OH)(OCH3), -P(O)(OCH3)(O CH3), -P(O)(OH)(NH2), -P(O)(OH)(NHCH3), -P(O)(OH)N(CH3)2, -NHC(O)CH3, -NHC (O)CH2CH3, -NHC(O)CH(CH3)2, -NHC(O)OCH3, -NHC(O)OCH2CH3, -NHC(O)OCH(CH3)2, -NHC(O)OCH2CH2CH3, -NHC(O)OCH2CH2CH2CH3, and -NHC(O)OCH2CH2CH2CH2CH3, R 23 is C1-C5 alkyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(heterocycle), -(C0-2 alkyl)(aryl), or -(C0-C2 alkyl)(heteroaryl), each of which may be substituted; R 24 is hydrogen, C1-C6 alkyl, -(C1-C2 alkyl)(C3-C6 cycloalkyl), -(C1-C2 alkyl)(C3-C6 heterocycle), -(C0-C2 alkyl)(aryl), or -(C0-C2 alkyl)(heteroaryl), each of which, except for hydrogen, may be substituted; R 25 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(C3-C6 heterocycle), -(C0-C2 alkyl)(aryl), or -(C0-C2 alkyl)(heteroaryl), each of which, except for hydrogen, may be substituted; R 26 are independently selected from hydrogen, C1-C6 alkyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(heterocycle), -(C0-C2 alkyl)(aryl), or -(C0-C2 alkyl)(heteroaryl), each of which, except for hydrogen, is optionally substituted; R 27 is hydrogen or optionally substituted C1-C6 alkyl, R28 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(C3-C6 heterocycle), -(C0-C2 alkyl)(aryl), or -(C0-C2 alkyl)(heteroaryl), each of which may be substituted; R 29 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(C3-C6 heterocycle), -(C0-C2 alkyl)(aryl), or -(C0-C2 alkyl)(heteroaryl), each of which, except for hydrogen, may be substituted; Or R 27 and R 29 may form a heterocycle together with the nitrogen to which they are attached; R 30 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -(C0-C2 alkyl)(C3-C6 cycloalkyl), -(C0-C2 alkyl)(C3-C6 heterocycle), -(C0-C2 alkyl)(aryl), or -(C0-C2 alkyl)(heteroaryl), each of which, except for hydrogen, may be substituted; Or R 29 and R 30 may be bonded together to form a heterocycle; x is 1, 2 or 3.
[0069] In another embodiment, the compound of formula IIa: [ka] (In the formula, Y, R 3 , R 4 and R 22 is as defined above.
[0070] In another embodiment, the compound of formula IIb: [ka] (In the formula, Y, R 3 , R 4 and R 22 is as defined above.
[0071] In a typical embodiment, the compound is a β-D isomer (i.e., naturally occurring configuration) with respect to the corresponding nucleoside. In an alternative configuration, the compound is provided as a β-L isomer. The compound is typically at least 90% free of the opposite enantiomer, and may be at least 98%, 99% or even 100% free of the opposite enantiomer. Unless otherwise stated, the compound is at least 90% free of the opposite enantiomer.
[0072] In another embodiment, the compound has formula III: [ka] (In the formula, R 7 is hydrogen, C 1~6 Alkyl, C 3~7 cycloalkyl, heteroaryl, heterocyclic group, or aryl, including but not limited to, phenyl, or naphthyl, where phenyl or naphthyl is C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, F, Cl, Br, I, Nitro, Cyano, C 1~6 Haloalkyl, -N(R 7’ )2, C 1~6 Acylamino, NHSO2C 1~6 Alkyl, -SO2N(R 7’ ) 2, COR 7’’ , and -SO2C 1~6 may be substituted with alkyl (R 7’ are independently hydrogen or C 1~6 is alkyl, R 7’’ -OR 11 or N(R 7 )2), R 8 is hydrogen, C 1~6alkyl, or R 9a Or R 9b and R 8 are joined together to form a cyclic ring containing the adjacent N and C atoms (CH2) n where n is 2 to 4; R 9a and R 9b teeth, (i) Hydrogen, C 1~6 Alkyl, cycloalkyl, -(CH2) c (NR 9’ )2, C1 ~6 Hydroxyalkyl, --CH2SH, --(CH2)2S(O)(Me, --(CH2)3NHC(=NH)NH2, (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, --(CH2) c COR 9’’ , aryl and aryl(C 1~3 alkyl)-, and the aryl group is independently selected from hydroxyl, C 1~6 Alkyl, C 1~6 optionally substituted with a group selected from alkoxy, halogen, nitro and cyano; (ii)R 9a and R 9b are all C 1~6 is alkyl, (iii)R 9a and R 9b together form a spiro ring (CH2) r and (iv) R 9a is hydrogen, and R 9b and R 8 are joined together to form a cyclic ring containing the adjacent N and C atoms (CH2) n and (v)R 9b is hydrogen, and R 9a and R 8 are joined together to form a cyclic ring containing the adjacent N and C atoms (CH2) n where c is 1 to 6, n is 2 to 4, r is 2 to 5, and R 9’ are independently hydrogen or C 1~6is alkyl, R 9’’ -OR 11 Or -N(R 11’ )2) and (vi)R 9a is hydrogen, and R 9b is hydrogen, CH3, CH2CH3, CH(CH3)2, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2Ph, CH2-indol-3-yl, -CH2CH2SCH3, CH2CO2H, CH2C(O)NH2, CH2CH2COOH, CH2CH2C(O)NH2, CH2CH2CH2NH2, -CH2CH2CH2NHC(NH)NH2, CH2-imidazol-4-yl, CH2OH, CH(OH)CH3, CH2((4'-OH)-Ph), CH2SH, or lower cycloalkyl; or (vii) R. 9a is CH3, CH2CH3, CH(CH3)2, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2Ph, CH2-indol-3-yl, -CH2CH2SCH3, CH2CO2H, CH2C(O)NH2, CH2CH2COOH, CH2CH2C(O)NH2, CH2CH2CH2CH2NH2, -CH2CH2CH2NHC(NH)NH2, CH2-imidazol-4-yl, CH2OH, CH(OH)CH3, CH2((4'-OH)Ph), CH2SH or lower cycloalkyl; R 9b is hydrogen, R 10 is optionally substituted by hydrogen, alkoxy, di(lower alkyl)-amino, or halogen; 1~6 Alkyl, C 1~6 Haloalkyl, C 3~7 cycloalkyl, heterocycloalkyl, aminoacyl, aryl such as phenyl, heteroaryl such as pyridinyl, substituted aryl or substituted heteroaryl; R 11 may be replaced by C 1~6 Alkyl, optionally substituted cycloalkyl, optionally substituted C 2~6 Alkynyl, optionally substituted C 2~6 alkenyl, or optionally substituted acyl, including but not limited to C(O)(C1~6 alkyl), Y, R 3 , R 12 and R 22 is as defined herein).
[0073] In one embodiment, a compound of formula IV: [ka] (Wherein, the variables Y, R 3 , R 7 , R 8 , R 9a , R 9b , R 10 and R 22 discloses compounds of the formula (described herein).
[0074] In one embodiment, the compound of formula V: [ka] (Wherein, the variables Y, R 3 , R 7 , R 8 , R 9a , R 9b , R 10 and R 22 discloses compounds of the formula (described herein).
[0075] In an alternative embodiment, compounds, methods and compositions for the treatment of a host infected with or exposed to Hepatitis C are provided.
[0076] In one embodiment, the compound of formula VI: [ka] (In the formula, R 41 is halogen (especially F or Cl), OR 3 (including OH), N3, NH2 or CN; and the variables Y, R 3 , R 4 and R 12 Disclosed is a compound of formula (described herein).
[0077] In one embodiment, the compound of formula VII: [ka] (Wherein, the variables Y, R 3 , R 4 , R 12 and R 41 discloses compounds of the formula (described herein).
[0078] β-D-2'-deoxy-2'-α-fluoro-2'-β-C-substituted-N 6 Metabolism of -substituted 2,6-diaminopurine nucleotides β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-N as phosphoramidate 6 The metabolism of β-D-methyl-2,6-diaminopurine nucleosides involves the production of the 5'-monophosphate and the deoxyribonuclease N to generate β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-guanine nucleosides as the 5'-monophosphate. 6 This involves the subsequent assimilation of the 5'-methyl-2,6-diaminopurine base. The monophosphate is further assimilated to the active species, namely the 5'-triphosphate, where β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-guanine triphosphate has IC 50 = 0.15 μM. 6 The metabolic pathway for .alpha.-methyl-2,6-diaminopurine nucleoside phosphoramidate is illustrated in Scheme 1 below. [ka]
[0079] β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6 The metabolism of β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-N 6This involves both the formation of .alpha.-dimethyl-2,6-diaminopurine nucleoside triphosphate and also the production of the corresponding guanine nucleoside triphosphate. The metabolic pathways are shown in Schemes 2 and 3 below. [ka] JPEG2024160265000041.jpg122169
[0080] Stabilized Phosphate Prodrugs Stabilized phosphate prodrugs are moieties capable of delivering monophosphate, diphosphate, or triphosphate in vivo. For example, McGuigan disclosed phosphoramidates in U.S. Patent Nos. 8,933,053, 8,759,318, 8,658,616, 8,263,575, 8,119,779, 7,951,787, and 7,115,590. Alios cites Alios also disclosed thiophosphoramidates in U.S. Patent Nos. 8,895,723 and 8,871,737, which are incorporated herein by reference. Thus, cyclic nucleotides were disclosed in U.S. Patent No. 8,772,474, which is incorporated herein by reference. Idenix disclosed cyclic phosphoramidates and phosphoramidate / SATE derivatives in WO 2013 / 177219, which is incorporated herein by reference. Idenix also disclosed substituted carbonyloxymethyl phosphoramidate compounds in WO 2013 / 039920, which is incorporated herein by reference. Hostetler disclosed lipid phosphate prodrugs. For example, See U.S. Patent No. 7,517,858. Hostetler also discloses phosphonate protons. Lipid conjugates of drugs have been disclosed. See, e.g., U.S. Patent Nos. 8,889,658, 8,846,643, 8,710,030, 8,309,565, 8,008,308, and 7,790,703. Emory University disclosed nucleotide sphingoid and lipid derivatives in WO 2014 / 124430. RFS Pharma disclosed purine nucleoside monophosphate prodrugs in WO 2010 / 091386. Cocrystal Pharma Inc. also disclosed purine nucleoside monophosphate prodrugs in WO 2010 / 091386. Purine nucleoside monophosphate prodrugs were disclosed in U.S. Pat. No. 9,173,893, the disclosure of which is incorporated herein by reference. The HepDirect™ technology was disclosed in an article entitled "Design, Synthesis, and Characterization of a Series of Cytochrome P(450) 3A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver," (J. Am. Chem. SoC. 126, 5154-5163 (2004)). Further phosphate prodrugs include, but are not limited to, phosphate esters, 3',5'-cyclic phosphates including CycloSAL, SATE derivatives (S-acyl-2 thioester) prodrugs, and DTE (dithiodiethyl) prodrugs. For literature reviews disclosing non-limiting examples, see A. Ray and K. Hostetler, "Application of kinase bypass strategies to nucleoside antivirals," Antiviral Research (2011) 277-291, M. Sofia, "Nucleotide prodrugs for HCV therapy," Antiviral Chemistry and Chemotherapy 2011; 22-23-49, and S. Peyrottes et al., "SATE Pronucleotide Approaches: An Overview," Mini Reviews in Medicinal Chemistry 2004, 4, 395. In one embodiment, a 5'-prodrug described in any of these patent applications or publications is added to the R of the compound presented. 4 It can be used in the following positions.
[0081] In an alternative embodiment, stabilized phosphate prodrugs include, but are not limited to, those described in U.S. Patent Nos. 9,173,893 and 8,609,627, which are incorporated herein by reference, including methods of making. For example, the 5'-prodrugs of Formula I-V can be represented by the following groups: [ka]
[0082] In an alternative embodiment, the 3',5'-prodrugs of Formulas I-V may be represented by the following groups: [ka] (In the formula, When chirality is present at the phosphorus center, it is wholly or partially R p Or S p or any mixture thereof, Z is O or S; R 33 OR 34 , [ka] and derived fatty alcohols (such as, but not limited to, [ka] is selected from In the formula, R 34 , R 35 and R 36 is defined as follows: R 31 and R 32 can provide nucleoside monophosphates or thiomonophosphates when administered in vivo, which may or may not be partially or completely resistant to 6-NH2 deamination in biological systems. 31 and R 32 are independently selected from: (a) OR 34 , where R 34 is selected from H, Li, Na, K, phenyl and pyridinyl, phenyl and pyridinyl are (CH2) 0~6 CO2R 37 and (CH2) 0~6 CON(R 37 ) 2 is substituted with 1 to 3 substituents independently selected from the group consisting of R 37 are independent of each other, H, C 1~20 Alkyl, carbon chain derived from fatty alcohol (oleyl alcohol, octacosanol, triacontanol, linoleyl alcohol, etc.), or lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C 3~10Cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, aryl such as phenyl, heteroaryl such as pyridinyl, C substituted with substituted aryl or substituted heteroaryl 1~20 is alkyl, where the substituent is C 1~5 Alkyl or lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C 3~10 Cycloalkyl or cycloalkyl-substituted C 1~5 It is an alkyl. (b) [ka] (c) Esters of D- or L-amino acids [ka] In the formula, R 36 is limited to side chains occurring in natural L-amino acids, R 35 is H, C 1~20 Alkyl, carbon chain derived from fatty alcohol (oleyl alcohol, octacosanol, triacontanol, linoleyl alcohol, etc.), or lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C 3~10 Cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, aryl such as phenyl, heteroaryl such as pyridinyl, C substituted with substituted aryl or substituted heteroaryl 1~20 is alkyl, where the substituent is C 1~5 Alkyl or lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C 3~10 Cycloalkyl or cycloalkyl-substituted C 1~5 It is an alkyl. (d)R 31 and R 32 may together form a ring, [ka] In the formula, R 38is H, C 1~20 Alkyl, C 1~20 Alkenyl, carbon chain derived from fatty alcohol (oleyl alcohol, octacosanol, triacontanol, linoleyl alcohol, etc.), or lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C 3~10 C substituted with cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, aryl such as phenyl, heteroaryl such as pyridinyl, substituted aryl, or substituted heteroaryl 1~20 is alkyl, where the substituent is C 1~5 Alkyl or lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C 3~10 Cycloalkyl or cycloalkyl-substituted C 1~5 It is an alkyl. (e)R 31 and R 32 may together form a ring selected from: [ka] During the ceremony, R 39 is O or NH, R 40 is H, C 1~20 Alkyl, C 1~20 Alkenyl, carbon chains derived from fatty acids (oleic acid, linoleic acid, etc.), lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C 3~10 Cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, aryl such as phenyl, heteroaryl such as pyridinyl, C substituted with substituted aryl or substituted heteroaryl 1~20 is alkyl, where the substituent is C 1~5 Alkyl or lower alkyl, alkoxy, di(lower alkyl)-amino, fluoro, C 3~10 Cycloalkyl or cycloalkyl-substituted C 1~5 It is an alkyl.
[0083] The above compounds can be prepared, for example, by preparing the 5'-OH analogs and then converting these to the monophosphate analogs.
[0084] Embodiment In certain embodiments, (i) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, and R 4 is a stabilized phosphate prodrug. (ii) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, and R 4 is a stabilized thiophosphate prodrug. (iii) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, and R 4 is a phosphoramidate. (iv) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, and R 4 is a thiophosphoramidate. (v) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, and R 4 is the monophosphate. (vi) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R2 is hydrogen, and R 3 is hydrogen, and R 4 is a diphosphate. (vii) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, and R 4 is a triphosphate. (viii) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 3 is hydrogen, and R 4 is a stabilized phosphate prodrug. (ix) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 3 is hydrogen, and R 4 is a stabilized thiophosphate prodrug. (x) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 3 is hydrogen, and R 4 is a phosphoramidate. (xi) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 3 is hydrogen, and R 4 is a thiophosphoramidate. (xii) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 3 is hydrogen, and R 4 is the monophosphate. (xiii) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 3 is hydrogen, and R 4 is a diphosphate. (xiv) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 3 is hydrogen, and R 4 is a triphosphate. (xv) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is hydrogen, and R 4 is a stabilized phosphate prodrug. (xvi) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is hydrogen, and R 4 is a stabilized thiophosphate prodrug. (xvii) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is hydrogen, and R 4 is a phosphoramidate. (xviii) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is hydrogen, and R 4 is a thiophosphoramidate. (xix) In formula Ia, Y is NR 1 R2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is hydrogen, and R 4 is the monophosphate. (xx) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is methyl, R 4 is a diphosphate. (xxi) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is hydrogen, and R 4 is a triphosphate. (xxii) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is propyl, R 3 is hydrogen, and R 4 is a stabilized phosphate prodrug. (xxiii) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is propyl, R 3 is hydrogen, and R 4 is a stabilized thiophosphate prodrug. (xxiv) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is propyl, R 3 is hydrogen, and R 4 is a phosphoramidate. (xxv) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is propyl, R3 is hydrogen, and R 4 is a thiophosphoramidate. (xxvi) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is propyl, R 3 is hydrogen, and R 4 is the monophosphate. (xxvii) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is propyl, R 3 is hydrogen, and R 4 is a diphosphate. (xxviii) In formula Ia, Y is NR 1 R 2 and Y is NR 1 R 2 and R 1 is methyl, R 2 is propyl, R 3 is hydrogen, and R 4 is a triphosphate. (xxix) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is ethyl, and R 3 is hydrogen, and R 4 is a stabilized phosphate prodrug. (xxx) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is ethyl, and R 3 is hydrogen, and R 4 is a stabilized thiophosphate prodrug. (xxxi) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is ethyl, and R 3 is hydrogen, and R4 is a phosphoramidate. (xxxii) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is ethyl, and R 3 is hydrogen, and R 4 is a thiophosphoramidate. (xxxiii) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is ethyl, and R 3 is hydrogen, and R 4 is the monophosphate. (xxxiv) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is ethyl, and R 3 is hydrogen, and R 4 is a diphosphate. (xxxv) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is ethyl, and R 3 is hydrogen, and R 4 is a triphosphate. (xxxvi) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 3 is hydrogen, and R 4 is a stabilized phosphate prodrug. (xxxvii) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 3 is hydrogen, and R 4 is a stabilized thiophosphate prodrug. (xxxviii) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 3 is hydrogen, and R 4 is a phosphoramidate. (xxxix) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 3 is hydrogen, and R 4 is a thiophosphoramidate. (xl) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 3 is hydrogen, and R 4 is the monophosphate. (xli) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 3 is hydrogen, and R 4 is a diphosphate. (xlii) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 Meth R 3 is hydrogen, and R 4 is a triphosphate. (xliii) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, and R 4 is a stabilized phosphate prodrug. (xliv) In formula Ib, Y is NR 1 R 2 and R1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, and R 4 is a stabilized thiophosphate prodrug. (xlv) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, and R 4 is a phosphoramidate. (xlvi) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, and R 4 is a thiophosphoramidate. (xlvii) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, and R 4 is the monophosphate. (xlviii) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, and R 4 is a diphosphate. (xlix) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, and R 3 is hydrogen, and R 4 is a triphosphate. (l) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is hydrogen, and R4 is a stabilized phosphate prodrug. (li) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is hydrogen, and R 4 is a stabilized thiophosphate prodrug. (lii) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is hydrogen, and R 4 is a phosphoramidate. (liii) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is hydrogen, and R 4 is a thiophosphoramidate. (liv) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is hydrogen, and R 4 is the monophosphate. (lv) In formula Ib, Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is methyl, R 4 is a diphosphate. (lvi) In formula Ia, Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is hydrogen, and R 4 is a triphosphate.
[0085] In an alternative embodiment of any of the above, the compound is R 22 In any of these particular embodiments, R 22 is F, amide or carbamate. In other particular aspects of the above embodiment, R 22 are chloro, bromo, cyano, azido, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and n-pentyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, 1-methylbutyl, 1-ethylpropyl, vinyl, allyl, 1-butynyl, 2-butynyl, acetylenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(CH2)-cyclopropyl, -(CH2)-cyclobutyl, -(CH2)-cyclopentyl, -(CH2)-cyclohexyl, aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, tetrahydrofuran, thiolane, pyrazolidine, piperidine, oxane, thiane, -(CH2)-aziridine, -(CH2)-oxy Ran, -(CH2)-thiirane, -(CH2)-azetidine, -(CH2)-oxetane, -(CH2)-thietane, -(CH2)-pyrrolidine, -(CH2)-tetrahydrofuran, -(CH2)-thiolane, -(CH2)-pyrazolidine, -(CH2)-piperidine, -(CH2)-oxane, -(CH2)-thiane, phenyl, pyridyl, -ONHC(=O)OCH3, -ONHC (=O)OCH2CH3, -NHOH, NHOCH3, -OCH3, OC2H5, -OPh, OCH2Ph, -SCH3, -SC2H5, -SPh, SCH2Ph, -NH(CH2)2NH2, -NH(CH2)2N(CH3)2, -NHNH2, -NHNHCH3, -N=NH, -N=NCH3, -N=NCH2CH3, -NHC(O)NHNH2, -NHC(S)NHNH2, -C(O )NHNH2, -NHSO2CH3, -NHSO2CH2CH3, -SO2NHCH3, -SO2N(CH3)2, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2, -CO2CH3, -CO2CH2CH3, -CO2Ph, CO2CH2Ph, -SO2CH3, -SO2CH2CH3, -SO2Ph, -SO2CH2Ph, [ka] , -P(O)H(OH), -P(O)H(OCH3), -P(O)(OH)(OH), -P(O)(OH)(OCH3), -P(O)(OCH3)(O CH3), -P(O)(OH)(NH2), -P(O)(OH)(NHCH3), -P(O)(OH)N(CH3)2, -NHC(O)CH3, -NHC (O)CH2CH3, -NHC(O)CH(CH3)2, -NHC(O)OCH3, -NHC(O)OCH2CH3, -NHC(O)OCH(CH3)2, -NHC(O)OCH2CH2CH3, -NHC(O)OCH2CH2CH2CH3 and -NHC(O)OCH2CH2CH2CH2CH3.
[0086] In an alternative embodiment of compounds (i) to (lvi), an L-nucleoside is used in formula I to formula VII.
[0087] In an alternative embodiment, R of formula I 12 The variable is CH2F.
[0088] In an alternative embodiment, R of formula I 12 The variable is CHF2.
[0089] In an alternative embodiment, R of formula I 12 The variable is CF3.
[0090] In one embodiment, there is provided a compound of formula Ia: Non-limiting examples of compounds of formula Ia include: [ka] JPEG2024160265000052.jpg211169JPEG2024160265000053.jpg210169JPEG2024160265000054.jpg83169
[0091] In one embodiment, a thiophosphoramidate of formula Ia is provided. Non-limiting examples of thiophosphoramidates of formula Ia include, but are not limited to, the following: [ka] JPEG2024160265000056.jpg207169JPEG2024160265000057.jpg211169JPEG2024160265000058.jpg125169
[0092] In one embodiment, a stabilized phosphate prodrug of formula Ia is provided. Non-limiting examples of stabilized phosphate prodrugs of formula Ia include: [ka] JPEG2024160265000060.jpg84169
[0093] In another embodiment, there is provided a compound of formula Ia: Non-limiting examples of compounds of formula Ia include: [ka] JPEG2024160265000062.jpg216169JPEG2024160265000063.jpg216169JPEG2024160265000064.jpg214169
[0094] In one embodiment, a thiophosphoramidate of formula Ia is provided. Non-limiting examples of thiophosphoramidates of formula Ia include, but are not limited to, the following: [ka] JPEG2024160265000066.jpg204169JPEG2024160265000067.jpg164169JPEG2024160265000068.jpg86169
[0095] In one embodiment, a stabilized phosphate prodrug of formula Ia is provided. Non-limiting examples of stabilized phosphate prodrugs of formula Ia include: [ka] JPEG2024160265000070.jpg153169
[0096] In one embodiment, there is provided a compound of formula II: Non-limiting examples of compounds of formula II include: [ka] JPEG2024160265000072.jpg187169JPEG2024160265000073.jpg185169JPEG20241602650 00074.jpg189169JPEG2024160265000075.jpg213169JPEG2024160265000076.jpg167169
[0097] In one embodiment, there is provided a compound of formula I. Non-limiting examples of compounds of formula I include: [ka] JPEG2024160265000078.jpg176169JPEG2024160265000079.jpg91169
[0098] In one embodiment, there is provided a compound of formula II: Non-limiting examples of compounds of formula II include: [ka]
[0099] In one embodiment, R 4 teeth, [ka] It is.
[0100] In one embodiment, there is provided a compound of formula II: Non-limiting examples of compounds of formula II include: [ka] JPEG2024160265000083.jpg219169JPEG2024160265000084.jpg189169JPEG2024160265000085.jpg196169JPEG2024160265000086.jpg119169
[0101] In some embodiments, R 3 is H and R 4 teeth, [ka] It is.
[0102] In some embodiments, R 3 is H and R 4 teeth, [ka] It is.
[0103] In some embodiments, R 3 is H and R 4 teeth, [ka] It is.
[0104] In one embodiment, there is provided a compound of formula II: Non-limiting examples of compounds of formula II include: [ka] JPEG2024160265000091.jpg179169JPEG2024160265000092.jpg179169JPEG202 4160265000093.jpg216169JPEG2024160265000094.jpg181169JPEG20241602650 00095.jpg217169JPEG2024160265000096.jpg218169JPEG2024160265000097.j pg216169JPEG2024160265000098.jpg219169JPEG2024160265000099.jpg213169
[0105] In some embodiments, R 3 is H and R 4 teeth, [ka] It is.
[0106] In some embodiments, R 3 is H and R 4 teeth, [ka] It is.
[0107] In some embodiments, R 3 is H and R 4 teeth, [ka] It is.
[0108] In some embodiments, R 1 is CH3 and R 2 is H and R 3 is H and R 4 teeth, [ka] It is.
[0109] In some embodiments, R 1 is CH3 and R 2 is H and R 3 is H and R 4 teeth, [ka] It is.
[0110] In some embodiments, R 1 is CH3 and R 2 is H and R 3 is H and R 4 teeth, [ka] It is.
[0111] In some embodiments, R 1 is CH3 and R 2 is CH3 and R 3 is H and R 4 teeth, [ka] It is.
[0112] In some embodiments, R 1 is CH3 and R 2 is CH3 and R 3 is H and R 4 teeth, [ka] It is.
[0113] In some embodiments, R 1 is CH3 and R 2 is CH3 and R 3 is H and R4 teeth, [ka] It is.
[0114] In some embodiments, R 1 is cyclopropyl, R 2 is CH3 and R 3 is H and R 4 teeth, [ka] It is.
[0115] In some embodiments, R 1 is cyclopropyl, R 2 is CH3 and R 3 is H and R 4 teeth, [ka] It is.
[0116] In some embodiments, R 1 is cyclopropyl, R 2 is CH3 and R 3 is H and R 4 teeth, [ka] It is.
[0117] II. Definition The following terms are used to describe the present invention. Certain terms are specifically defined herein. If not, the term is given the meaning as recognized by one of ordinary skill in the art applying the term in the context of its use in describing the present invention.
[0118] The term "alkyl", in its context, refers to a straight or branched chain, fully saturated, optionally substituted (e.g., by halogen, including F) hydrocarbon radical or alkyl group. For example, an alkyl group may have 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms (i.e., C1-C8 alkyl), 1, 2, 3, 4, 5, or 6 carbon atoms (i.e., C1-C6 alkyl), or 1 to 4 carbon atoms (i.e., C1-C4 alkyl). Examples of suitable alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, neopentyl, hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl.
[0119] The term "alkenyl" refers to a non-aromatic hydrocarbon group containing at least one double bond between adjacent carbon atoms and, unless otherwise stated herein, a structure similar to an alkyl group. For example, an alkenyl group may have 2 to 8 carbon atoms (i.e., C2-C8 alkenyl), or 2 to 4 carbon atoms (i.e., C2-C4 alkenyl). Examples of suitable alkenyl groups include, but are not limited to, ethenyl or vinyl (-CH=CH2), allyl (-CH2CH=CH2), 1-butenyl (-C=CH-CH2CH3), and 2-butenyl (-CH2CH=CHCH2). As described herein, an alkenyl group may be substituted.
[0120] The term "alkynyl" refers to a non-aromatic hydrocarbon group containing at least one triple bond between adjacent carbon atoms and, unless otherwise stated herein, a structure similar to an alkyl group. For example, an alkynyl group may have 2 to 8 carbon atoms (i.e., C2-C8 alkynyl), or 2 to 4 carbon atoms (i.e., C2-C4 alkynyl). Examples of alkynyl groups include, but are not limited to, acetylenic, or ethynyl, and propargyl. Alkynyl groups may be substituted as described herein.
[0121] The term "acyl" refers to a moiety, --C(O)R, in which a carbonyl moiety is attached to R, e.g., --C(O)alkyl. R may be selected from alkoxy, alkyl, cycloalkyl, lower alkyl (i.e., C1-C4), alkoxyalkyl, including methoxymethyl, aralkyl, including benzyl, aryloxyalkyl, including phenoxymethyl, and the like, aryl, including phenyl, which may be substituted with halogen, C1-C4 alkyl, or C1-C4 alkoxy. In one embodiment, the term "acyl" refers to monophosphate, diphosphate, or triphosphate.
[0122] The term "lower acyl" refers to an acyl group in which the carbonyl moiety is lower alkyl (ie, C1-C4).
[0123] The term "alkoxy" refers to the group -OR', where -OR' is -O-alkyl, -O-alkenyl, -O-alkynyl, -O-(C0-C2)(cycloalkyl), -O-(C0-C2)(heterocyclo), -O-(C0-C2)(aryl), or -O-(C0-C2)(heteroaryl), each of which may be substituted.
[0124] The term "amino" refers to the group -NH2.
[0125] The term "amino acid" or "amino acid residue" refers to any amino acid of D- or L-natural or non-natural origin. Representative amino acids include, but are not limited to, alanine, β-alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, proline, serine, threonine, valine, tryptophan, or tyrosine, among others.
[0126] The term "azido" refers to the group -N3.
[0127] The term "aryl" or "aromatic", in context, refers to a monovalent aromatic radical having a single ring (e.g., phenyl or benzyl), which may be substituted (unless otherwise stated herein) or unsubstituted, or fused rings (e.g., naphthyl, anthracenyl, phenanthrenyl, etc.), and may be attached to a compound according to the invention at any available stable position on the ring(s) or as otherwise shown in the chemical structure provided. As described herein, aryl groups may be substituted.
[0128] "Cycloalkyl", "carbocycle" or "carbocyclyl" means a saturated i.e., a ring having 3 to 7 carbon atoms as a monocyclic ring that is saturated (e.g., cycloalkyl) or partially unsaturated (e.g., cycloalkenyl, cycloalkadienyl, etc.). Monocyclic carbocycles have 3 to 7 ring atoms, more typically 5 or 6 ring atoms. Non-limiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, and 1-cyclohex-3-enyl.
[0129] The term "cyano" refers to the group --CN.
[0130] The term "halogen" or "halo" refers to chloro, bromo, fluoro or iodo.
[0131] Heteroaryl ring systems are saturated or unsaturated rings containing one or more nitrogen, oxygen, or sulfur atoms in a (single) ring, including, but not limited to, imidazole, furyl, pyrrole, furanyl, thien, thiazole, pyridine, pyrimidine, purine, pyrazine, triazole, oxazole, or fused ring systems such as indole, quinoline, etc., among others, which may be optionally substituted as described above. Heteroaryl groups include nitrogen-containing heteroaryl groups, such as, in particular, pyrrole, pyridine, pyridone, pyridazine, pyrimidine, pyrazine, pyrazole, imidazole, triazole, triazine, tetrazole, indole, isoindole, indolizine, purine, indazole, quinoline, isoquinoline, quinolizine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, imidazopyridine, imidazotriazine, pyrazinopyridazine, acridine, phenanthridine, carbazole, carbazoline, perimidine, phenanthroline, phenacene, oxadiazole, benzimidazole, pyrrolopyridine, pyrrolopyrimidine. and pyridopyrimidines; sulfur-containing aromatic heterocycles such as thiophene and benzothiophene; oxygen-containing aromatic heterocycles such as furan, pyran, cyclopentapyran, benzofuran and isobenzofuran; and aromatic heterocycles containing two or more heteroatoms selected from nitrogen, sulfur and oxygen such as thiazole, thiadizole, isothiazole, benzoxazole, benzothiazole, benzothiadiazole, phenothiazine, isoxazole, furazan, phenoxazine, pyrazoloxazole, imidazothiazole, thienofuran, furopyrrole, pyridoxazine, furopyrrol, pyridox ... Examples of suitable aryl groups include pyrimidine, furopyrimidine, thienopyrimidine, and oxazole, all of which may be optionally substituted.
[0132] The term "heterocycle" or "heterocyclo" refers to a cyclic group containing at least one heteroatom, i.e., O, N, or S, which may be aromatic (heteroaryl) or non-aromatic. Examples of non-aromatic heterocyclic groups for use in the present invention include, for example, pyrrolidinyl, piperidinyl, piperazinyl, N-methylpiperazinyl, imidazolinyl, pyrazolidinyl, imidazolidinyl, morpholinyl, tetrahydropyranyl, azetidinyl, oxetanyl, oxathiolanyl, pyridone, 2-pyrrolidone, ethyleneurea, 1,3-dioxolane, 1,3-dioxane, 1,4-dioxane, phthalimide, and succinimide, among others, all of which may be optionally substituted.
[0133] The term "hydroxyl" refers to the group --OH.
[0134] The term "nitro" refers to the group --NO.sub.2.
[0135] The term "pharmaceutically acceptable salt" or "prodrug" refers to a β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N-(2-amino-1,2-dihydro-1,2-trifluoro-2,3 ... 6- is used throughout the specification to describe any pharma- ceutically acceptable form of substituted purine nucleotides, such as esters, phosphoramidates, thiophosphoramidates, phosphate esters, salts of esters, or related groups. Examples of pharma-ceutically acceptable salts are organic acid addition salts formed with acids that form physiologically acceptable anions, such as tosylates, methanesulfonates, acetates, citrates, malonates, tartrates, succinates, benzoates, ascorbates, α-ketoglutarate, and α-glycerophosphate. Suitable inorganic salts can also be formed, including sulfates, nitrates, bicarbonates, and carbonates. Pharmaceutically acceptable salts can be obtained, for example, by reacting a sufficiently basic compound, such as an amine, with a suitable acid that results in a physiologically acceptable anion, using standard techniques well known in the art. Alkali metal (e.g., sodium, potassium, or lithium) or alkaline earth metal (e.g., calcium) salts of carboxylic acids can also be made.
[0136] A "pharmacologically acceptable prodrug" refers to a compound that is metabolized in the host, e.g., hydrolyzed or oxidized, to form a compound of the present invention. Typical examples of prodrugs include compounds that have a biologically labile protecting group on a functional moiety of an active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated, thiophosphoramidated, dethiophosphoramidated, phosphoramidated, or dephosphoramidated to produce an active compound. The compounds of the present invention have antiviral activity against HCV or are metabolized to a compound that exhibits such activity. β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N 6-Substituted purine nucleosides may also be administered as 5'-phosphoether lipids, bisphosphoramidates, 3',5'-cyclic phosphoramidates, 3',5'-cyclic thiophosphoramidates, DTE conjugates, mixed phosphoramidate-SATE derivatives, or "SATE" derivatives.
[0137] The term "phosphate" refers to the group -P(O)(OH).
[0138] In one embodiment, the term purine or pyrimidine base includes, but is not limited to, adenine, N 6 -Alkylpurines, N 6 -acyl purine (wherein acyl is -C(O)alkyl, -C(O)(aryl)C0-C4alkyl, or -C(O)(C0-C4alkyl)aryl), N 6 -Benzylpurine, N 6 -Haloprin, N 6 -Vinylpurine, N 6 -Acetylene purine, N 6 -Acylpurine, N 6 -Hydroxyalkylpurine, N 6 -Thioalkylpurines, N 2 -Alkylpurines, N 2 -Alkyl-6-thiopurine, thymine, cysteine tosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidines including 6-azacytosine, 2- and / or 4-mercaptopyrimidines, uracil, 5-halouracils including 5-fluorouracil, C 5 -Alkylpyrimidines, C 5 -benzylpyrimidine, C 5 -Halopyrimidines, C 5 -vinylpyrimidine, C 5 -Acetylene pyrimidine, C 5 -Acylpyrimidine, C 5 -Hydroxyalkylpurine, C 5 -Amidopyrimidine, C 5 -Cyanopyrimidine, C 5 -Nitropyrimidine, C 5 -aminopyrimidine, N 2-Alkylpurines, N 2 -alkyl-6-thiopurine, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolo-pyrimidinyl. Purine bases include, but are not limited to, guanine, adenine, hypoxanthine, 2,6-diaminopurine, and 6-chloropurine. Functional oxygen and nitrogen groups on the base can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art and include benzyl, trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, trityl, alkyl groups, and acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl. Alternatively, the purine or pyrimidine base may be substituted to form a viable prodrug that can be cleaved in vivo. Examples of suitable substituents include acyl moieties.
[0139] The term "substituted" or "optionally substituted" indicates that the moiety may have at least one additional substituent, including, but not limited to, halogen (F, Cl, Br, I), OH, phenyl, benzyl, N3, CN, acyl, alkyl including methyl, alkenyl, alkynyl, alkoxy, haloalkyl including CHF2, CH2F and CF3, and the like. In one embodiment, the term "substituted" or "optionally substituted" indicates that the moiety may have at least one additional substituent, including, but not limited to, azido, cyano, halogen (fluoro, chloro, bromo, or iodo), alkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, haloalkyl, hydroxyl, alkoxy, amino, -NH(C1-C6 unsubstituted alkyl), -NH(C1-C6 substituted alkyl), -NH-(C0-C2 alkyl)(C3-C8 cycloalkyl), -NH-(C0-C2 alkyl)(C3-C8 heterocycle), - and may have at least one additional substituent including NH-(C0-C2 alkyl)(aryl), -N(C1-C6 unsubstituted alkyl)2, -N(C1-C6 unsubstituted alkyl)(C1-C6 substituted alkyl), -N(C1-C6 substituted alkyl)2, -NH-(C0-C2 alkyl)(C3-C8 cycloalkyl), -NH-(C0-C2 alkyl)(C3-C8 heterocycle), -NH-(C0-C2 alkyl)(aryl), acyl, nitro, sulfonic acid, sulfate, phosphonic acid, phosphate, phosphonate, or thiol.
[0140] formula R 14 S(O)2OR 15 The term "sulfonate ester" represented by R 14 where R 14 is alkyl, haloalkyl, aralkyl or aryl. R 15 is alkyl, aryl, or aralkyl.
[0141] The term "sulfonic acid" refers to the group -SO2OH.
[0142] The term "thiol" refers to the group --SH.
[0143] The term "nitrogen protecting group" as used herein refers to a moiety that is covalently attached to nitrogen and can be removed, typically substituted with hydrogen where appropriate.For example, the nitrogen protecting group may be a group that is removed in vivo after administration to a host, in vitro by cells, or may be removed during a manufacturing process.Suitable nitrogen protecting groups useful in the present invention are described by Greene and Wuts in Protective Groups in Organic Synthesis (1991) New York, John Wiley and Sons, Inc.
[0144] The term "oxygen protecting group" as used herein refers to a moiety that is covalently attached to oxygen, can be removed, and is typically replaced with hydrogen when appropriate.For example, oxygen protecting group may be a group that is removed in vivo after administration to a host, in vitro by cells, or may be removed during a manufacturing process.Suitable oxygen protecting groups useful in the present invention are described by Greene and Wuts in Protective Groups in Organic Synthesis (1991) New York, John Wiley and Sons, Inc.
[0145] "Phosphate" refers to the group -OP(O)(OH).
[0146] "Phosphate ester" refers to monophosphates, diphosphates and triphosphates, unless otherwise indicated.
[0147] The term "phosphoamidate", "phosphoramidate" or "phosphoroamidate" refers to a moiety having a phosphorus bonded to three oxygen groups and an amine (which may be substituted). Suitable phosphoramidates useful in the present invention are described in Madela, Karolina and McGuigan in 2012, "Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs", Future Medicinal Chemistry 4(5), pages 625-650 10:1021 / jm300074y, and Dominique, McGuigan and Balzarini in 2004, "Aryloxy Phosphoramidate Triesters as Pro-Tides", Mini Reviews in Medicinal Chemistry 4(4), pages 371-381. Additional phosphoramidates useful in the present invention are described in U.S. Patents 5,233,031, 7,115,590, 7,547,704, 7,879,815, 7,888,330, 7,902,202, 7,951,789, 7,964,580, 8,071,568, 8,148,349, 8,263, 8,326, 8,366, 8,387, 8,389, 8,426, 8,426, 8,527, 8,547,704, 7,879,815, 7,888,330, 7,902,202, 7,951,789, 7,964,580, 8,071,568, 8,148,349, 8,263, 8,326, 8,327 ... ,575, 8,324,179, 8,334,270, 8,552,021, 8,563,530, 8,580,765, 8,735,372, 8,759,318, EP 2120565, EP 1143995, U.S. Patent No. 6,455,513, and U.S. Patent No. 8,334,270. Other phosphoramidates are described in the nucleoside patents described in the Background of the Invention.
[0148] Phosphoramidate groups for use in the present invention include those of the following structure: [ka]
[0149] Other phosphoramidates of use in the present invention include those of the following structures: [ka] During the ceremony, RP1 is an optionally substituted linear, branched, or cyclic alkyl group, or an optionally substituted aryl, heteroaryl, or heterocyclic group, or linked combinations thereof; R P2 -NR N1 R N2 group or a B′ group, During the ceremony, R N1 and R N2 are each independently H, C 1~8 alkyl, (C3-C7 cycloalkyl)C0-C4 alkyl, (aryl)C0-C4 alkyl-, (C3-C6 heterocyclo)C0-C4 alkyl-, or (heteroaryl)C0-C4 alkyl-, which may be substituted, or R N1 and R N2 joins with the nitrogen atom to which it is attached to form a 3- to 7-membered heterocycle; B' is [ka] It is based on During the ceremony, R 16 is hydrogen, (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C8 cycloalkyl)C0-C4 alkyl-, (aryl)C0-C4 alkyl-, (C3-C6 heterocyclo)C0-C4 alkyl-, (heteroaryl)C0-C4 alkyl-, or the side chain of an amino acid, for example (unless otherwise stated herein) alanine, β-alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, proline, serine, threonine, valine, tryptophan or tyrosine (often R 16 is hydrogen, methyl, isopropyl or isobutyl; R 17is hydrogen, (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C8 cycloalkyl)C0-C4 alkyl-, (aryl)C0-C4 alkyl-, (C3-C6 heterocyclo)C0-C4 alkyl-, (heteroaryl)C0-C4 alkyl-, or the side chain of an amino acid, for example (unless otherwise stated herein) alanine, β-alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, proline, serine, threonine, valine, tryptophan or tyrosine (often R 17 is hydrogen, methyl, isopropyl or isobutyl; R 18 is hydrogen or C1-C3 alkyl, or R 16 and R 17 may form a (C3-C7)cycloalkyl or (C3-C7)heterocyclic group, Or R 18 and R 16 Or R 17 may form a (C3-C6) heterocyclic group, R 19 is hydrogen, (C1-C6) alkyl, (C3-C6) alkenyl, (C3-C6) alkynyl, (C3-C8 cycloalkyl) C0-C4 alkyl-, (aryl) C0-C4 alkyl-, (C3-C6 heterocyclo) C0-C4 alkyl-, (heteroaryl) C0-C4 alkyl-, Or B' is [ka] It is based on During the ceremony, R 20 is hydrogen, (C1-C3) alkyl, (C3-C8 cycloalkyl)C0-C4 alkyl-, (aryl)C0-C4 alkyl-, (C3-C6 heterocyclo)C0-C4 alkyl-, or (heteroaryl)C0-C4 alkyl-, R21 is hydrogen, (C1-C3) alkyl, (C3-C8 cycloalkyl)C0-C4 alkyl-, (aryl)C0-C4 alkyl-, (C3-C6 heterocyclo)C0-C4 alkyl-, or (heteroaryl)C0-C4 alkyl-, R 18 and R 19 is defined above.
[0150] Preferred R P1 Groups include optionally substituted phenyl, naphthyl, and monocyclic heteroaryl groups, particularly groups that enhance the bioavailability of the compound in the cells of a patient (especially lipophilic groups), which show reduced toxicity, enhanced therapeutic index, and enhanced pharmacokinetics (the compound is metabolized and excreted more slowly).
[0151] The term phosphoramidate is used throughout this specification to describe the group found at the 5' or 3' position of the furanose ring of a nucleoside compound, forming the prodrug form of the nucleoside compound.In one embodiment, phosphoramidates can be found at both the 5' and 3' positions of the furanose ring of a nucleoside compound, forming the prodrug form of the nucleoside compound.In another embodiment, phosphoramidates found at the 5' position of the furanose ring of a nucleoside can form a cyclic phosphoramidate compound by forming a bond with the 3'-hydroxyl substituent at the 3' position of the furanose ring of a nucleoside compound, forming the prodrug form of the nucleoside compound.
[0152] The term "thiophosphoramidate", "thiophosphoramidate" or "thiophosphoroamidate" refers to a moiety having a phosphorus bonded to a sulfur, two oxygen groups and an amine (which may be substituted). Thiophosphoramidates useful in the present invention are described in U.S. Pat. No. 8,772,474 and WO 2012 / 040124.
[0153] Thiophosphoramidate groups for use in the present invention include those of the following structure: [ka]
[0154] Other thiophosphoramidates include those of the following structure: [ka] During the ceremony, R P1 is an optionally substituted linear, branched, or cyclic alkyl group, or an optionally substituted aryl, heteroaryl, or heterocyclic group, or linked combinations thereof; R P2 -NR N1 R N2 group or a B′ group, During the ceremony, R N1 and R N2 are each independently H, C 1~ C8 alkyl, (C3-C7 cycloalkyl)C0-C4 alkyl-, (aryl)C0-C4 alkyl-, (C3-C6 heterocyclo)C0-C4 alkyl-, or (heteroaryl)C0-C4 alkyl-, or R N1 and R N2 joins with the nitrogen atom to which it is attached to form a 3- to 7-membered heterocycle; B' is [ka] It is based on During the ceremony, R 16is hydrogen, (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C8 cycloalkyl)C0-C4 alkyl-, (aryl)C0-C4 alkyl-, (C3-C6 heterocyclo)C0-C4 alkyl-, (heteroaryl)C0-C4 alkyl-, or the side chain of an amino acid, for example (unless otherwise stated herein) alanine, β-alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, proline, serine, threonine, valine, tryptophan or tyrosine (often R 16 is hydrogen, methyl, isopropyl or isobutyl; R 17 is hydrogen, (C1-C8) alkyl, (C2-C8) alkenyl, (C2-C8) alkynyl, (C3-C8 cycloalkyl)C0-C4 alkyl-, (aryl)C0-C4 alkyl-, (C3-C6 heterocyclo)C0-C4 alkyl-, (heteroaryl)C0-C4 alkyl-, or the side chain of an amino acid, for example (unless otherwise stated herein) alanine, β-alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, proline, serine, threonine, valine, tryptophan or tyrosine (often R 17 is hydrogen, methyl, isopropyl or isobutyl; R 18 is hydrogen or C1-C3 alkyl, or R 16 and R 17 may form a (C3-C7)cycloalkyl or (C3-C7)heterocyclic group, Or R 18 and R 16 Or R 17 may form a (C3-C6) heterocyclic group, R 19is hydrogen, (C1-C6) alkyl, (C3-C6) alkenyl, (C3-C6) alkynyl, (C3-C8 cycloalkyl) C0-C4 alkyl-, (aryl) C0-C4 alkyl-, (C3-C6 heterocyclo) C0-C4 alkyl-, (heteroaryl) C0-C4 alkyl-, Or B' is [ka] It is based on R 18 , R 19 , R 20 and R 21 is as defined above.
[0155] Preferred R P1 Groups include optionally substituted phenyl, naphthyl, and monocyclic heteroaryl groups, particularly groups that enhance the bioavailability of the compound in the cells of a patient (especially lipophilic groups), which show reduced toxicity, enhanced therapeutic index, and enhanced pharmacokinetics (the compound is metabolized and excreted more slowly).
[0156] Thiophosphoramidates can be found at the 5' or 3' position of the furanose ring of a nucleoside compound to form a prodrug form of the nucleoside compound.In one embodiment, thiophosphoramidates can be found at both the 5' and 3' positions of the furanose ring of a nucleoside compound to form a prodrug form of the nucleoside compound.In another embodiment, thiophosphoramidates found at the 5' position of the furanose ring of a nucleoside can form a cyclic thiophosphoramidate compound by forming a bond with the 3'-hydroxyl substituent at the 3' position of the furanose ring of a nucleoside compound to form a prodrug form of the nucleoside compound.
[0157] The term "D-configuration" as used in the context of the present invention refers to the principle configuration that mimics the natural configuration of the sugar moiety, as opposed to non-naturally occurring nucleosides or the "L" configuration. The term "β" or "β anomer" is used in reference to nucleoside analogs in which the nucleoside base is formed (positioned) above the plane of the furanose moiety in the nucleoside analog.
[0158] The terms "co-administer" and "co-administration", or combination therapy, are used to describe the administration of at least one 2'-deoxy-2'-α-fluoro-2'-β-C-nucleoside compound according to the present invention in combination with at least one other active agent, for example, at least one additional anti-HCV agent, including other 2'-deoxy-2'-α-fluoro-2'-β-C-nucleoside agents disclosed herein, if appropriate. The timing of co-administration is best determined by the specialist treating the patient. Sometimes it is preferred that the agents are administered at the same time. Alternatively, the drugs selected for combination therapy may be administered to the patient at different times. Of course, when more than one virus or other infection or other condition is present, the compounds of the present invention may be combined with other agents to treat the other infections or conditions as necessary.
[0159] The term "host" as used herein refers to a unicellular or multicellular organism, including cell lines and animals, typically humans, in which the HCV virus can replicate. The term host specifically refers to infected cells, cells transfected with all or part of the HCV genome, as well as animals, particularly primates (including chimpanzees) and humans. In most animal applications of the present invention, the host is a human patient. However, veterinary uses are clearly anticipated by the present invention in certain indications (such as chimpanzees). The host may be, for example, a cow, a horse, a bird, a dog, a cat, etc.
[0160] Isotope Substitution The present invention includes compounds and the use of compounds with substitution of a desired isotope of an atom in an amount greater than natural abundance, i.e., enriched, of the isotope. Isotopes are atoms with the same atomic number but different mass numbers, i.e., the same number of protons but different numbers of neutrons. As a general example and without limitation, for example, deuterium ( 2 H) and tritium ( 3 H) may be used anywhere in the depicted structures. Alternatively, or in addition, isotopes of carbon, such as 13 C and 14 C may also be used. A preferred isotopic substitution is the replacement of hydrogen with deuterium at one or more positions on the molecule to improve drug performance. Deuterium can be attached at the site of bond cleavage during metabolism (α-deuterium kinetic isotope effect) or adjacent or near the site of bond cleavage (β-deuterium kinetic isotope effect). Achillion Pharmaceuticals, Inc. (International Publication No. WO 2014 / 169278 and WO 2014 / 169280 describe the deuteration of nucleotides, including at the 5-position of the molecule, to improve their pharmacokinetics or efficacy.
[0161] Substitution with isotopes such as deuterium can confer certain therapeutic advantages due to greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements. Substitution of hydrogen at a site of metabolic degradation with deuterium can reduce the rate of metabolism or eliminate metabolism at that bond. At any position in a compound where a hydrogen atom can be present, the hydrogen atom can be substituted with protium ( 1 H), deuterium ( 2 H) and tritium ( 3 Any isotope of hydrogen may be used, including H. Thus, unless the context clearly dictates otherwise, references herein to compounds include all possible isotopic forms.
[0162] The term "isotope-labeled" analogues includes "deuterated analogues,"13 C-labeled analogues or deuterated / 13 The term "deuterated analog" refers to an analog that is a "C labeled analog" or ... 1 H) is converted to H-isotope, namely deuterium ( 2 H). Deuterium substitution may be partial or complete. Partial deuterium substitution means that at least one hydrogen is replaced by at least one deuterium. In certain embodiments, the isotope is enriched to 90%, 95%, or 99% or more in the isotope at any desired position. In some embodiments, it is deuterium that is enriched to 90%, 95%, or 99% at the desired position. Unless specified to the contrary, deuteration is at least 80% at the selected position. Deuteration of a nucleoside may occur at any replaceable hydrogen that provides the desired result.
[0163] III. Methods of Treatment or Prevention Treatment, as used herein, refers to the administration of an active compound to a host infected with the HCV virus.
[0164] The term "prophylactic" or preventative, when used, refers to administration of an active compound to prevent or reduce the likelihood of viral disease occurring. The present invention includes both therapeutic and prophylactic or preventative therapies. In one embodiment, an active compound is administered to a host who has been exposed to the Hepatitis C virus and is therefore at risk for infection therewith. The present invention relates to a method for the treatment or prevention of Hepatitis C virus, including drug-resistant and multi-drug resistant forms of HCV, and associated disease states, conditions or complications of HCV infection, including cirrhosis of the liver and associated hepatotoxicity, as well as other conditions secondary to HCV infection, such as weakness, loss of appetite, weight loss, breast enlargement (especially in men), rashes (especially on the palms of the hands), blood clotting problems, spider veins in the skin, confusion, coma (encephalopathy), fluid accumulation in the abdominal cavity (ascites), esophageal varices, portal hypertension, renal failure, splenomegaly, low blood counts, anemia, thrombocytopenia, jaundice, and hepatocellular carcinoma, comprising administering to a patient a therapeutically effective amount of at least one β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N-α ... 6 The method includes administering a -substituted purine nucleotide, optionally in combination with at least one additional biologically active agent, such as an additional anti-HCV agent, and further in combination with a pharma- ceutical acceptable carrier additive and / or excipient to a host in need thereof.
[0165] In yet another aspect, the present invention provides a method for preventing HCV infection or associated or subsequent disease states, symptoms or complications, including, inter alia, cirrhosis of the liver and associated liver toxicity, weakness, loss of appetite, weight loss, breast enlargement (especially in men), rashes (especially on the palms of the hands), blood clotting problems, spider veins in the skin, confusion, coma (encephalopathy), accumulation of fluid in the abdominal cavity (ascites), esophageal varices, portal hypertension, kidney failure, splenomegaly, low blood counts, anemia, thrombocytopenia, jaundice, and hepatocellular (liver) cancer. In another embodiment, the present invention provides a method of preventing or preventing HCV infection in a patient at risk for hepatitis, the method comprising administering to the patient an effective amount of at least one compound according to the invention as described above in combination with a pharma- ceutically acceptable carrier, excipient or vehicle, and optionally in combination with another anti-HCV agent. In another embodiment, the active compounds of the present invention can be administered to a patient after liver transplantation in the setting of hepatitis to protect the new organ.
[0166] If desired, the 5'-stabilized β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N-acetylglucosamine salt can be administered to a recipient either directly or indirectly to provide the parent compound, or as any salt or prodrug which is active in itself. 6 -substituted purine nucleotides can be administered. Non-limiting examples are pharma- ceutically acceptable salts and compounds modified at functional groups, such as hydroxyl or amine functional groups, to modify the biological activity, pharmacokinetics, half-life, controlled delivery, lipophilicity, absorption rate, ease of phosphorylation to the active 5'-triphosphate, or efficiency of delivery using a desired route of administration of the compound. Methods for modifying the properties of active compounds to achieve targeted properties are known to those skilled in the art or can be readily determined by standard methods, such as acylation, phosphorylation, thiophosphoramidation, phosphoramidation, phosphonation, alkylation, or pegylation.
[0167] IV. Pharmaceutical Compositions In an embodiment of the invention, the pharmaceutical composition according to the invention comprises an anti-HCV virally effective amount of at least one 5'-stabilized β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N-amino-D-2'-α-fluoro-2'-β-C-substituted-2 ... 6 -Substituted purine nucleotide compounds.
[0168] In an embodiment of the invention, a pharmaceutical composition according to the invention comprises an anti-HCV effective amount of at least one active β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N-α-fluoro-2'-β-C-substituted-2-amino-N-methyl-2' ... 6 -Substituted purine nucleotide compounds.
[0169] The present invention provides a method for treating hepatitis C virus infection by administering to a patient a β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N 6 In an alternative embodiment, the present invention includes a pharmaceutical composition comprising one of the β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N-substituted purine nucleotide compounds of the present invention, or a salt or prodrug thereof, in a pharma- ceutical carrier or excipient. ... 6 The present invention also includes pharmaceutical compositions comprising one of the -substituted purine nucleotide compounds, or a salt or prodrug thereof, in a pharma- ceutically acceptable carrier or excipient.
[0170] Those skilled in the art will recognize that the therapeutically effective amount will vary depending on the infection or condition being treated, its severity, the treatment regimen employed, the pharmacokinetics of the drugs used, as well as the patient or subject (animal or human) being treated, and that such therapeutic amount can be determined by the attending physician or specialist.
[0171] The 5'-stabilized β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N 6The -substituted purine nucleotide compounds may be formulated in a mixture with a pharma- ceutically acceptable carrier. Generally, it is desirable to administer pharmaceutical compositions in oral dosage form, although certain formulations may be administered by other routes, including parenteral, intravenous, intramuscular, topical, transdermal, buccal, subcutaneous, suppository, and nasal spray. Intravenous and intramuscular formulations are often administered in sterile saline. Those skilled in the art may modify the formulation to make it more soluble in water or other vehicles, for example, by methods well within the ordinary skill in the art. This can be readily accomplished by some minor modification (salt formulation, esterification, etc.) and it is also within the routine skill of one of ordinary skill in the art to modify the route of administration and dosing regimen of a particular compound in order to tailor the pharmacokinetics of the compounds of the invention for maximum beneficial effect in the patient.
[0172] In certain pharmaceutical dosage forms, the prodrug forms of the compounds of the present invention are preferred, including in particular acylated (acetylated or otherwise) and ether (alkyl and related) derivatives, phosphate esters, thiophosphoramidates, phosphoramidates, and various salt forms of the compounds of the present invention.Those skilled in the art will recognize how to easily convert the compounds of the present invention into prodrug forms to facilitate the delivery of the active compound to the target site of the host organism or patient.When applicable, the favorable pharmacokinetic parameters of the prodrug forms are utilized in the delivery of the active compound to the target site of the host organism or patient to maximize the intended effect of the compounds.
[0173] The amount of compound contained in the therapeutically active formulation according to the present invention is an amount effective for treating HCV infection, reducing the likelihood of HCV infection, or inhibiting, reducing, and / or eliminating HCV, or its secondary effects, including disease states, conditions, and / or complications secondary to HCV. In general, the therapeutically effective amount of the compound of the present invention in a pharmaceutical dosage form is usually in the range of about 0.001 mg / kg to about 100 mg / kg or more per day to a patient, often slightly less than about 0.1 mg / kg to significantly more than about 25 mg / kg per day, depending on the compound used, the condition or infection being treated, and the route of administration. The active nucleoside compound according to the present invention is often administered to a patient in an amount ranging from about 0.1 mg / kg to about 15 mg / kg per day, depending on the pharmacokinetics of the drug in the patient. This dosage range generally results in an effective blood concentration of the active compound which may range from about 0.001 micrograms to about 100 micrograms, or from about 0.05 micrograms to about 100 micrograms per cc of the patient's blood.
[0174] Often, to treat, prevent, or delay the onset of these infections and / or to reduce the likelihood of HCV viral infection or secondary disease states, symptoms, or complications of HCV, the compositions are administered in an oral dosage form in an amount ranging from about 250 micrograms up to about 500 mg or more at least once daily, for example, at least 25 milligrams, 50 milligrams, 100 milligrams, 150 milligrams, 250 milligrams, or 500 milligrams up to four times daily. The compounds of the invention are often administered orally, but may also be administered parenterally, topically, or in suppository form, and intranasally as nasal drops or otherwise as described herein.
[0175] In the case of co-administration of a compound of the invention in combination with another anti-HCV compound as described elsewhere herein, the amount of the compound according to the invention administered is from about 0.01 mg / kg to a patient to substantially more than about 500 mg / kg to a patient, depending on the second agent co-administered, as well as the efficacy against the virus, the condition of the patient and the severity of the disease or infection being treated, and the route of administration. The other anti-HCV agent may be administered, for example, in an amount ranging from about 0.01 mg / kg to about 500 mg / kg. In certain preferred embodiments, these compounds may be administered in an amount ranging from about 0.5 mg / kg to about 50 mg / kg or more (usually up to about 100 mg / kg), often depending on the pharmacokinetics of the two agents in the patient. These dosage ranges generally provide effective blood levels of the active compound in the patient.
[0176] For purposes of this invention, a prophylactically or preventatively effective amount of a composition according to the invention falls within the same concentration ranges as set forth above for a therapeutically effective amount, and is usually the same as the therapeutically effective amount.
[0177] Administration of the active compound may range from continuous (intravenous infusion) to several oral or nasal infusions per day. Administration may include oral (e.g. QID), or transdermal administration, and may include oral, topical, parenteral, intramuscular, intravenous, subcutaneous, transdermal (which may include a penetration enhancer), buccal, and suppository administration, among other routes of administration. Enteric-coated oral tablets may also be used to enhance the bioavailability of the compound for oral routes of administration. The most effective dosage form will depend on the bioavailability / pharmacokinetics of the particular agent selected, as well as the severity of the patient's disease. Oral dosage forms are particularly preferred due to ease of administration and expected favorable patient compliance.
[0178] To prepare pharmaceutical compositions according to the invention, a therapeutically effective amount of one or more compounds according to the invention is often mixed essentially with a pharma- ceutically acceptable carrier according to conventional pharmaceutical compounding techniques to produce a dosage. The carrier may take a variety of forms, depending on the dosage form desired, for example, for oral or parenteral administration. In preparing pharmaceutical compositions into oral dosage forms, any of the usual pharmaceutical media may be used. Thus, for liquid oral preparations such as suspensions, elixirs and solutions, suitable carriers and additives may be used, including water, glycols, oils, alcohols, flavorings, preservatives, colorings, and the like. For solid oral preparations such as powders, tablets, capsules, and solid preparations such as suppositories, suitable carriers and additives may be used, including sugar carriers such as starch, dextrose, manifolds, lactose, and related carriers, diluents, granulating agents, lubricants, binders, disintegrants, and the like. If desired, the tablets or capsules may be enteric coated or sustained release by standard techniques. The use of these dosage forms may significantly enhance the bioavailability of the compound in the patient.
[0179] For parenteral formulations, the carrier will usually comprise sterile water or aqueous sodium chloride solution, but may contain other ingredients, including those that aid in dispersion. Where sterile water is to be used and maintained as sterile, the composition and carrier must, of course, also be sterilized. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be utilized.
[0180] Liposomal suspensions (including liposomes targeted to viral antigens) may also be prepared by conventional methods to produce pharma- ceutically acceptable carriers, which may be suitable for delivery of the free nucleoside, acyl / alkyl nucleoside, or phosphate ester prodrug forms of the nucleoside compounds according to the invention.
[0181] In an exemplary embodiment according to the invention, the compounds and compositions are used to treat, prevent, or delay HCV infection, or secondary disease states, symptoms, or complications of HCV.
[0182] V. Combination and Alternative Therapy It is well recognized that drug-resistant mutants of the virus may emerge after prolonged treatment with antiviral agents. Drug resistance most typically occurs through mutations in genes that code for enzymes used in viral replication. The efficacy of a drug against HCV infection may be extended, enhanced, or restored by administering the compound in combination with or alternating with another (perhaps even two or three other) antiviral compound that induces different mutations or acts through a different pathway than that of the principle drug. Alternatively, the pharmacokinetics, biodistribution, half-life, or other parameters of the drug may be altered by such combination therapy (which may include alternation therapy, if deemed coordinated). The disclosed β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N 6 -substituted purine nucleotides are NS5B polymerase inhibitors, and it may be useful to administer such compounds to a host in combination with, for example, the following: (1) Protease inhibitors (NS3 / 4A protease inhibitors, etc.), (2) NS5A inhibitor, (3) another NS5B polymerase inhibitor, (4) NS5B non-substrate inhibitors (5) interferon alpha-2a, which may be pegylated or otherwise modified, and / or ribavirin; (6) non-substrate inhibitors, (7) helicase inhibitors, (8) antisense oligodeoxynucleotide (S-ODN), (9) aptamer, (10) nuclease-resistant ribozymes, (11) iRNA, including microRNA and siRNA, (12) An antibody, partial antibody, or domain antibody against a virus, or (13) A viral antigen or partial antigen that induces a host antibody response.
[0183] The present invention relates to β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified 6 Non-limiting examples of anti-HCV agents that can be administered in combination with -substituted purine nucleotides are as follows: (i) protease inhibitors such as telaprevir (Incivec™), boceprevir (Victoris™), simeprevir (Olysio™), paritaprevir (ABT-450), ACH-2684, AZD-7295, BMS-791325, danoprevir, filibuster, GS-9256, GS-9451, MK-5172, setrobuvir, sovaprevir, tegobuvir, VX-135, VX-222 and AL-220; (ii) NS5A inhibitors such as ACH-2928, ACH-3102, IDX-719, daclatasvir, ledipasvir, and ombitasvir (ABT-267) (iii) NS5B inhibitors such as ACH-3422, AZD-7295, clemizole, ITX-5061, PPI-461, PPI-688, Sovaldi™, MK-3682 and mericitabine; (iv) NS5B inhibitors such as ABT-333 and MBX-700, and (v) Antibodies such as GS-6624.
[0184] β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N 6 When -substituted purine nucleotides are administered to treat severe hepatitis C virus infections that are linked to liver cancer or cirrhosis, in one embodiment, the method is similar to that described, for example, by Andrew Zhu in "New Agents on To treat hepatocellular carcinoma (HCC), as described in "The Horizon in Hepatocellular Carcinoma" Therapeutic Advances in Medical Oncology, V 5(1), (January 2013), 41-50. The above compounds can be administered in combination or alternation with another drug typically used in the treatment of HCC. Examples of compounds suitable for combination therapy when the host has or is at risk for HCC include antiangiogenic agents, sunitinib, brivanib, linifanib, ramucirumab, bevacizumab, cediranib, pazopanib, TSU-68, lenvatinib, antibodies against EGFR, mTor inhibitors, MEK inhibitors, and histone deacetylase inhibitors.
[0185] The currently approved drugs for influenza are amantadine, rimantadine and oseltamivir.Any of these drugs can be used in combination or alternation with the active compounds presented herein to treat viral infections that are susceptible to them.Ribavirin is used to treat measles, influenza A, influenza B, parainfluenza, severe RSV bronchiolitis and SARS, as well as other viral infections, and is therefore particularly useful in combination with the compounds of the present invention for treating hosts infected with single-stranded RNA viruses.Palivizumab is approved for use in infants at high risk for RSV infection.
[0186] There are currently no drugs approved for the treatment of West Nile virus. Physicians recommend hospitalization, intravenous fluids, and It is recommended to provide intensive supportive care, which may include the use of a ventilator to assist breathing, medications to manage seizures, brain swelling, nausea and vomiting, and antibiotics to prevent bacterial infections to prevent further deterioration of the disease. This highlights the importance of the compounds of the present invention to viral medical therapy.
[0187] VI. β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N 6 -The process of creating substituted purine nucleotides General methods for providing the compounds of the invention are known in the art or described herein. The synthesis of 2'-chloro nucleotides is described in US Patent Publication No. 20150366888, WO 2014058801, WO 2015 / 066370, and WO 2015200219.
[0188] The following abbreviations are used by the synthesis facility: CBr4: Carbon tetrabromide DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene DCM: dichloromethane THF: Tetrahydrofuran (THF), anhydrous EtOAc: ethyl acetate EtOH: Ethanol Li(OtBu)3AlH: Lithium tri-tert-butoxyaluminum hydride Na2SO4: Sodium sulfate (anhydrous) MeCN: Acetonitrile MeNH2: Methylamine MeOH: Methanol Na2SO4: Sodium sulfate NaHCO3: Sodium bicarbonate NH4Cl: Ammonium chloride NH4OH: Ammonium hydroxide PE: Petroleum ether Ph3P: Triphenylphosphine Silica gel (230~400 mesh, Sorbent) t-BuMgCl: t-Butyl magnesium chloride t-BuOK: Sodium tert-butoxide t-BuOH: tert-butanol EXAMPLES
[0189] general law 1 H, 19 F and 31P NMR spectra were recorded on a 300 MHz Fourier transform Bruker spectrometer. Spectra were obtained from samples prepared in 5 mm diameter tubes in CDCl3, CD3OD or DMSO-d6. Spin multiplicities are indicated by the symbols s (singlet), d (doublet), t (triplet), m (multiplet), and br (broad). Coupling constants (J) are reported in units of Hz. MS spectra were obtained using electrospray ionization (ESI) on an Agilent Technologies 6120 quadrupole MS instrument. The reactions were typically carried out in dry PBS using anhydrous solvents from Sigma-Aldrich. All common chemicals were purchased from commercial sources. [ka] i) Li(OtBu)3AlH, THF, -30°C → -15°C; ii) PPh3, CBr4, DCM, -20°C → 0°C; iii) 2-Amino-6-chloropurine, tBuOK, tBuOH / MeCN 9:1, 65°C; iv) MeNH2 (33%), MeOH, 85°C; v) Isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate, tBuMgCl, THF, 0°C → room temperature.
[0190] Example 1. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate
[0191] Step 1. Preparation of ((2R,3R,4R,5R)-3-(benzoyloxy)-5-bromo-4-fluoro-4-methyltetrahydrofuran-2-yl)methyl benzoate (2). To a solution of (2R)-3,5-di-O-benzoyl-2-fluoro-2-C-methyl-D-ribono-γ-lactone (24.8 g, 66.6 mmol) in dry THF (333 mL) was added dropwise under nitrogen atmosphere and cooled to −30° C. After the addition was complete, the reaction mixture was allowed to warm slowly to −15° C. over 90 min, after which EtOAc was added (300 mL) and the mixture was quenched with saturated aqueous NH4Cl (200 mL). The resulting solution was filtered over Celite™ and the filtrate was extracted twice with EtOAc. The combined organics were dried (Na2SO4), filtered, and concentrated. The residue was taken up in dry DCM (225 mL) under nitrogen atmosphere and cooled to -20 °C before adding PPh3 (19.1 g, 72.8 mmol). After stirring at -20 °C for 10 min, CBr4 (26.0 g, 78.4 mmol) was added and the reaction mixture was slowly warmed to 0 °C over 2 h. The resulting mixture was poured onto a silica gel column and eluted with PE / EtOAc (gradient from 100:0 to 80:20). Fractions containing α-bromofuranoside were collected and concentrated to give product 2 (18.1 g, 41.3 mmol, 62% over two steps) as a viscous colorless oil. 1 H NMR(300MHz,CDCl3)δ 8.15~8.11(m,2H), 8.04~8.01(m,2H), 7.64~7.55(m,2H), 7.51~7.41(m,4H), 6.34(d,J=1.6Hz,1H), 5.29(dd,J=5.5 ,3.1Hz,1H), 4.89~4.85(m,1H), 4.78(dd,J=12.5,3.2Hz,1H), 4.63(dd,J=12.5,4.5Hz,1H), 1.72(d,J=21.6Hz,3H). 19 F NMR(282MHz, CDCl3)δ -150.0.
[0192] Step 2. Preparation of (2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-(benzoyloxymethyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate (3). 2-Amino-6-chloropurine (2.63 g, 15.5 mmol) was suspended in t-BuOH (54 mL) under nitrogen atmosphere. The reaction mixture was heated to 30° C., and then potassium tert-butoxide (1.69 g, 15.1 mmol) was added. After 45 min, a solution of bromofuranoside 2 (2.24 g, 5.12 mmol) dissolved in anhydrous MeCN (6 mL) was added, and the reaction mixture was heated to 65° C. for 16 h, and then cooled to room temperature. Saturated aqueous NH4Cl (70 mL) was added, and the resulting solution was extracted with EtOAc (3×60 mL). The combined organics were dried (Na2SO4), filtered, and concentrated. The residue was purified twice by column chromatography (PE / EtOAc 80:20 to 0:100 followed by a gradient of 60:40 to 20:80) to give the product 3 (1.56 g, 2.96 mmol, 57%) as a white solid. 1 H NMR(300MHz,CDCl3)δ 8.05~8.02(m,2H), 7.95~7.92(m,2H), 7.88(s,1H), 7.63~7.57(m,1H), 7.53~7.41(m,3H), 7.35~7.30(m,2H), 6.43(dd,J=22.6,9.1Hz,1H), 6 .12(d,J=18.3Hz,1H), 5.34(brs,2H), 5.00(dd,J=11.9,4.5Hz,1H), 4.79~4.73(m,1H), 4.60(dd,J=11.9,5.3Hz,1H), 1.34(d,J=22.6Hz,3H). 19 F NMR(282MHz, CDCl3)δ -157.0. C 25 H 22 FN5O5[M+H] + MS(ESI) m / z calculated 526.9; found 527.0.
[0193] Step 3. Preparation of (2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol (4). To a solution of compound 3 (575 mg, 1.09 mmol) in MeOH (9 mL) was added methylamine (33% in absolute EtOH, 1.7 mL, 1.81 mmol). The reaction mixture was heated to 85° C. in a sealed tube for 16 h, cooled to room temperature and concentrated. The residue was purified by column chromatography (DCM / MeOH 100:0 to 85:15 gradient) followed by reverse phase column chromatography (HO / MeOH 100:0 to 0:100 gradient) to give product 4 (286 mg, 0.91 mmol, 84%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 8.06(s,1H), 6.11(d,J=18.1Hz,1H), 4.41(dd,J=24.4,9.1Hz,1H), 4.07~4.01 (m,2H), 3.86(dd,J=12.9,3.3Hz,1H), 3.04(brs,3H), 1.16(d,J=22.3Hz,3H). 19 F NMR(282MHz,CD3OD)δ -163.7. C 12 H 19 FN6O3[M+H] + MS (ESI) m / z calculated 313.1; found 313.2.
[0194] Step 4. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (5). To a solution of compound 4 (114 mg, 365 μmol) in dry THF (4 mL) was added t-butyl magnesium chloride (1.0 M in THF, 0.66 mL, 660 μmol) over 10 min under nitrogen atmosphere, cooled to 0° C. The reaction mixture was stirred at 0° C. for 15 min and then at room temperature for an additional 15 min. After cooling the reaction mixture to 0° C., a solution of isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate in dry THF (1 mL), Ross, BS, Reddy, PG, Zhang, HR, Rachak onda, S., and Sofia, MJ, J. Org. Chem., (2011), (253 mg, 558 μmol) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 30 min, then at room temperature for 18 h, after which it was quenched with saturated aqueous NH4Cl (4 mL) and extracted with EtOAc (3×5 mL). The combined organics were dried, filtered (Na2SO4), and concentrated. The residue was purified by column chromatography (DCM / MeOH 100:0 to 90:10 gradient) followed by reverse phase column chromatography (H2O / MeOH 100:0 to 0:100 gradient) to give product 5 (mixture of diastereomers, 101 mg, 174 μmol, 48%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 7.83(s,0.55H), 7.82(s,0.45H), 7.38~7.16(m,5H), 6.15(d,J=18.5Hz,0.45H), (d,J=18.8Hz,0.55H), 4.99~4.88(H2O and double, m, 1H), 4.65-4.36 (m, 3H), 4.25-4.17 (m, 1H), 3.97-3.85 (m, 1H), 3.05 (brs, 3H), 1.32-1.28 (m, 3H), 1.25-1.15 (m, 9H). 19 F NMR (282MHz, CD3OD) δ -162.8(s), -163.3(s). 31 PNMR(121MHz,CD3OD)δ 4.10(s), 3.99(s). C 24 H 34 FN7O7P[M+H] + MS(ESI) m / z calculated 582.2; found 582.2. [ka] i) Me2NH:HCl, DBU, MeOH, 85°C; v) isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate, tBuMgCl, THF, 0°C.
[0195] Example 2. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(dimethylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (7).
[0196] Step 1. Preparation of (2R,3R,4R,5R)-5-(2-amino-6-(dimethylamino)-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol (6). To a solution of compound 3 (500 mg, 0.95 mmol) from Example 1 in MeOH (6 mL) was added dimethylamine hydrochloride (783 mg, 9.6 mmol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (1.43 mL, 9.6 mmol). The reaction mixture was heated at 85° C. in a sealed tube for 6 h, cooled to room temperature and concentrated. The residue was purified by column chromatography (DCM / MeOH 100:0 to 85:15 gradient) followed by reverse phase column chromatography (HO / MeOH 100:0 to 0:100 gradient) to give product 6 (200 mg, 0.61 mmol, 64%) as a white solid. obtained. 1 H NMR(300MHz,CD3OD)δ 8.07(s,1H), 6.14(d,J=18.1Hz,1H), 4.41(dd,J=24.4,9.2Hz,1H), 4.08~4.02 (m,2H), 3.87(dd,J=12.8,2.9Hz,1H), 3.42(brs,6H), 1.16(d,J=22.0Hz,3H). 19 F NMR(282MHz,CD3OD)δ -163.8. C 13 H 20 FN6O3[M+H] + MS(ESI) m / z calculated 327.2; found 327.2.
[0197] Step 2. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(dimethylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (7). A solution of compound 6 (80 mg, 245 μmol) in dry THF (4 mL) was cooled to 0° C. under nitrogen atmosphere and tert-butyl magnesium chloride (1.0 M in THF, 0.64 mL, 640 μmol) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 15 min and then at room temperature for an additional 15 min. The reaction mixture was cooled to 0° C. and then a solution of isopropyl((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate (167 mg, 367 μmol) dissolved in dry THF (4 mL) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 30 min and at room temperature for 18 h. The reaction was quenched with saturated aqueous NH4Cl (4 mL) and extracted with EtOAc (3×5 mL). The combined organics were dried, filtered (Na2SO4), and concentrated. The residue was purified by column chromatography (DCM / MeOH 100:0 to 90:10 gradient) followed by reverse-phase column chromatography (HO / MeOH 100:0 to 0:100 gradient) to give the product 7 (mixture of diastereomers, 35 mg, 58 μmol, 24%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 7.83(s,0.5H), 7.82(s,0.5H), 7.34~7.16(m,5H), 6.15(d,J=18.7Hz,0.5H), 6.13(d,J=18.8Hz,0.5H), 4.99~4.85(overlaps with H2O, m ,1H), 4.65~4.26(m,3H), 4.27~4.12(m,1H), 3.99~3.81(m,1H), 3.42,3.41(2brs,6H), 1.36~1.25(m,3H), 1.24~1.11(m,9H). 19F NMR (282MHz, CD3OD) δ -162.7(s), -163.2(s). 31 PNMR(121MHz,CD3OD)δ 4.08(s), 4.00(s). C 25 H36 FN7O7P[M+H] + MS (ESI) m / z calculated 596.5; found 596.2. [ka] i) a) N-Methylcyclopropylamine hydrochloride, Et3N, MeOH, 100 °C; b) NH4OH, MeOH, 100 °C; ii) isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate, tBuMgCl, THF, 0 °C.
[0198] Example 3. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(N-methyl-cyclopropylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (9).
[0199] Step 1. Preparation of (2R,3R,4R,5R)-5-(2-amino-6-(N-methyl-cyclopropylamino)-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol (8). To a solution of compound 3 (600 mg, 1.14 mmol) in MeOH (10 mL) was added N-methylcyclopropylamine hydrochloride (366 mg, 3.40 mmol) and triethylamine (470 μL, 3.40 mmol). The reaction mixture was heated at 100° C. in a sealed tube for 15 h and cooled to room temperature. An aqueous solution of 30% NH4OH (4 mL) was added and the reaction mixture was heated at 100° C. in a sealed tube for 2 h, cooled and concentrated. The residue was purified by column chromatography (DCM / MeOH 100:0 to 90:10 gradient) to give product 8 (351 mg, 0.99 mmol, 87%) as a white solid. 1H NMR(300MHz,CD3OD)δ 8.13(s,1H), 6.15(d,J=18.0Hz,1H), 4.40(dd,J=24.3,9.0Hz,1H), 4.06~4.02(m,2H), 3.89~3.83(m ,1H), 3.32(m,3H), 3.18~3.11(m,1H), 1.16(d,J=22.2Hz,3H), 0.96~0.89(m,2H), 0.74~0.69(m,2H). 19 F NMR(282MHz,CD3OD)δ -163.8. C 15 H 22 FN6O3[M+H] + MS (ESI) m / z calculated 353.2; found 353.2.
[0200] Step 2. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(N-methyl-cyclopropylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (9). To a solution of compound 8 (200 mg, 0.57 mmol) in dry THF (15 mL) at 0° C., tert-butyl magnesium chloride (1.0 M in THF, 680 μL, 0.68 mmol) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 15 min and then at room temperature for an additional 15 min. The reaction mixture was cooled to 0° C. and a solution of isopropyl((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate (283 mg, 0.62 mmol) dissolved in dry THF (4 mL) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 30 min and at room temperature for 18 h. The reaction was quenched with saturated aqueous NH4Cl (4 mL) and extracted with EtOAc (3×5 mL). The combined organics were dried over Na2SO4 and concentrated. The residue was purified by column chromatography (DCM / MeOH 100:0 to 90:10 gradient) followed by reverse phase column chromatography (HO / MeOH 100:0 to 0:100 gradient) to give the product 9 (mixture of two diastereoisomers, 160 mg, 0.26 mmol, 45%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 7.85(m,1H), 7.38-7.16(m,5H), 6.18(d,J=18.6Hz) and 6.16(d,J=18.9Hz,1H), 4.95~4.90(overlaps with H2O, m,1H), 4.58~4.47(m,3H), 4.22~ 4.19(m,1H), 3.95~3.87(m,1H), 3.36~3.34(overlaps with MeOH, m,3H), 3.19~3.12(m,1H), 1.32~1.22(m,12H), 0.96~0.89(m,2H), 0.74~0.69 (m,2H). 31 PNMR(121MHz,CD3OD)δ 4.11(s), 4.02(s). C 27 H 38 FN7O7P[M+H] + MS (ESI) m / z calculated 622.2; found 622.2. [ka] i) 2,6-Dichloropurine, tBuOK, tBuOH / MeCN, 65°C; ii) MeNH2, MeOH, 130°C; iii) Isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate, tBuMgCl, THF, 0°C to room temperature
[0201] Example 4. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2,6-bis-methylamino-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (12).
[0202] Step 1. Preparation of (2R,3R,4R,5R)-5-(2,6-dichloro-9H-purin-9-yl)-2-(benzoyloxymethyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate (10). Compound 2,6-dichloropurine (1.30 g, 6.86 mmol) was suspended in t-BuOH (25 mL) under nitrogen atmosphere. Potassium tert-butoxide (778 mg, 6.92 mmol) was added in one portion and the reaction mixture was stirred at room temperature. After 1 h, a solution of bromofuranoside 2 (1.0 g, 2.29 mmol) dissolved in anhydrous MeCN (20 mL) was added and the reaction mixture was heated at 65 °C overnight and then cooled to room temperature. Saturated aqueous NH4Cl was added and the resulting solution was extracted with EtOAc (3 times). The combined organics were dried over Na2SO4 and concentrated. The residue was purified by column chromatography (PE / EtOAc The product was purified by elution with a gradient of 100:0 to 0:100 to give the product 10 (148 mg, 0.27 mmol, 12%) as a sticky solid. 1 H NMR(300MHz,CDCl3)δ 8.31(s,1H), 8.12~8.09(m,2H), 8.02~7.99(m,2H), 7.64~7.39(m,6H), 6.38(d,J=17) .2Hz,1H), 6.02(dd,J=21.2,8.9Hz,1H), 4.90~4.68(m,3H), 1.33(d,J=22.4Hz,3H). 19 F NMR(282MHz, CDCl3)δ -158.0. C 25 H 20 Cl2FN4O5[M+H] + MS (ESI) m / z calculated 546.4; found 546.3.
[0203] Step 2. Preparation of (2R,3R,4R,5R)-5-(2,6-bis-methylamino-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol (11). Compound 10 (148 mg, 0.27 mmol) was dissolved in methylamine (33% in EtOH, 3 The solution (100 mL) was heated in a sealed tube at 130° C. for 4 days, cooled to room temperature and concentrated. The residue was purified by column chromatography (DCM / MeOH 100:0 to 50:50 gradient) followed by reverse phase column chromatography (HO / MeOH 100:0 to 0:100 gradient) to give the product 11 (33 mg, 0.10 mmol, 37%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 8.00(s,1H), 6.12(d,J=18.5Hz,1H), 4.51(dd,J=24.4,9.5Hz,1H), 4.06~3.85(m,3H), 3.04(s,3H), 2.93(s,3H), 1.20(d,J=22.4Hz,3H). 19 F NMR(282MHz,CD3OD)δ -163.2. C 13 H 20 FN6O3[M+H] + MS(ESI) m / z calculated 327.2; found 327.2.
[0204] Step 3. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2,6-bis-methylamino-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (12). To a solution of compound 11 (55 mg, 0.17 mmol) in dry THF (2 mL) at 0° C. was added tert-butyl magnesium chloride (1 M in THF, 304 L, 0.30 mmol) dropwise over 10 min. The reaction mixture was stirred at 0° C. for 15 min and then at room temperature for an additional 15 min. The solution was cooled to 0° C. and a solution of isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate (115 mg, 0.25 mmol) dissolved in dry THF (1 mL) was added dropwise over 10 min. The mixture was allowed to warm slowly to room temperature and stirred for 4 days. The reaction was quenched with saturated aqueous NH4Cl and extracted with EtOAc (3×). The combined organics were dried over Na2SO4 and concentrated. The residue was purified by column chromatography (gradient of DCM / MeOH 100:0 to 50:50) to give the product 12 (mixture of diastereomers, 13 mg, 0.02 mmol, 13%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 7.78(s,1H), 7.35~7.12(m,5H), 6.13(d,J=19.1Hz,0.53H), 6.10(d,J=19.2Hz,0.47H), 4.99~4.78(overlaps with H2O, m,1 H), 4.72~4.46(m,3H), 4.24~4.15(m,1H), 3.79~3.92(m,1H), 3.02(brs,3H), 2.92(s+s,3H), 1.29~1.11(m,12H). 19 F NMR (282MHz, CD3OD) δ -162.0(s), -162.3(s). 31 PNMR(121MHz,CD3OD)δ 3.97(s), 3.89(s). C 25 H 36 FN7O7P[M+H] + MS (ESI) m / z calculated 596.6; found 596.2. [ka] i) TIPDSCl2, imidazole, DMF; ii) isobutyryl chloride, pyridine; iii) TBAF, THF; iv) isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate, tBuMgCl, THF, 0°C.
[0205] Example 5. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-isobutyramido-6-methylamino-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (16).
[0206] Step 1. Preparation of compound 13. To a solution of compound 4 (286 mg, 0.92 mmol) and imidazole (370 mg, 5.43 mmol) in dry DMF (6 mL) at 0° C. was added 1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (300 μL, 0.94 mmol). The reaction mixture was stirred at room temperature for 2 h, diluted with EtOAc (50 mL), and the suspension was washed with saturated aqueous NH4Cl and brine (40 mL each). The organics were dried over Na2SO4 and concentrated. The residue was purified by column chromatography (PE / EtOAc 7:3 to 3:7 gradient) to give product 13 (283 mg, 0.51 mmol, 56%) as a white solid. C 24 H 44 FN6O4Si2[M+H] + MS(ESI) m / z calculated 555.8; found 555.2.
[0207] Step 2. Preparation of compound 14. To a solution of compound 13 (200 mg, 0.36 mmol) in dry pyridine (3 mL) at 0° C., was added isobutyryl chloride (38 μL, 0.36 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction was quenched by adding water (500 μL). The mixture was concentrated and coevaporated with toluene (3×10 mL). The residue was purified by column chromatography (PE / EtOAc 1:0 to 1:1 gradient) to give product 14 (99 mg, 0.16 mmol, 44%) as a white solid. C 28 H 50 FN6O5Si2[M+H] + MS (ESI) m / z calculated 625.9; found 625.3.
[0208] Step 3: (2R,3R,4R,5R)-5-(2-isobutylamido-6-methylamino) Preparation of -9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol (15). To a solution of compound 14 (90 mg, 0.14 mmol) in dry THF (2 mL) was added tetrabutylammonium fluoride (1 M in THF, 38 μL, 0.38 mmol). The mixture was stirred at room temperature for 2 h and concentrated. The residue was purified by column chromatography (DCM / MeOH 10:0 to 9:1 gradient) followed by reverse phase column chromatography (HO / MeOH 100:0 to 0:100 gradient) to give product 15 (42 mg, 0.11 mmol, 77%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 8.31(s,1H), 6.29(d,J=17.9Hz,1H), 4.70~4.60(m,1H), 4.07~3.98(m,2H), 3. 89(dd,J=12.5,3.4Hz,1H), 3.10(brs,3H), 2.87(brs,1H), 1.23~1.16(m,9H). 19 F NMR(282MHz,CD3OD)δ -163.8. C 16 H 24 FN6O4[M+H] + MS(ESI) m / z calculated 383.4; found 383.2.
[0209] Step 4. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-isobutyramido-6-methylamino-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (16). To a solution of compound 15 (27 mg, 0.07 mmol) in dry THF (1 mL) at 0° C., t-butyl magnesium chloride (1.0 M in THF, 130 μL, 0.13 mmol) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 15 min and then at room temperature for an additional 15 min. The reaction mixture was cooled to 0° C. and a solution of isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate (50 mg, 0.11 mmol) dissolved in dry THF (1 mL) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 30 min and then at room temperature for 18 h, after which it was quenched with saturated aqueous NH4Cl (2 mL) and extracted with EtOAc (3×5 mL). The combined organics were dried over Na2SO4 and concentrated. The residue was purified by column chromatography (DCM / MeOH 100:0 to 95:5 gradient) followed by reverse-phase column chromatography (HO / MeOH 100:0 to 0:100 gradient) to give the product 16 (mixture of two diastereoisomers, 25 mg, 0.04 mmol, 54%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 8.05(s,1H), 7.33~7.13(m,5H), 6.27(d,J=18.6Hz) and 6.21(d,J=19.1Hz,1H), 5.10~4.95(m,1H), 4.93~4.78(overlapping with H2O, m ,1H), 4.60~4.42(m,2H), 4.26~4.18(m,1H), 3.90~3.80(m,1H), 3.09(brs,3H), 2.84~2.80(m,1H), 1.33~1.15(m,18H). 31 PNMR(121MHz,CD3OD)δ 3.69(s). 31 PNMR(121MHz,CD3OD)δ 4.11(s), 3.99(s). C 28 H40 FN7O8P[M+H] + MS (ESI) m / z calculated 652.6; found 652.3. [ka] i) N-Methylethylamine, MeOH, 100° C.; ii) Isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate, tBuMgCl, THF, 0° C.
[0210] Example 6. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(N-methyl-ethylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (18).
[0211] Step 1. Preparation of (2R,3R,4R,5R)-5-(2-amino-6-(N-methyl-ethylamino)-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol (17). To a solution of compound 3 (150 mg, 0.29 mmol) in MeOH (4 mL) was added N-methylethylamine (245 μL, 2.90 mmol). The reaction mixture was heated at 100° C. in a sealed tube for 15 h, cooled to room temperature and concentrated. The residue was purified by column chromatography (DCM / MeOH 100:0 to 90:10 gradient) to give product 31 (89 mg, 0.26 mmol, 89%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 8.06(s,1H), 6.13(d,J=18.0Hz,1H), 4.40(dd,J=24.9,8.7Hz,1H), 4.11~4.01(m,4H), 3.98~3.83(m,1H), 3.34(br.s,3H), 1.24~1.11(m,6H). 19 F NMR(282MHz,CD3OD)δ -163.7. C 14 H 22 FN6O3[M+H]+ MS(ESI) m / z calculated 341.2; found 341.2.
[0212] Step 2. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(N-methyl-ethylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (18). To a solution of compound 17 (30 mg, 0.09 mmol) in dry THF (2 mL) at 0° C., tert-butyl magnesium chloride (1.0 M in THF, 110 μL, 0.11 mmol) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 15 min and then at room temperature for an additional 15 min. The reaction mixture was cooled to 0° C. and a solution of isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate (48 mg, 0.11 mmol) dissolved in dry THF (1 mL) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 30 min and at room temperature for 18 h. The reaction was quenched with saturated aqueous NH4Cl (4 mL) and extracted with EtOAc (3×5 mL). The combined organics were washed with Na2SO The mixture was dried over 4 and concentrated. The residue was purified by column chromatography (DCM / MeOH 100:0 to 90:10 gradient) to give the product 18 (mixture of two diastereoisomers, 22 mg, 0.04 mmol, 40%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 7.69(m,1H), 7.26~7.04(m,5H), 6.05(d,J=18.6Hz) and 6.03(d,J=18.9Hz,1H), 4.86~4.79(overlapping with H2O, m ,1H), 4.50~4.32(m,3H), 4.12~4.06(m,1H), 3.96~3.79(m,3H), 3.25(br.s,3H), 1.24~1.02(m,15H). 31 PNMR(121MHz,CD3OD)δ 4.07(s), 4.00(s). C 26 H 38 FN7O7P[M+H] +MS(ESI) m / z calculated 609.3; found 609.2. [ka] i) N-Methylpropylamine, MeOH, 100° C.; ii) Isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate, tBuMgCl, THF, 0° C.
[0213] Example 7. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(N-methyl-propylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (20).
[0214] Step 1. Preparation of (2R,3R,4R,5R)-5-(2-amino-6-(N-methyl-propylamino)-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol (19). To a solution of compound 3 (150 mg, 0.29 mmol) in MeOH (4 mL) was added N-methylpropylamine (295 μL, 2.90 mmol). The reaction mixture was heated at 100° C. in a sealed tube for 15 h, cooled to room temperature and concentrated. The residue was purified by column chromatography (DCM / MeOH 100:0 to 90:10 gradient) followed by reverse phase column chromatography (HO / MeOH 100:0 to 0:100 gradient) to give product 19 (80 mg, 0.23 mmol, 78%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 8.04(s,1H), 6.13(d,J=18.3,1H), 4.40(dd,J=24.2,9.2Hz,1H), m,4.06~3.84( m,5H), 1.68(sept,J=7.5Hz,2H), 1.15(d,J=22.2Hz,3H), 0.93(t,J=7.5Hz,3H). 19 F NMR(282MHz,CD3OD)δ -163.8. C 15H 24 FN6O3[M+H] + MS(ESI) m / z calculated 355.2; found 355.2.
[0215] Step 2. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(N-methyl-propylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (20). To a solution of compound 19 (30 mg, 0.09 mmol) in dry THF (2 mL) at 0° C., tert-butyl magnesium chloride (1.0 M in THF, 110 μL, 0.11 mmol) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 15 min and then at room temperature for an additional 15 min. The reaction mixture was cooled to 0° C. and a solution of isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate (46 mg, 0.11 mmol) dissolved in dry THF (1 mL) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 30 min and at room temperature for 18 h. The reaction was quenched with saturated aqueous NH4Cl (4 mL) and extracted with EtOAc (3×5 mL). The combined organics were dried over Na2SO4 and concentrated. The residue was purified by column chromatography (gradient of DCM / MeOH 100:0 to 90:10) to give the product 20 (mixture of two diastereoisomers, 22 mg, 0.03 mmol, 33%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 7.78,7.77(s+s,1H), 7.37~7.13(m,5H), 6.15(d,J=18.6Hz) and 6.13(d,J=18.9Hz,1H), 4.97~4.89(overlaps with H2O, m,1H), 4.63~4.30(m,3H), 4. 22~4.14(m,1H), 4.02~3.84(m,2H), 1.74~1.63(3H,m), 1.32~1.27(m,3H), 1.23~1.13(m,9H), 0.94(t,J=7.4Hz) and 0.93(t,J=7.4Hz,3H). 31PNMR(121MHz,CD3OD)δ 4.05(s), 4.00(s). C 27 H 40 FN7O7P[M+H] + MS (ESI) m / z calculated 623.3; found 623.2. [ka] i) a) N-Methylcyclobutylamine hydrochloride, Et3N, MeOH, 100°C; b) NH4OH, MeOH, 100°C; ii) isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate, tBuMgCl, THF, 0°C.
[0216] Example 8. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(N-methyl-cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (22).
[0217] Step 1. Preparation of (2R,3R,4R,5R)-5-(2-amino-6-(N-methyl-cyclobutylamino)-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol (21). To a solution of compound 3 (150 mg, 0.29 mmol) in MeOH (4 mL) was added N-methylcyclobutylamine hydrochloride (105 mg, 0.90 mmol) and triethylamine (190 μL, 1.00 mmol). The reaction mixture was heated at 100° C. in a sealed tube for 15 h and cooled to room temperature. An aqueous solution of 30% NH4OH (1 mL) was added and the reaction mixture was heated at 100° C. in a sealed tube for 2 h, cooled and concentrated. The residue was purified by column chromatography (DCM / MeOH 100:0 to 90:10 gradient) to give product 21 (90 mg, 0.25 mmol, 86%) as a pale yellow solid. 1H NMR(300MHz,CD3OD)δ 8.09(s,1H), 6.14(d,J=18.0Hz,1H), 5.80~5.70(m,1H), 4.44~4.33(m,1H), 4.06~4.02(m,2H), 3.88~3.84(m,1H), 3.34(s,3H), 2.38~2.19(m,4H), 1.79~1.71(m,2H), 1.17(d,J=22.2Hz,3H). 19 F NMR(282MHz,CD3OD)δ -163.8. C 16 H 24 FN6O3[M+H] + MS(ESI) m / z calculated 367.2; found 367.2.
[0218] Step 2. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(N-methyl-cyclobutylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (22). To a solution of compound 21 (50 mg, 0.14 mmol) in dry THF (2 mL) at 0° C., tert-butyl magnesium chloride (1.0 M in THF, 210 μL, 0.21 mmol) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 15 min and then at room temperature for an additional 15 min. The reaction mixture was cooled to 0° C. and a solution of isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate (74 mg, 0.16 mmol) dissolved in dry THF (2 mL) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 30 min and at room temperature for 18 h. The reaction was quenched with saturated aqueous NH4Cl (4 mL) and extracted with EtOAc (3×5 mL). The combined organics were dried over Na2SO4 and concentrated. The residue was purified by column chromatography (DCM / MeOH 100:0 to 90:10 gradient) followed by reverse-phase column chromatography (HO / MeOH 100:0 to 0:100 gradient) to give the product 22 (mixture of two diastereoisomers, 24 mg, 0.04 mmol, 28%) as a white solid. 1H NMR(300MHz,CD3OD)δ 7.79(s,0.2H), 7.77(s,0.8H), 7.38~7.12(m,5H), 6.18(d,J=17.6Hz) and 6.16(d,J=17.5Hz,1H), 4.95~4.81(m,2H), 4.62~4.43( m,3H), 4.25~4.18(m,1H), 3.96~3.83(m,1H), 3.38(s) and 3.36(s,3H), 2.38~2.21(m,4H), 1.75~1.63(m,2H), 1.32~1.16(m,12H). 31 PNMR(121MHz,CD3OD)δ 4.04(s), 3.97(s). C 28 H 40 FN7O7P[M+H] + MS(ESI) m / z calculated 636.3; found 636.2.
[0219] Modification of the 2-amino moiety in active compounds Those skilled in the art can add substituents to the 2-aminopurine moiety by methods well known to those skilled in the art. One non-limiting process is provided here, and others can be readily adapted. ((2R,3R,4R,5R)-3-(benzoyloxy)-5-bromo-4-fluoro-4-methyltetrahydrofuran-2-yl)methyl benzoate can be prepared by the addition of 2,6-dichloropurine, a mixture of commercially available 2,6-dichloropurine, a base, and an organic solvent. and treating at elevated temperature to produce (2R,3R,4R,5R)-5-(2,6-dichloro-9H-purin-9-yl)-2-(benzoyloxymethyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate. In one embodiment, the base is potassium tert-butoxide. In one embodiment, the organic solvent mixture comprises tert-butanol and acetonitrile. The compound (2R,3R,4R,5R)-5-(2,6-dichloro-9H-purin-9-yl)-2-(benzoyloxymethyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate is treated with an amine, a base, and an organic solvent at ambient temperature to produce 2-chloro-N 6In one embodiment, the amine is methylamine. In one embodiment, the base is triethylamine. In one embodiment, the organic solvent is ethanol. Those skilled in the art will recognize that treatment with an amine and a base simultaneously removes the benzoate group of the nucleoside to produce a deprotected furanose moiety. The 2-chloro-N-substituted purine is then reacted at elevated temperatures of about 100° C. in a sealed tube. 6 The N-substituted purine of the present invention is treated with an amine and about an organic solvent. 2 ,N 6 In one embodiment, the amine is methylamine. In one embodiment, the organic solvent is ethanol. 2 ,N 6 A -disubstituted purine nucleoside can be treated with a base, isopropyl((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate, and an organic solvent at low temperature to produce a compound of Formula I-V. In one embodiment, the base is tert-butyl magnesium chloride. In one embodiment, the organic solvent is tetrahydrofuran.
[0220] Preparation of stereospecific phosphorus enantiomers Certain active compounds described herein have chiral phosphorus moieties. Any of the active compounds described herein can be provided as isolated phosphorus enantiomer forms, for example, at least 80%, 90%, 95% or 98% R or S enantiomers, using methods known to those skilled in the art. For example, there are many publications that describe methods of obtaining such compounds, including, but not limited to, column chromatography, as described in Example 17 below and in U.S. Patent Nos. 8,859,756, 8,642,756 and 8,333,309 to Ross, et al.
[0221] Example 9. Separation of stereoisomers of compound 5. The stereoisomers of compound 5 were separated on a Phenominex Luna column using the following conditions. Column: Phenominex Luna 5 micron C18(2) 250 x 10 mm Part number OOG-4252-BO Sample concentration: approximately 50 mg / ml in acetonitrile Injection volume: 50μl Mobile phase A: HPLC grade water Mobile phase B: HPLC grade acetonitrile Flow rate: 5ml / min UV: 283 nm gradient:
[0222] [Table 1] Run Time: 45 minutes Column temperature: 40℃
[0223] A semi-preparative chromatogram of the sample is shown in FIG.
[0224] The combined fractions were evaluated using an analytical column under the following conditions. Column: Phenominex Luna 5 micron C18(2) 250 x 2 mm Part Number OOG-4252-BO Injection volume: 10μl Mobile phase A: HPLC grade water Mobile phase B: HPLC grade acetonitrile Flow rate: 0.2ml / min UV: 283 nm gradient:
[0225] [Table 2] Run Time: 45 minutes Column temperature: 40℃
[0226] The combined fractions for each stereoisomer were evaporated to dryness using a rotovap with a bath temperature of 30° C. The resulting solid was dissolved in 1 ml of acetonitrile and diluted with 1 The mixture was transferred to a .7 ml microcentrifuge tube and the solvent was evaporated by vacuum centrifugation at 30°C.
[0227] The data for the final sample is as follows: 1. First eluting peak: Compound 5 No. 1 (5-1) (21.7 mg - 97.8% ee). 2. Second eluting peak: Compound 5 No. 2 (5-2) (13.2 mg - 95.9% ee).
[0228] The final weights of the first and second peaks should be approximately equal to their percentages in the original mixture. The corresponding percentages were 62.2% and 37.8%, respectively.
[0229] Stereospecific synthesis of compounds of formulas I-VII [ka]
[0230] Example 10. Preparation of (2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)-4-fluoro-4-methyltetrahydrofuran-3-ol (23).
[0231] Step 1. Preparation of (2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)-4-fluoro-4-methyltetrahydrofuran-3-ol (23). Compound (2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-(benzoyloxymethyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate, 3 (80 g, 140 mmol) was added to a solution of trimethylamine in methanol (7 M, 800 mL) and stirred at room temperature overnight. The mixture was concentrated and then purified by column chromatography (DCM:MeOH=100:1) to obtain (2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)-4-fluoro-4-methyl-tetrahydrofuran-3-ol (23) (40 g, 90%). [ka]
[0232] Example 11. Preparation of ((((S)-(2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate. [ka]
[0233] Step 1. Preparation of (2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-3-ol (4). To a solution of (2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)-4-fluoro-4-methyl-tetrahydrofuran-3-ol (2.0 g, 1.0 equiv.) in dioxane (15 mL) was added aqueous MeNH2 (5.0 equiv.). After stirring at room temperature overnight, TLC showed that the starting material was consumed. The mixture was concentrated and purified by column chromatography (DCM:MeOH=40:1 to 30:1) to give (2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-3-ol (1.6 g, 81.6%) as a white powder. [M+H] + =313.5 [ka]
[0234] Step 2. Preparation of ((((S)-(2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate. The compound (2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-3-ol (1.47 g, 1.0 equiv.) and PPAL-S (2.35 g, 1.1 equiv.) were dissolved in anhydrous THF (29 mL). After the mixture was cooled to -10°C, t-BuMgCl (5.8 mL, 1.7 M, 2.1 equiv.) was added slowly under a blanket of N2. After stirring at room temperature for 45 min, the mixture was quenched with saturated aqueous NH4Cl and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with water, brine (30 mL), dried over anhydrous Na2SO4 and concentrated. The crude product was purified by column chromatography (DCM:MeOH=50:1 to 20:1) to give (((S)-(2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (1.1 g, 40.3%) as a white powder. 1 H NMR(400MHz,CD3OD)δ 7.81(s,1H), 7.33~7.16(m,5H), 6.10(d,J=18.4Hz,1H), 4.90~4.84(m ,5H), 4.55~4.46(m,3H), 4.20~4.16(m,1H), 3.91~3.87(m,1H), 3.30(m,1H), 3.03(s,3H), 1.30~1.20(m,12H). [M+H] + =582.8. [ka]
[0235] Example 12. Preparation of isopropyl ((((S)-(2R,3R,4R,5R)-5-(2-amino-6-(dimethylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (25). [ka]
[0236] Step 1. Preparation of (2R,3R,4R,5R)-5-(2-amino-6-(dimethylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-3-ol. To a solution of (2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)-4-fluoro-4-methyl-tetrahydrofuran-3-ol (2.8 g, 8 mmol) in dioxane (20 mL) was added aqueous dimethylamine (5 mL). After stirring at room temperature for 3 h, TLC showed that the starting material was consumed. The mixture was concentrated and purified by column chromatography (DCM:MeOH=60:1) to give (2R,3R,4R,5R)-5-(2-amino-6-(dimethylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-3-ol (2.2 g). 1 H NMR(400MHz,CD3OD)δ 8.08(s,1H), 6.13(d,J=18.0Hz,1H), 4.43(dd,J=9.2,9.2Hz,1H), 4.06(d,J =10.8Hz,2H), 3.90(m,1H), 3.37(s,3H), 3.06(s,3H), 1.18(d,J=22Hz,3H). [ka]
[0237] Step 2. Preparation of isopropyl ((((S)-(2R,3R,4R,5R)-5-(2-amino-6-(dimethylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (25). The compound (2R,3R,4R,5R)-5-(2-amino-6-(dimethylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-3-ol (8 g, 1.0 equiv.) and PPAL-S (11.1 g, 1 equiv.) were dissolved in anhydrous THF (100 mL). The mixture was cooled to -5°C to 0°C, and t-BuMgCl (30.5 mL, 1.7 M, 2.1 equiv.) was added slowly under N2 atmosphere. After stirring at room temperature for 2 h, the mixture was quenched with saturated aqueous NH4Cl solution and extracted with EtOAc (3 x 70 mL). The combined organic layer was washed with water, brine (30 mL), dried over anhydrous Na2SO4, and concentrated. The crude product was purified by column chromatography (DCM:MeOH=50:1) to give isopropyl ((((S)-(2R,3R,4R,5R)-5-(2-amino-6-(dimethylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (9.5 g, 65%) as a white powder. 1 H NMR(400MHz,CD3OD)δ 7.81(s,1H), 7.35~7.19(m,5H), 6.15(d,J=18.8Hz,1H), 4.90(m,1H), 4.54~4.49(m,3H) , 4.22~4.19(m,1H), 3.90(m,1H), 3.43(s,3H), 1.32(d,J=7.2Hz,3H), 1.24~1.17(m,9H). 31 P NMR (160 MHz, CD3OD) δ 3.89. [ka]
[0238] Example 13. Preparation of isopropyl ((((R)-(2R,3R,4R,5R)-5-(2-amino-6-(dimethylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (26).
[0239] The compounds (2R,3R,4R,5R)-5-(2-amino-6-(dimethylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-3-ol (3 g, 1.0 equiv.) and PPAL-R (4.17 g, 1 equiv.) were dissolved in anhydrous THF (60 mL). The mixture was cooled to -5°C to 0°C, and t-BuMgCl (11.4 mL, 1.7 M, 2.1 equiv.) was added slowly under N2 atmosphere. After stirring at room temperature for 16 h, the mixture was quenched with saturated aqueous NH4Cl and EtOAc (50 mL). The mixture was extracted with 100 mL of ethyl acetate (3×). The combined organic layers were washed with water, brine (30 mL), dried over anhydrous Na2SO4, and concentrated. The crude product was purified by column chromatography (DCM:MeOH=50:1) to give isopropyl ((((R)-(2R,3R,4R,5R)-5-(2-amino-6-(dimethylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (2.2 g, 41%) as a white powder. 1 H NMR(400MHz,CD3OD)δ 7.8(s,1H), 7.35~7.29(m,5H), 6.18(d,J=18.8Hz,1H), 4.92(m,1H), 4.60(m,1H), 4. 51~4.23(m,3H), 3.90(m,1H), 3.44(s,6H), 1.29(d,J=6Hz,3H), 1.22~1.16(m,10H). 31 P NMR (160 MHz, CD3OD) δ 3.98. [ka]
[0240] Example 14. Preparation of isopropyl ((((S)-(2R,3R,4R,5R)-5-(2-amino-6-(methylcyclopropanamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate. [ka]
[0241] Step 1: Preparation of (2R,3R,4R,5R)-5-(2-amino-6-(methylcyclopropanamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-3-ol (8). K2CO3 (53 g, 500 mmol) was added to an aqueous solution of N-methylcyclopropanamine hydrochloride (100 mL). After stirring at room temperature for 10 min, a solution of (2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-(hydroxymethyl)-4-fluoro-4-methyl-tetrahydrofuran-3-ol (35 g, 109 mmol) in dioxane (300 mL) was added. The mixture was stirred at room temperature for 16 h. After stirring for 1 h, HPLC showed the reaction was complete. The mixture was concentrated and purified by column chromatography (DCM:MeOH=60:1) to give (2R,3R,4R,5R)-5-(2-amino-6-(methylcyclopropaneamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-3-ol (30 g, 82%). 1 H NMR(400MHz,CD3OD)δ 8.16(s,1H), 6.17(d,J=18.0Hz,1H), 4.41(dd,J=9.2,9.2Hz,1H), 4.06(m,2H), 3.90 (m,1H), 3.37(s,3H), 3.16(m,1H), 1.18(d,J=22.4Hz,3H), 0.94(m,2H), 0.74(m,2H). [M+H] + =353.2. [ka]
[0242] Step 2: Preparation of isopropyl ((((S)-(2R,3R,4R,5R)-5-(2-amino-6-(methylcyclopropanamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate. The compound (2R,3R,4R,5R)-5-(2-amino-6-(methylcyclopropanamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-3-ol (8 g, 1.0 equiv.) and PPAL-S (10.3 g, 1 equiv.) were dissolved in anhydrous THF (100 mL). After the mixture was cooled to -5°C to 0°C, t-BuMgCl (28 mL, 1.7 M, 2.1 equiv.) was added slowly under N2 atmosphere. The mixture was stirred at room temperature for 1 h, quenched with saturated aqueous NH4Cl solution, and extracted with EtOAc (3 x 70 mL). The combined organic layer was washed with water, brine (30 mL), dried over anhydrous Na2SO4, and concentrated. The crude product was purified by column chromatography (DCM:MeOH=100:1 to 50:1) to give isopropyl ((((S)-(2R,3R,4R,5R)-5-(2-amino-6-(methylcyclopropanamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate (9.5 g, 65%) as a white powder. 1 H NMR(400MHz,CD3OD)δ 7.86(s,1H), 7.35~7.19(m,5H), 6.17(d,J=19.2Hz,1H), 4.91(m,1H), 4.52(m,3H), 4.21(m,1H), 3 .93(m,1H), 3.35(s,3H), 3.16(m,1H), 2.0(s,1H), 1.26~1.16(m,12H), 0.93(m,2H), 0.73(m,2H). 31 P NMR(160MHz,CD3OD)δ 3.90 [ka]
[0243] Example 15. Preparation of isopropyl ((((R)-(2R,3R,4R,5R)-5-(2-amino-6-(methylcyclopropanamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate.
[0244] The compounds (2R,3R,4R,5R)-5-(2-amino-6-(methylcyclopropanamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-3-ol (3 g, 1.0 equiv.) and PPAL-R (2.8 g, 1 equiv.) were dissolved in anhydrous THF (60 mL). After the mixture was cooled to -5°C to 0°C, t-BuMgCl (7.6 mL, 1.7 M, 2.1 equiv.) was added slowly under N2. The mixture was then stirred at room temperature for 1 h, quenched with saturated aqueous NH4Cl solution, and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with water, brine (30 mL), dried over anhydrous Na2SO4, and concentrated. The crude product was purified by column chromatography (DCM:MeOH = 100:1 to 50:1) to give the product (3 g, 55%) as a white powder. 1 H NMR(400MHz,CD3OD)δ 7.81(s,1H), 7.30~7.25(m,5H), 6.16(d,J=24.8Hz,1H), 4.84(m,1H), 4.84~4.50(m,3H), 4.22~4.19(m, 1H), 3.88(m,1H), 3.33(s,3H), 3.14(m,1H), 2.0(s,1H), 1.28~1.13(m,12H), 0.92(m,2H), 0.90(m,2H). 31 P NMR (160 MHz, CD3OD) δ 3.99. [ka]
[0245] Example 16. Preparation of compound 32. [ka]
[0246] Step 1. Preparation of compound 29. To a solution of 6 (3.0 g, 1.0 equiv.) in pyridine (30 mL) was added TIPDSCl2 (4.35 g, 1.5 equiv.) at 0 °C. After stirring at room temperature for 4 h, TLC showed that the starting material was consumed. The mixture was diluted with EtOAc, washed with 1 M aqueous HCl, saturated aqueous NaHCO3, brine, dried over anhydrous Na2SO4, and concentrated to give 29 (6.3 g, 100%) as a yellow oil. [ka]
[0247] Step 2. Preparation of compound 30. To a mixture of compound 29 (800 mg, 1.0 equiv.), DMAP (16 mg, 0.1 equiv.), pyridine (1.6 mL) and DCM (10 mL) was added isobutyryl chloride (209 mg, 1.5 equiv.) at 0° C. After stirring at room temperature for 2 h, TLC showed that the starting material was consumed. The mixture was quenched with water, washed with 1M aqueous HCl, saturated aqueous NaHCO3, brine, dried over anhydrous Na2SO4 and concentrated. The crude product was purified by column chromatography to give product 30 (563 mg, 62.3%) as a white oil. 1 H NMR (400MHz, CDCl3) δ 7.98(s,1H), 787(s,1H), 6.20(d,J=16.0Hz,1H), 4.32~4.07(m,4H), 3.50(s,6H), 2.3(m,1H), 1.29~1.05(m,45H). [ka]
[0248] Step 3. Preparation of compound 31. To a mixture of 30 (560 mg, 1.0 equiv.) in THF (10 mL) was added Et3N·3HF (706 mg, 5 equiv.) and Et3N (890 mg, 10 equiv.) at room temperature. After stirring at room temperature for 1.5 h, TLC showed that the starting material was consumed. The mixture was concentrated and purified by column chromatography to give 31 (288 mg, 830 mL) as a white powder. %) was obtained. 1 H NMR (400MHz, CDCl3) δ 7.72(s,1H), 5.96(d,J=44.0Hz,1H), 5.22(m,1H), 4.13~3.99(m,4H), 3.42(s,6H), 2.83~2.63(m,2H), 1.29~1.17(m,9H). [ka]
[0249] Step 4. Preparation of compound 32. Compound 31 (280 mg, 1.0 equiv.) and PPAL-S (320 mg, 1 equiv.) were dissolved in anhydrous THF (10 mL). After the mixture was cooled to -5°C, t-BuMgCl (0.87 mL, 1.7 M, 2.1 equiv.) was added slowly under N2 atmosphere. The mixture was stirred at room temperature for 2 h, quenched with saturated aqueous NH4Cl solution, and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with water, brine (20 mL), dried over anhydrous Na2SO4, and concentrated. The crude product was purified by column chromatography to give the product (260 mg, 50%) as a white powder. 1 H NMR(400MHz,CD3OD)δ 7.98(s,1H), 7.25(m,5H), 6.23(d,J=18.8Hz,1H), 4.52(m,3H), 4.38(m, 1H), 3.81(m,1H), 3.75(m,1H), 3.48(s,6H), 2.81(m,1H), 1.32(m,18H). [M+H=666.9. [ka]
[0250] Example 17. Preparation of compound 35. [ka]
[0251] Step 1. Preparation of compound 33. To a mixture of 29 (2.0 g, 1.0 equiv), DMAP (0.04 g, 0.1 equiv), pyridine (4 mL) and DCM (20 mL) was added AcCl (0.414 g, 1.5 equiv) at 0 °C. After stirring at room temperature for 2 h, TLC showed that the starting material was consumed. The mixture was quenched with water, washed with 1 M aqueous HCl, saturated aqueous NaHCO3, then brine, dried over anhydrous Na2SO4 and concentrated. The crude product was purified by column chromatography to give product 33 (1.73 g, 80.8%) as a white oil. 1 H NMR(400MHz,CDCl3)δ 7.99(s,1H), 7.74(s,1H), 6.20(d,J=20.0Hz,1H), 4.33~4.11(m,4H), 3.50(s,6H), 2.63(s,3H), 2.3(m,1H), 1.26~1.05(m,29H). [M+H] + =611.9. [ka]
[0252] Step 2. Preparation of compound 34. To a mixture of 33 (1.58 g, 1.0 equiv.) in THF (20 mL) was added Et3N·3HF (2.1 g, 5 equiv.) and Et3N (2.6 g, 10 equiv.) at room temperature. After stirring at room temperature for 1.5 h, TLC showed that the starting material was consumed. The mixture was concentrated and purified by column chromatography to give 34 (782 mg, 82%) as a white powder. [M+H] + =369.6. [ka]
[0253] Step 3. Preparation of compound 35. Compound 34 (136 mg, 1.0 equiv.) and PPAL-S (184 mg, 1.1 equiv.) were dissolved in anhydrous THF (3 mL). The mixture was cooled to -5°C and then t-BuMgCl (0.5 mL, 1.7 M, 2.1 equiv.) was added slowly under N2 atmosphere. The mixture was stirred at room temperature for 30 min, quenched with saturated aqueous NH4Cl, and extracted with EtOAc (3 x 10 mL). The combined organic phase was washed with water, brine (20 mL), dried over anhydrous, and concentrated. The crude product was purified by column chromatography (DCM:MeOH = 50:1 to 20:1) to give phosphoramidate 35 (150 mg, 63.8%) as a white powder. 1 H NMR(400MHz,CD3OD)δ 7.81(s,1H), 7.35~7.16(m,5H), 6.10(d,J=18.4Hz,1H), 4.87(m,1H), 4.52~4 .46(m,3H), 4.21(m,1H), 3.91~3.87(m,1H), 3.03(s,3H), 1.30~1.13(m,12H). 31 P NMR (160 MHz, CD3OD) δ 3.84. 19 F NMR(376MHz,CD3OD)δ -162.79.
[0254] β-D-2'-deoxy-2'-α-fluoro-2'-β-ethynyl-N 6 Synthesis of -substituted 2,6-diaminopurine nucleotides [ka]
[0255] Example 18. β-D-2'-deoxy-2'-α-fluoro-2'-β-ethynyl-N 6 A general route to -substituted 2,6-diaminopurine nucleotides [ka]
[0256] Step 1. Preparation of compound 36. To a solution of 6-chloroguanosine (100 g, 332 mmol) in pyridine (400 mL), TPDSCl2 (110 mL, 1.05 equiv.) was added dropwise at -5°C to 5°C under N2 atmosphere. After stirring at that temperature for 2 h, TLC showed that the starting material was consumed. DCM (600 mL) was added, followed by TMSCl (85 mL, 2 equiv.) dropwise at 0°C to 5°C. After stirring at that temperature for 2 h, TLC showed that the intermediate was consumed.
[0257] Isobutyryl chloride was added dropwise at 0°C-5°C. After stirring at that temperature for 2 hours, TLC showed that the intermediate was consumed. Water was added and the contents were extracted with DCM. Then, The organic phase was washed with 0.5N HCl to remove pyridine. After the contents were washed to pH 5-6, pTSA·H2O (9.2 g, 484.5 mmol) was added at 0°C-5°C. After stirring at that temperature for 1 h, TLC showed that the intermediate was consumed. Water was then added and the organic phase was washed with water, saturated aqueous NaHCO3, and brine. After drying over Na2SO4, the solvent was removed in vacuum. The residue was then purified by column chromatography (PE / EA=100 to 10 / 1) to give the product (82 g, 40%) as a light yellow solid. 1 H NMR(400MHz,DMSO-d6)δ 10.88(s,1H), 8.55(s,1H), 5.91(d,J=1.6Hz,1H), 5.53(d,J=4.6Hz,1H), 4.72~4.58(m,2H), 4.16(dd,J=12.4,4.8Hz,1H), 4.00(ddd,J= 7.7,4.8,2.6Hz,1H), 3.93(dd,J=12.4,2.7Hz,1H), 2.78(h,J=6.9Hz,1H), 1.26~1.12(m,3H), 1.10(d,J=6.7Hz,6H), 1.09~0.88(m,24H). [ka]
[0258] Step 2. Preparation of compound 37. To a solution of 36 (10.0 g, 16.3 mmol) in DCM (100 mL) was added Dess-Martin periodinane at room temperature and the reaction was stirred for 12 h. TLC showed that the starting material was consumed. The reaction mixture was then diluted with DCM (200 mL) and washed with saturated aqueous Na2S2O3 and brine. The organic phase was then dried over Na2SO4 and concentrated to give crude 37 (12 g) as a light yellow solid. Crude 53 can be used directly in the next step without purification. [ka]
[0259] Step 3. Preparation of compound 38. To a solution of ethynyltrimethylsilane (18.6 mL, 142.7 mmol) in THF (240 mL) was added n-BuLi (46 mL, 2.5 M, 115.0 mmol) dropwise at -15°C to -20°C under N2 atmosphere. After stirring for 30 min, the reaction was cooled to -70°C and 37 (crude, 16.3 mmol) in THF (60 mL) was added at that temperature. The contents were then warmed to 0°C. TLC showed that the starting material was consumed. Saturated aqueous NH4Cl was added and the reaction was extracted three times with EA (100 mL). The organic phases were combined, washed with brine and then further dried over Na2SO4. After concentration in vacuum, the residue was purified by column chromatography (PE / EA=100→10 / 1) to give a light yellow solid (6 .0g, 52%) was obtained. [ka]
[0260] Step 4. Preparation of compound 39. To a solution of 38 (6.0 g, 8.4 mmol) in DCM (240 mL) was added pyridine (4.2 mL, 52.9 mmol) under N2 atmosphere. The reaction was cooled to -70 °C and DAST (12 mL, 90.4 mmol) was added. The contents were then warmed to -30 °C. TLC showed that the starting material was consumed. The reaction was poured into saturated aqueous NaHCO3 and then extracted with DCM (200 mL). The organic phase was washed with brine and dried over Na2SO4. After concentration in vacuum, the residue was purified by column chromatography (PE / EA = 100 → 10 / 1) to give a light yellow solid (3.8 g, 63%). [ka]
[0261] Step 5. Preparation of compound 40. To a solution of 39 (3.8 g, 5.3 mmol) in THF (120 mL) was added AcOH (1.3 g, 22 mmol) and TBAF (4.2 g, 15.9 mmol) at room temperature. The reaction was stirred at room temperature for 30 min. TLC showed that the starting material was consumed. After concentration in vacuo, the residue was purified by column chromatography (EA) to give the product (2.0 g, 95%) as a white solid. [ka]
[0262] General procedure for amino substitution and deprotection: A solution of 40 (350 mg, 0.88 mmol) in dioxane (20 mL) was added at room temperature to methanol or an aqueous solution of the corresponding amine (free base or salt as hydrochloride and DIEA ) was added. The contents were stirred at room temperature for 1-12 hours. TLC showed that the starting material was consumed. After concentrating in vacuum, the residue was used directly in the next step without purification. The above mentioned residue was dissolved in methanol (10 mL). NaOH aqueous solution (2.5N, 10 mL) was added. After stirring at room temperature overnight, TLC showed that the starting material was consumed. The pH of the contents was adjusted to 7-8 with 1N HCl. The solution was concentrated and purified by column chromatography (DCM / MeOH=100→20 / 1) to give the products as off-white solids (yield: 40%-80% for two steps). Table 1 shows the structures of Compounds 57-63, and the corresponding mass spectra and the NMR spectrum for each compound. 1 H NMR is shown.
[0263] [Table 3]
[0264] Example 19. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-dimethylamino-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-ethynyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate [ka] i) Isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate, tBuMgCl, THF, 0° C.
[0265] Step 1. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-dimethylamino-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-ethynyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate. To a solution of compound 41 (30 mg, 0.09 mmol) in dry THF (2 mL) at 0° C. was added tert-butyl magnesium chloride (1.0 M in THF, 125 μL, 0.13 mmol) dropwise over 10 min. The reaction mixture was stirred at 0° C. for 15 min and then at room temperature for an additional 15 min. The reaction mixture was cooled to 0° C. and a solution of isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate (49 mg, 0.11 mmol) dissolved in dry THF (2 mL) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 30 min and at room temperature for 18 h. The reaction was quenched with saturated aqueous NH4Cl (4 mL) and extracted with EtOAc (3×5 mL). The combined organics were dried over Na2SO4 and concentrated. The residue was purified by column chromatography (gradient DCM / MeOH 100:0 to 90:10) to give the product (mixture of two diastereoisomers, 12 mg, 0.02 mmol, 24%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 7.79(s,0.45H), 7.77(s,0.55H), 7.36~7.14(m,5H), 6.28(d,J=17.4Hz) and 6.26(d,J=17.5Hz,1H), 5.00~4.44(m ,5H), 4.23~4.16(m,1H), 3.69~3.81(m,1H), 3.42(bs,3H), 3.40(bs,3H), 1.32~1.26(m,3H), 1.20~1.15(m,6H). 31 P NMR (121MHz, CD3OD) δ 4.04(s), 3.98(s). C 26 H 34 FN7O7P[M+H] + MS(ESI) m / z calculated 606.2; found 606.2.
[0266] Example 20. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-methylamino-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-ethynyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate. [ka] i) Isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate, tBuMgCl, THF, 0° C.
[0267] Step 1. Isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-aminopropyl) Preparation of 6-methylamino-9H-purin-9-yl-4-fluoro-3-hydroxy-4-ethynyltetrahydrofuran-2-yl)methoxy-phenoxy-phosphoryl-L-alaninate. To a solution of compound 42 (30 mg, 0.09 mmol) in dry THF (2 mL) at 0° C. was added tert-butyl magnesium chloride (1.0 M in THF, 125 μL, 0.13 mmol) dropwise over 10 min. The reaction mixture was stirred at 0° C. for 15 min and then at room temperature for an additional 15 min. The reaction mixture was cooled to 0° C. and a solution of isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate (49 mg, 0.11 mmol) dissolved in dry THF (2 mL) was added dropwise over 10 min. The reaction mixture was stirred at 0° C. for 30 min and at room temperature for 18 h. The reaction was quenched with saturated aqueous NH4Cl (4 mL) and extracted with EtOAc (3×5 mL). The combined organics were dried over Na2SO4 and concentrated. The residue was purified by column chromatography (gradient DCM / MeOH 100:0 to 90:10) to give the product (mixture of two diastereoisomers, 9 mg, 0.02 mmol, 18%) as a white solid. 1 H NMR(300MHz,CD3OD)δ 7.81,7.79(0.9s+0.1s,1H), 7.36~7.14(m,5H), 6.26(d,J=17.4Hz,0.1H) and 6.24(d,J=17.4Hz,0.9H), 4.93~4.89(overlapping with H2O, m,1H), 4.80~4.78(m,1H), 4.53~4.49(m,2H), 4.21~4.18(m,1H), 3.95~3.84(m,1H), 3.23~3.20(m,1H), 3.04(bs,1H), 1.31~1.14(m,9H).31 P NMR (121MHz, CD3OD) δ 4.06(s), 3.97(s). C 25 H 32 FN7O7P[M+H] + MS (ESI) m / z calculated 592.2; found 592.2.
[0268] Example 21. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(N-methylcyclopropylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-ethynyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate [ka] i) Isopropyl ((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate, tBuMgCl, THF, 0° C.
[0269] Step 1. Preparation of isopropyl ((((R,S)-(2R,3R,4R,5R)-5-(2-amino-6-(N-methylcyclopropylamino)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-ethynyltetrahydrofuran-2-yl)methoxy)-phenoxy-phosphoryl)-L-alaninate. To a solution of compound 43 (40 mg, 0.11 mmol) in dry THF (2 mL) at 0° C. was added tert-butyl magnesium chloride (1.0 M in THF, 160 μL, 0.16 mmol) dropwise over 10 min. The reaction mixture was stirred at 0° C. for 15 min and then at room temperature for an additional 15 min. The reaction mixture was cooled to 0° C. and a solution of isopropyl((R,S)-(pentafluorophenoxy)-phenoxy-phosphoryl)-L-alaninate (55 mg, 0.12 mmol) dissolved in dry THF (2 mL) was added dropwise over 10 min. The reaction mixture The mixture was stirred at 0° C. for 30 min and at room temperature for 18 h. The reaction was quenched with saturated aqueous NH4Cl (4 mL) and extracted with EtOAc (3×5 mL). The combined organics were dried over Na2SO4 and concentrated. The residue was purified by column chromatography (gradient DCM / MeOH 100:0 to 90:10) to give the product (mixture of two diastereoisomers, 18 mg, 0.03 mmol, 26%) as a white solid. 1 H NMR (300MHz, CD3OD) δ 7.84,7.82(s+s,1H), 7.35~7.14(m,5H), 6.30(d,J=17.4Hz) and 6.26(d,J=1 7.6Hz, 1H), 4.99~4.89 (overlaps with H2O, m, 1H), 4.82~4.69 (m, 1H), 4.59~4.46 (m, 2) H), 4.21(m,1H), 3.96~3.82(m,1H), 3.24~3.22(m,1H), 3.17~3.11(m,1H)1 .31~1.26(m,3H), 1.20~1.15(m,6H), 0.93~0.89(m,2H), 0.75~0.68(m,2H). 31 P NMR (121MHz, CD3OD) δ 4.06(s), 3.98(s). C 28 H 36 FN7O7P[M+H] + MS (ESI) m / z calculated 632.2; found 632.2.
[0270] Example 22. Preparation of PPAL-S [ka]
[0271] Step 1. Preparation of racemic PPAL To a stirred solution of phenyl dichlorophosphate (250 g) in EtOAc (800 mL) at -10°C was added isopropyl L-alaninate (200 g) in triethylamine (120 g). The reaction was stirred at -10°C for 1 h. Compound 2,3,4,5,6-pentafluorophenol (220 g) in triethylamine (120 g) and EtOAc (400 mL) was added at -5°C and stirred at that temperature for 0.5 h. The reaction mixture was warmed to 25°C and stirred at room temperature for 2 h. The solution was filtered, washed with EtOAc (2 x 200 mL) and the combined organic phase was evaporated under vacuum to give solid PPAL-RS (racemic).
[0272] Step 2. Preparation of PPAL-RS To a stirred solution of PPAL-RS in EtOAc (200 mL) and n-heptane (1.4 L) was added 2,3,4,5,6-pentafluorophenol (10.1 g) in triethylamine (6 g) and stirring was continued for about 4 to 8 hours. After the solid was less than 0.5% R isomer, the solid was filtered. The solid was dissolved in EtOAc (4 L), washed with water (2 x 100 mL), brine (1 L), dried over anhydrous Na2SO4, and filtered. The solvent was removed under vacuum to give PPAL-S (350 g). 1 H NMR(400MHz,DMSO-d6)δ=7.42~7.40(m,2H), 7.24~7.22(m,3H), 6.87(dd,J=14.1,9.9Hz,1H), 4. 90~4.84(m,1H), 3.94~3.88(m,1H), 1.27(dd,J=7.1,1.1Hz,3H), 1.15(dd,J=6.2,1.2Hz,6H)ppm. 13 P NMR (160MHz, DMSO-d6) δ=0.37ppm.
[0273] Example 23. Preparation of PPAL-R [ka]
[0274] Phenyl dichlorophosphate (189.6 g, 0.90 mol) and anhydrous EtOAc (750 mL) were added to a three-necked round bottom flask equipped with a mechanical stirrer. The solution was cooled to -10 °C under nitrogen atmosphere. Isopropyl L-alaninate (118 g, 0.90 mmol) and triethylamine (100 g, 1.1 equiv.) were added to the above solution. A pre-cooled (<10 °C) mixture of 2,3,4,5,6-pentafluorophenol (165 g, 1 equiv.) and triethylamine (90.5 g, 1 equiv.) in EtOAc (300 mL) was added to the above mixture at -5 °C via an addition funnel and the resulting mixture was stirred between 20 °C and 25 °C for 1 h. The white precipitate (TEA·HCl) was filtered off and rinsed with EtOAc. The filtrate was concentrated under reduced pressure to give about 280 g of PPAL-RS (S / R=1 / 1) as a white solid. PPAL-RS (280 g) was triturated in 300 mL of heptane / EtOAc (20:1) at room temperature for 5 min. The white suspension was filtered and the solid was rinsed with a mixture of heptane / EtOAc (20:1). The filtrate was cooled to 8° C. and the solid was collected by filtration. Crude PPAL-R (10 g) was obtained with a chiral purity of 95%. The crude product was purified according to the above steps. PPAL-R (5 g) was obtained with a chiral purity of NLT 98%. 1 H NMR(400MHz,DMSO-d6)δ=7.43~7.39(m,2H), 7.27~7.22(m,3H), 6.87(dd,J=14.1,9.9Hz,1H), 4 .89~4.85(m,1H), 3.95~3.90(m,1H), 1.27(dd,J=7.1,1.1Hz,3H), 1.14(dd,J=6.2,1.2Hz,6H). 13 P NMR (160MHz, DMSO-d6) δ=0.35.
[0275] Example 24: Preparation of compound 52. [ka]
[0276] Step 1. Preparation of compound 49. To a solution of 48 (1.81 g, 3.23 mmol) in dioxane (18 mL) was added 40% aqueous CH3NH2 (16.2 mmol). The reaction was stirred at 40 °C for 2 h. The mixture was concentrated, diluted with EtOAc (50 mL), washed with water and brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated to give 49 (1.66 g, 92%) as a white solid. [ka]
[0277] Step 2. Preparation of compound 50. To a solution of 49 (1.34 g, 2.42 mmol) and 1-methylimidazole (794 mg, 9.68 mmol) in DCM (14 mL) was added pentyl chloroformate (547 mg, 3.63 mmol) slowly at 0 °C. The reaction was stirred at room temperature overnight. The mixture was concentrated and purified by column chromatography (PE:EtOAc = 5:1 to 2:1) to give 50 (1.01 g, 62%) as a white solid. 1 H NMR(400MHz,DMSO)δ 7.96(s,1H), 6.73(s,1H), 6.06~6.10(d,J=16.0Hz,1H), 4.09~4.30(m,2H), 3.97~4 .09(m,4H), 3.28(s,3H), 1.39~1.46(m,2H), 1.0~1.2(m,35H), 0.73~0.76(t,J=8.0H z,3H). [ka]
[0278] Step 3. Preparation of compound 51. To a solution of 50 (1.00 g, 1.5 mmol) in THF (11 mL) was added Et3N (2.0 mL, 15 mmol) and Et3N.3HF (1.21 g, 7.5 mmol) at 0 °C. The reaction was stirred at room temperature for 1.5 h. The mixture was concentrated and purified by column chromatography (MeOH:CH2Cl2 = 50:1) to give 75 (460 mg, 72.2%) as a white powder. [ka]
[0279] Step 4. Preparation of compound 52. To a solution of 51 (460 mg, 1.08 mmol) and PPAL-S (538 mg, 1.19 mmol) in anhydrous THF (9 mL) was added t-BuMgCl (2.27 mmol) slowly at 5°C-10°C under N2. The reaction was stirred at room temperature for 40 min. The mixture was quenched with saturated aqueous NH4Cl, extracted with EtOAc, washed with 5% aqueous K2CO3 and brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by column chromatography (CH2Cl2:MeOH=15:1) to give 52 (280 mg, 37.3%) as a white powder. 1 H NMR(400MHz,DMSO)δ 8.12(s,1H), 7.34~7.38(m,2H), 7.18~7.23(m,3H), 6.74(s,2H), 6.11~ 6.16(d,J=16.0Hz,1H), 5.99~6.05(m,1H), 5.84(m,1H), 4.77~4.81(m, 1H), 4.30~4.41(m,3H), 4.03~4.11(m,3H), 3.78~3.80(m,1H), 3.3(s,3 H), 1.44~1.51(m,2H), 1.00~1.21(m,16H), 0.76~0.80(t,J=8.0Hz,3H). [M+H] + =696.6.
[0280] Example 25: Preparation of compound 56. [ka]
[0281] Step 1. Preparation of compound 48. To a solution of 23 (600 mg, 1 equiv.) in pyridine (30 mL) was added TIPDSCl2 (1.5 equiv.) at 0° C. The resulting solution was left at room temperature for 2 h. The mixture was quenched with ice water and extracted with EtOAc. The organic layer was washed with 1 M aqueous HCl, saturated aqueous sodium bicarbonate, and saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, and concentrated to give the crude residue. The residue was purified by chromatography (MeOH:CH2Cl2=1:50) to give 48 (998 mg, 94.4%) as a white solid foam. [ka]
[0282] Step 2. Preparation of compound 53. A mixture of 48 (800 mg, 1 equiv.), pyridine (3.2 mL), and DMAP (34.9 mg, 0.2 equiv.) in DCM (20 mL) was stirred at room temperature. N-Amyl chloroformate (3.2 mL) was added dropwise at 0° C., and the mixture was stirred at room temperature for 1 day. The organic layer was washed with 1 M aqueous HCl, saturated aqueous sodium bicarbonate, and saturated aqueous sodium chloride, and then with anhydrous sodium sulfate. The residue was purified by chromatography on silica gel (MeOH:CH2Cl2=1:50) to give 53 (255 mg, 26%) as a white solid foam. [ka]
[0283] Step 3. Preparation of compound 54. To a solution of 53 (270 mg, 1 equiv.) in 1,4-dioxane (10 mL) was added dropwise 40% aqueous CH3NH2 (225.7 mg, 5 equiv.). The mixture was stirred at room temperature for 2 h and then concentrated in vacuo. The residue was chromatographed on silica gel (methanol:dichloromethane=1:40) to give 54 (220 mg, 81.7%) as a white solid foam. [ka]
[0284] Step 4. Preparation of compound 55. Triethylamine (1011.9 mg, 10 equiv.) and Et3N·3HF (806.05 mg, 5 equiv.) were added to an ice-cold solution of 54 (668 mg, 1 equiv.) in THF (10 mL) and the mixture was stirred at room temperature for 2 h. The mixture was concentrated and chromatographed on silica gel (MeOH:CH2Cl2=1:30) to give 55 (492 mg, 84%) as a white solid foam. [ka]
[0285] Step 5. Preparation of compound 56. To a mixture of 55 (113 mg, 1 equiv.) and PPAL-S (120 mg, 1 equiv.) in THF (4 mL) was added 1.7 M t-BuMgCl in THF (0.327 mL, 2.1 equiv.) dropwise at -10 °C. The mixture was stirred at room temperature for 1 h and then quenched with saturated aqueous NH4Cl. The aqueous phase was extracted with EtOAc and the organic phase was washed with brine, dried and concentrated to give the crude residue. The residue was subjected to flash chromatography to give 56 (126 mg, 68.5%) as a white solid. 1 H NMR(400MHz,DMSO)δ 8.00(s,1H), 7.10~7.45(m,5H), 6.15~6.20(d,J=20.0Hz,1H), 5.00~5.25(s,1H), 4.80~4.86(m,1H), 4.45~4.70(m,2H), 4.12~4.19(m,3H), 3.80~3.85(m,1H), 3.04(s,3H), 1.60~1.75(m,2H), 1.10~1.40(m,16H), 0.76~0.80(t,J=8.0Hz,3H). 31 P NMR(160MHz,DMSO)δ 3.57.[M+H] + =696.5.
[0286] Example 26: Preparation of compound 60. [ka] JPEG2024160265000174.jpg42169
[0287] Step 1. Preparation of compound 57. To a solution of 6 (20 g, 1 equiv.) in CH3CN (100 mL) was added, successively, imidazole (16.6 g), TIPDSCl2 (28.9 g, 1.5 equiv.) at 5±5°C. The resulting solution was allowed to stand at room temperature for 4 h. The mixture was quenched with ice water and extracted with EtOAc. The organic layer was washed with water, saturated aqueous sodium bicarbonate, saturated aqueous sodium chloride, dried over anhydrous sodium sulfate, and concentrated to give a crude residue (32 g). [ka]
[0288] Step 2. Preparation of compound 58. To a solution of 57 (9.8 g, 1 equiv.) in THF (4 mL) was added THF (50 mL, 4.8 equiv. 1.7 M t-BuMgCl in 58 (1.05 equiv.) was added dropwise at 0°C-5°C. The mixture was stirred at room temperature for 0.5 h and n-amyl chloroformate (2.7 g, 1.05 equiv.) was added slowly. The mixture was stirred at 0°C-5°C for 3-4 h. The mixture was quenched with saturated aqueous NH4Cl. The aqueous phase was extracted with EtOAc (200 mL) and the organic phase was washed with brine, dried and concentrated to give 58 (10.7 g) as an oil. [ka]
[0289] Step 3. Preparation of compound 59. Triethylamine (10.119 g) and Et3N·3HF (8.6 g, 5 equiv.) were added to an ice-cold solution of 58 (7.3 g, 1 equiv.) in THF (100 mL) and the mixture was stirred at room temperature for 1 h. The mixture was concentrated and chromatographed on silica gel (MeOH:CH2Cl2=1:30) to give 59 (4.3 g, 91%) as a white solid. [ka]
[0290] Step 4. Preparation of compound 60. To a mixture of 59 (2 g, 1 equiv.) and PPAL-S (2.3 g, 1.1 equiv.) in THF (40 mL) was added 1.7 M t-BuMgCl in THF (5.6 mL, 2.1 equiv.) dropwise at −5° C. The mixture was stirred at −20±5° C. for 1 h and then quenched with saturated aqueous NH4Cl. The aqueous phase was extracted with EtOAc and the organic phase was washed with brine, dried and concentrated to give the crude residue. The residue was subjected to flash chromatography to give 60 (1.5 g, 47%) as a white solid. 1 H NMR(400MHz,CD3OD)δ 7.9(s,1H), 7.1~7.2(m,5H), 6.2(d,J=20Hz,1H), 5.1(br,1H), 4.84(m,1H), 4.49(m,,2H), 4.16(m,1H), 4 .13(m,2H), 3.86(m,1H), 3.45(br,6H), 1.70(m,2H), 1.26(m,4H), 1.20(m,6H), 1.14(m,6H), 0.93(m,3H). [M+H] + =710.5.
[0291] Biological Data Example 27. Assay Methodology and Additional Biological Data Antiviral efficacy (EC 50 ) and cytotoxicity (TC 50 For parallel determination of HCV genotype 1b expression, Huh-7 luc / neo ET cells carrying a dicistronic HCV genotype 1b luciferase reporter replicon were plated at 7.5 × 10 3 Plates were incubated for 24 hours prior to compound addition. Six consecutive doses of the test substance were A 3.2-fold (one half log) dilution series (high test concentration of 100.0 μM or high test concentration of 1.0 μM) and human interferon-alpha 2b (high test 10.0 U / ml) were prepared in cell culture medium and added to the cells cultured in triplicate wells for each dilution. Six wells in the test plate received medium alone as untreated controls. After 72 hours of culture in the presence of compounds, one plate was used for determination of cytotoxicity by staining with XTT and the other for antiviral potency by determination of luciferase reporter activity. TC 50 and E.C. 50 Cytotoxicity and efficacy data were collected and imported into a customized Excel workbook to determine the EC value. The data for the compounds of Formula I to Formula VII are shown in Table 7 below. Additionally, Figure 2 shows the HCV replication inhibition curves for compound 5-2 and sofosbuvir. As can be seen from Figure 2, compound 5-2 had an EC 50 = 4nM, whereas sovosbuvir has an EC 50 = 53 nM. The y-axis is the percentage of virus control and the x-axis is the concentration of drug in μM. Figure 3 shows the HCV replication inhibition curves for Compound 25 and Sofosbuvir. Compound 25 has an EC 50 = 4 nM, sovosbuvir has an EC 50 = 53 nM. The y-axis is percent of virus control and the x-axis is drug concentration in μM. Figure 4 shows an intra-assay comparison of anti-HCV activity for Compound 5-2, Compound 25, Compound 27 and Sofosbuvir. The y-axis is percent of virus control and the x-axis is drug concentration in μM.
[0292] HCV genotypes from various patients, including wild type and resistance-associated variants, were used to determine their relative replication susceptibility to test compounds. Viral RNA isolated from HCV patient plasma was used to prepare replicon resistance test vectors (RTVs) containing the NS5B genomic region. The NS5B regions were each amplified by reverse transcription polymerase chain reaction, cloned into the HCV replicon RTV, and then transferred by electroporation into Huh-7 cells. After 72-96 h of incubation in the absence and presence of serially diluted test compounds, viral replication was measured by luciferase activity and the 50% inhibitory concentration (IC 50 value) was determined.
[0293] Table 2 shows the IC values for compound 25, compound 27, compound 5-2, and sofosbuvir against various clinical isolates, including wild type and resistance-associated mutants. 50 and IC 95 Report the value of .
[0294] All compounds were significantly more effective against HCV replication than sofosbuvir, and none of the compounds 25, 27, and 5-2 showed any evidence of cross-resistance to the L159F, L159F, S282T, and C316N mutants.
[0295] [Table 4]
[0296] To determine the sensitivity of the wild-type S282T mutant of HCV to the test compounds, Transient transfection assays were performed. Huh-7 cells were electroporated in the presence of RNA transcribed from the T7 promoter and from wild-type or S282T HCV replicon plasmids. Transfected cells were grown at 7.5 × 10 per well in Dulbecco's modified Eagle's medium. 3Cells were plated in 96-well plates. After 24 h of incubation, the medium was removed and replaced with fresh medium containing either no test compound or various concentrations of test compound. After an additional 96 h of incubation, anti-HCV activity was measured by luciferase endpoint using the Britelite™ Plus Luminescence Reporter Gene Kit (Perkin Elmer, Shelton, CT). Duplicate plates were treated and incubated in parallel for assessment of cytotoxicity by staining with the tetrazolium dye XTT.
[0297] Table 3 shows the IC for Compound 25, Compound 27, Compound 5-2 and Sofosbuvir against HCV wild type and S282T replicon. 50 and IC 95 Report the value of .
[0298] All compounds were significantly more effective against HCV replication than sovosbuvir, and none of compounds 25, 27, or 5-2 showed any evidence of cross-resistance to the S282T mutant.
[0299] [Table 5]
[0300] The stability of selected compounds in fresh human whole blood and human liver S9 fraction was determined in incubations containing 10 μM of test compound. After 0, 30, and 60 minutes of incubation, and up to 120 minutes, aliquots were removed and immediately extracted with 3 volumes of ice-cold methanol / acetonitrile (1:1, vol / vol). Extracts were centrifuged and the supernatants were analyzed by LC-MS / MS for the concentration of unchanged test compound and possible metabolites.
[0301] FIG. 5 shows the excellent stability of compound 5-2 and all the 2-amino derivatives in human blood.
[0302] Interestingly, Figure 6 shows that 2'-deoxy-2'-α-fluoro-2'-β-methyl-N 2 -Methyl-N 6 2'-Deoxy-2'-α-fluoro-2'-β-methyl-N-methyl-2,6-diaminopurine nucleoside phosphoramidate 6 The in vitro time course dealkylation of 5-aminopurine to 2-methyl-2,6-diaminopurine nucleoside phosphoramidate is shown. Furthermore, it shows an unexpected faster and more extensive distribution in the human liver S9 fraction compared to compound 5-2 and other 2-amino derivatives. Cleavage of the carbamate moiety by cleavage was observed (Figure 7).
[0303] Example 28. HCV(gt1b) NS5B polymerase assay Inhibition of HCV(gt1b) NS5B polymerase was determined in triplicate by measuring de novo polymerization in reaction mixtures containing a dilution series of TA, in vitro transcribed viral RNA complementary to the HCV(-) strand 3'UTR region, polymerase, radiolabeled ribonucleotides, 250 μM noncompeting rNTPs, and 1 μM competing rNTPs. 50% inhibition (IC 50 ) was determined from the inhibition curve obtained.
[0304] Example 29. Human bone marrow progenitor cell assay Fresh human bone marrow progenitor cells (Invitrogen) were suspended in either BFU-E or GM-CSF specific culture medium and cultured at 10 for a dilution series of TA in triplicate in 6-well plates. 5 After 14 days of incubation, CC 50 Colony counts were used to determine the values. BFU-E colonies were identified using the benzidine technique.
[0305] Compounds 25, 27 and 5-2 show no cytotoxicity to bone marrow stem cells in vitro.
[0306] Example 30. iPS cardiomyocyte assay iPS cardiomyocytes (Cellular Dynamics) 1.5 × 10 per well 4 Microphone in Cell After 48 h of incubation, cells were washed and serially diluted maintenance medium containing TA was added in triplicate. After a further 3-day incubation, cell viability was measured by staining with XTT and CC 50 values were calculated.
[0307] Compounds 25, 27 and 5-2 do not exhibit cytotoxicity to iPS cardiomyocytes in vitro.
[0308] Example 31. Human DNA polymerase assay Inhibition of human DNA polymerases α, β, and γ (CHIMERx) was determined by serial dilutions of TA, 0.05 mM dCTP, dTTP, and dATP, 10 μCi [ 32 P]-α-dGTP (800 Ci / mmol), 20 μg of activated calf thymus DNA, and additional reagents specific for each polymerase were measured in triplicate in a reaction mixture. After 30 min of incubation, 32 Incorporation of [P]-GTP was measured and the resulting incubation curves were expressed as IC 50 was used to calculate the values.
[0309] The triphosphate β-D-2'-deoxy-2'-α-fluoro-2'-β-methylguanine triphosphate as well as the triphosphate analogs of Compound 25, Compound 27, and Compound 5-2 do not inhibit human DNA polymerases α, β, or γ.
[0310] Example 32. Human hepatocyte co-cultures Cytotoxicity and hepatocyte health were assessed by measuring ALT leakage, urea production, albumin secretion and cellular ATP content in micropatterned human hepatocyte co-cultures (HepatoPac™, Hepregen Corporation) in triplicate, generated by seeding cryopreserved female human hepatocytes (single donor) and 3T3 J2 mouse fibroblasts in microtiter plates according to the procedure established by Hepregen. Culture medium was replaced every 2 or 3 days with fresh medium containing TA, test substances (0 μM, 1 μM, 10 μM or 30 μM) for 16 days. Spent culture medium was assayed on days 2, 5, 7, 9, 12, 16 and 21 for ALT and urea content, and on days 2, 5, 7 and 9 for albumin content. Cellular ATP levels were measured on days 9 and 2. Measured on day 1. ATP signals in stromal-only control cultures (murine 3T3 fibroblasts) were subtracted from those in human HepatoPac co-cultures to obtain hepatocyte-specific effects. See Tables 4, 5 and 6 below.
[0311] Compound 5-2 at concentrations up to 30 μM showed no signs of cytotoxicity as measured by ALT leakage, albumin secretion, urea production and cellular ATP content when incubated with micropatterned co-cultured human hepatocytes for up to 12 days. The slight signs of cytotoxicity detected with extended exposure (up to 21 days of culture) were significantly less than those observed with sofosbuvir. See Tables 4, 5 and 6 below.
[0312] INX-189 was highly cytotoxic to human co-cultured hepatocytes, showing reduced albumin secretion and cytotoxicity by all measures as early as day 2. Sovosbuvir showed greater cytotoxicity than AT-511 under the same conditions.
[0313] [Table 6]
[0314] [Table 7]
[0315] [Table 8]
[0316] Example 33. Metabolic Studies The metabolism of compound 25, compound 27 and compound 5-2 was investigated in fresh primary cultures of human, dog and mouse hepatocytes at a concentration of 10 μM. Human (XenoTech, mixed gender, collected from 10 donors) seeded in 6-well plates overcoated with Matrigel. Hepatocytes from male rats (BioreclamationIVT), male beagle dogs (BioreclamationIVT), and male ICR / CD-1 mice (BioreclamationIVT, 8 donors) were incubated in singlets with 10 μM TA for 2 h, 4 h, After 1, 6, 8 or 24 hours, the intracellular levels of nucleotide prodrugs and their potential metabolites (prodrugs, monophosphates, triphosphates and nucleosides) were quantified by LC-MS / MS. Concentrations below the limit of quantification (1.5 pmol / 10 for prodrugs, monophosphates and nucleosides) were <0.01 pmol / 10 for nucleosides. 6 12 pmol / 10 for cells and triphosphate 6 cells) was estimated from a standard curve.
[0317] The compound β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-guanine triphosphate was the major metabolite of compounds 25, 27, and 5-2 observed in cultured human hepatocytes, with an IC of 0.15 μM. 50 It is a potent inhibitor of HCV(gt1b) NS5B polymerase, having
[0318] FIG. 8 shows the major metabolites of compound 25 in human hepatocytes.
[0319] FIG. 9 shows the major metabolites of compound 27 in human hepatocytes.
[0320] FIG. 10 shows the major metabolic products of compound 5-2 in human hepatocytes.
[0321] Figure 11 shows the activation pathway for compounds 25, 27 and 5-2. As can be seen, compounds 25, 27 and 5-2 are converted to their corresponding monophosphate analogs and then metabolized to the common MP analog, β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-guanine monophosphate (compound 61). The monophosphate is then stepwise phosphorylated to the active triphosphate, β-D-2'-deoxy-2'-α-fluoro-2'-β-methyl-guanine triphosphate (compound 62).
[0322] Example 34. Control INX-189 (INX-08189 / BMS-986094) and sovosbuvir were used as controls in the above examples.
[0323] The two most potent nucleotide prodrugs, Compound 25 and Compound 27, showed CC values of >100 μM in Huh-7 cells, human bone marrow stem cells, and human cardiomyocytes. 50 The results demonstrated excellent selectivity, with significant differences in the β- and γ-values of 100 μM in all host cell lines, no inhibition of human DNA polymerases α, β, or γ, no activity against other RNA or DNA viruses, and no toxicity was observed up to concentrations of 100 μM.
[0324] Table 7 shows the EC 50 / EC 95 (μM) and CC 50 1 is a table describing the compounds tested in the HCV replicon assay with the results (in μM).
[0325] [Table 9] JPEG2024160265000184.jpg178149JPEG2024160265000185.jpg170150JPEG2024160265000186.jpg165149JPEG20241602650 00187.jpg142150JPEG2024160265000188.jpg163149JPEG2024160265000189.jpg175150JPEG2024160265000190.jpg131150
[0326] The β-D-2'-D-2'-α-fluoro-2'-β-C-substituted-2-modified-N 6 -substituted purine nucleotides exhibit significant activity against the HCV virus.The compounds according to the invention are assayed for the desired relative activity using conventional assays that are well known and found in the literature.
[0327] For example, the anti-HCV activity and cytotoxicity of the above compounds may be measured in an HCV subgenomic RNA replicon assay system in Huh7 ET cells (Korba, et al., (See Antiviral Research 2008, 77, 56). Results were compared with the positive control, 2'-C-Me cytosine {2'-C-Me-C} (Pierra, et al., Journal of Medicinal Chemistry 2006, 49, 6614.)
[0328] Another in-vitro assay for anti-Hepatitis C virus activity is US Pat. No. 7,718,718, issued to Stuyver, et al. and assigned to Pharmasset, Inc. It is described in issue 90.
[0329] The present specification is described with reference to the embodiments of the present invention. With the teachings herein, those skilled in the art can modify the present invention for the desired purpose, and such modifications are intended to be within the scope of the present invention.
Claims
1. The following formula I: 【Chemistry 1】 (In the formula, Y is NR 1 R 2 and R 1 is C 1 ~C 5 Alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and pentyl), C 1 ~C 5 Haloalkyl (CH 2 F, C.H.F. 2 , C.F. 3 , C.H. 2 CF 3 , C.F. 2 CH 3 , and C.F. 2 CF 3 Including), C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Cycloalkyl), -(C 0 ~C 2 alkyl) (heterocycle), -(C 0 ~C 2 alkyl) (aryl), -(C 0 ~C 2 alkyl)(heteroaryl), -OR 25 , -C(O)R 3C (-C(O)CH 3 , -C(O)CH 2 CH 3 , -C(O)CH(CH 3 ) 2 , -C(O)OCH 3 , -C(O)OC 2 H 5 , -C(O)OC 3 H 7 , -C(O)OC 4 H 9 , and -C(O)OC 5 H 11 including -C(S)R 3D , or -SO 2 R 28 each of which may be substituted; R 2 is hydrogen, optionally substituted C 1 ~C 5 Alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, and pentyl), C 1 ~C 5 Haloalkyl (CHF 2 , C.H.F. 2 , C.F. 3 , C.H. 2 CF 3 and C.F. 2 CF 3 ), optionally substituted -(C 0 ~C 2 Alkyl) (C 3 ~C 6 cycloalkyl), optionally substituted -(C 0 ~C 2 alkyl) (heterocycle), optionally substituted -(C 0 ~C 2 alkyl) (aryl), optionally substituted -(C 0 ~C 2 alkyl)(heteroaryl), -C(O)R 3C (-C(O)CH 3 , -C(O)CH 2 CH 3 , -C(O)CH(CH 3 ) 2 , -C(O)OCH 3 , -C(O)OC 2 H 5 , -C(O)OC 3 H 7 , -C(O)OC 4 H 9 , and -C(O)OC 5 H 11 including -C(S)R 3D , or -SO 2 R 28 and Here, R 1 and R 2 At least one of these is methyl, CH 2 F, C.H.F. 2 , or C.F. 3 and R 3 is hydrogen, 【Chemistry 2】 , diphosphate, triphosphate, optionally substituted carbonyl-linked amino acid or -C(O)R 3C and R 3A Yes, O - , OH, —O-optionally substituted aryl, —O-optionally substituted heteroaryl, or optionally substituted heterocyclyl; R 3B Yes, O - , OH, an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester; R 3C is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 )(heteroaryl), —O-alkyl, —O-alkenyl, —O-alkynyl, —O—(C 0 ~C 2 ) (cycloalkyl), —O—(C 0 ~C 2 ) (heterocyclo), —O—(C 0 ~C 2 ) (aryl), or —O—(C 0 ~C 2 ) (heteroaryl), each of which is optionally substituted; R 4 is a stabilized phosphate prodrug, including but not limited to a monophosphate, diphosphate, triphosphate, or a phosphoramidate, thiophosphoramidate, or any other moiety that is metabolized in vivo in a human or animal host to a monophosphate, diphosphate, or triphosphate; Or, R 3 and R 4 can form a 3',5'-cyclic prodrug with the oxygen to which they are attached, R 12 is CH 3 , C.H. 2 F, C.H.F. 2 , C.F. 3 or ethynyl, R 25 is hydrogen, C 1 ~C 6 Alkyl, C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Cycloalkyl), -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Heterocycle), -(C 0 ~C 2 alkyl) (aryl), or -(C 0 ~C 2 alkyl)(heteroaryl), each of which, except for hydrogen, is optionally substituted; R 28 is C 1 ~C 6 Alkyl, C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Cycloalkyl), -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Heterocycle), -(C 0 ~C 2 alkyl) (aryl), or -(C 0 ~C 2 alkyl) (heteroaryl), each of which may be substituted, or a pharma- ceutically acceptable salt thereof.
2. R 4 is a stabilized phosphate prodrug, R 12 CH 3 , C.H. 2 F, C.F. 2 H or CF 3 2. The compound of claim 1,
3. R 4 is a phosphoramidate, R 12 CH 3 , C.H. 2 F, C.F. 2 H or CF 3 3. The compound of claim 2,
4. Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, R 12 CH 3 , C.H. 2 F, C.F. 2 H or CF 3 3. The compound of claim 2,
5. Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 12 CH 3 , C.H. 2 F, C.F. 2 H or CF 3 3. The compound of claim 2,
6. Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 12 CH 3 , C.H. 2 F, C.F. 2 H or CF 3 3. The compound of claim 2,
7. R 12 CH 3 2. The compound of claim 1 ,
8. R 12 The compound of claim 1 , wherein is ethynyl.
9. The following formula: 【Chemistry 3】 (In the formula, R 7 is hydrogen, C 1~6 Alkyl, C 3 ~ 7 cycloalkyl, heteroaryl, heterocyclic group or aryl, where phenyl or naphthyl is C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, F, Cl, Br, I, Nitro, Cyano, C 1~6 Haloalkyl, -(CH 2 ) 1~6 COOH, -(CH 2 ) 1~6 COOC 1~6 Alkyl, -N(R 7’ ) 2 , C 1~6 Acylamino, NHSO 2 C 1~6 Alkyl, -SO 2 N (R 7’ ) 2 , C.O.R. 7’’ , and -SO 2 C 1~6 Alkyl (R 7’ are independently hydrogen or C 1~6 alkyl, R 7’’ Yes - OR 11 Or -N(R 7 ) 2 wherein R 8 is hydrogen, C 1~6 alkyl, or R 9a Or R 9b and R 8 (CH) are bonded together to form a cyclic ring containing the adjacent N atom and C atom. 2 ) n where n is 2 to 4; R 9a and R 9b teeth, (i) Hydrogen, C 1~6 Alkyl, cycloalkyl, -(CH 2 ) c (NR 9’ ) 2 , C 1~6 Hydroxyalkyl, -CH 2 SH, -(CH 2 ) 2 S(O)(Me, -(CH 2 ) 3 NHC (=NH)NH 2 , (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, -(CH 2 ) c C.O.R. 9’’ , aryl, and aryl (C 1~3 alkyl), and the aryl group is selected from hydroxyl, C 1~6 Alkyl, C 1~6 optionally substituted with a group selected from alkoxy, halogen, nitro, and cyano; (ii) R 9a and R 9b Both are C 1~6 is alkyl, (iii) R 9a and R 9b together form a spiro ring (CH 2 ) r and (iv) R 9a is hydrogen, R 9b and R 8 are joined together to form a cyclic ring containing the adjacent N atom and C atom (CH 2 ) n and (v) R 9b is hydrogen, R 9a and R 8 are joined together to form a cyclic ring containing the adjacent N atom and C atom (CH 2 ) n and where c is 1 to 6, n is 2 to 4, r is 2 to 5, and R 9’ are independently hydrogen or C 1~6 alkyl, R 9’’ Ga-OR 11 Or -N(R 11’ ) 2 ) and (vi) R 9a is hydrogen, R 9b is hydrogen, CH 3 , C.H. 2 CH 3 , CH(CH 3 ) 2 , C.H. 2 CH (CH 3 ) 2 , CH(CH 3 ) CH 2 CH 3 , C.H. 2 Ph, CH 2 -indol-3-yl, -CH 2 CH 2 SCH 3 , C.H. 2 CO 2 H, C.H. 2 C(O)NH 2 , C.H. 2 CH 2 COOH, CH 2 CH 2 C(O)NH 2 , C.H. 2 CH 2 CH 2 CH 2 N.H. 2 , -CH 2 CH 2 CH 2 NHC (NH) NH 2 , C.H. 2 -imidazol-4-yl, CH 2 OH, CH(OH)CH 3 , C.H. 2 ((4'-OH)-Ph), CH 2 SH or lower cycloalkyl; Or, (vii) R 9a is CH 3 , C.H. 2 CH 3 , CH(CH 3 ) 2 , C.H. 2 CH (CH 3 ) 2 , CH(CH 3 ) CH 2 CH 3 , C.H. 2 Ph, CH 2 -indol-3-yl, -CH 2 CH 2 SCH 3 , C.H. 2 CO 2 H, C.H. 2 C(O)NH 2 , C.H. 2 CH 2 COO H, C.H. 2 CH 2 C(O)NH 2 , C.H. 2 CH 2 CH 2 CH 2 N.H. 2 , -CH 2 CH 2 CH 2 NHC (NH) NH 2 , C.H. 2 -imidazol-4-yl, CH 2 OH, CH(OH)CH 3 , C.H. 2 ((4'-OH)-Ph), CH 2 SH or lower cycloalkyl; R 9b is hydrogen, R 10 is a C which may be substituted with hydrogen, alkoxy, di(lower alkyl)-amino or halogen. 1~6 Alkyl, C 1~6 Haloalkyl, C 3~7 cycloalkyl, heterocycloalkyl, aminoacyl, aryl such as phenyl, heteroaryl such as pyridinyl, substituted aryl or substituted heteroaryl; R 11 is optionally substituted C 1~6 Alkyl, optionally substituted cycloalkyl, optionally substituted C 2~6 Alkynyl, optionally substituted C 2~6 alkenyl, or optionally substituted acyl, including but not limited to C(O)(C 1~6 alkyl), Y, R 3 and R 12 is as defined in claim 1, or a pharma- ceutically acceptable salt thereof.
10. Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen or methyl, R 12 CH 3 10. The compound of claim 9,
11. Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl or hydrogen, R 3 is hydrogen, R 7 is phenyl, R 8 is hydrogen, R 9a is hydrogen, R 9b is methyl, R 10 is isopropyl, R 12 CH 3 10. The compound of claim 9,
12. Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 12 CH 3 10. The compound of claim 9,
13. Y is NR 1 R 2 and R 1 CH 3 and R 2 C(O)OR 3 and R 3 is hydrogen, R 12 CH 3 10. The compound of claim 9,
14. The following formula II: 【Chemistry 4】 (In the formula, Y is NR 1 R 2 and R 1 is C 1 ~C 5 Alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, and pentyl), C 1 ~C 5 Haloalkyl (CH 2 F, C.H.F. 2 , C.F. 3 , C.H. 2 CF 3 , C.F. 2 CH 3 and C.F. 2 CF 3 Including), C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Cycloalkyl), -(C 0 ~C 2 alkyl) (heterocycle), -(C 0 ~C 2 alkyl) (aryl), -(C 0 ~C 2 alkyl)(heteroaryl), -OR 25 , -C(O)R 3C (-C(O)CH 3 , -C(O)CH 2 CH 3 , -C( O)CH(CH 3 ) 2 , -C(O)OCH 3 , -C(O)OC 2 H 5 , -C(O)OC 3 H 7 , -C(O)OC 4 H 9 and -C(O)OC 5 H 11 including -C(S)R 3D , or -SO 2 R 28 each of which may be substituted; R 2 is hydrogen, optionally substituted C 1 ~C 5 Alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and pentyl), C 1 ~C 5 Haloalkyl (CHF 2 , C.H.F. 2 , C.F. 3 , C.H. 2 CF 3 and C.F. 2 CF 3 ), optionally substituted -(C 0 ~C 2 Alkyl) (C 3 ~C 6 cycloalkyl), optionally substituted -(C 0 ~C 2 alkyl) (heterocycle), optionally substituted -(C 0 ~C 2 alkyl) (aryl), optionally substituted -(C 0 ~C 2 alkyl)(heteroaryl), -C(O)R 3C (-C(O)CH 3 , -C(O)CH 2 CH 3 , -C(O)CH(CH 3 ) 2 , -C(O)OCH 3 , -C(O)OC 2 H 5 , -C(O)OC 3 H 7 , -C(O)OC 4 H 9 and -C(O)OC 5 H 11 including -C(S)R 3D , or -SO 2 R 28 where R 1 and R 2 At least one of them is methyl, CH 2 F, C.H.F. 2 Or CF 3 and R 3 is hydrogen, 【Chemistry 5】 , diphosphate, triphosphate, an optionally substituted carbonyl-linked amino acid, or -C(O)R 3C and R 3A Yes, O - , OH, —O-optionally substituted aryl, —O-optionally substituted heteroaryl, or optionally substituted heterocyclyl; R 3B Yes, O - , OH, an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester; R 3C is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 )(heteroaryl), —O-alkyl, —O-alkenyl, —O-alkynyl, —O—(C 0 ~C 2 ) (cycloalkyl), —O—(C 0 ~C 2 ) (heterocyclo), —O—(C 0 ~C 2 ) (aryl), —O—(C 0 ~C 2 ) (heteroaryl), -S-alkyl, -S-alkenyl, -S-alkynyl, -S-(C 0 ~C 2 ) (cycloalkyl), -S-(C 0 ~C 2 ) (heterocyclo), -S-(C 0 ~C 2 ) (aryl), or -S-(C 0 ~C 2 ) (heteroaryl), each of which is optionally substituted; R 3D is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 )(heteroaryl), —O-alkyl, —O-alkenyl, —O-alkynyl, —O—(C 0 ~C 2 ) (cycloalkyl), —O—(C 0 ~C 2 ) (heterocyclo), —O—(C 0 ~C 2 ) (aryl), or —O—(C 0 ~C 2 ) (heteroaryl), each of which is optionally substituted; R 4 is a stabilized phosphate prodrug, including but not limited to a monophosphate, diphosphate, triphosphate, or a phosphoramidate, thiophosphoramidate, or any other moiety that is metabolized in vivo in a human or animal host to a monophosphate, diphosphate, or triphosphate; Or, R 3 and R 4 may, together with the oxygen to which they are attached, form a 3',5'-cyclic prodrug, including but not limited to a 3',5'-cyclic phosphate prodrug; R 5 is C 1 ~C 5 Alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and pentyl), C 1 ~C 5 Haloalkyl (CHF 2 , C.H.F. 2 , C.F. 3 , C.H. 2 CF 3 and C.F. 2 CF 3 Including), C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, -(C 0 ~C 2 Alkyl) ( C 3 ~C 6 Cycloalkyl), -(C 0 ~C 2 alkyl) (heterocycle), -(C 0 ~C 2 alkyl) (aryl), -(C 0 ~C 2 alkyl)(heteroaryl), -OR 25 , -C(O)R 3C (-C(O)CH 3 , -C(O)CH 2 CH 3 , -C(O)CH(CH 3 ) 2 , -C(O)OCH 3 , -C(O)OC 2 H 5 , -C(O)OC 3 H 7 , -C(O)OC 4 H 9 and -C(O)OC 5 H 11 including -C(S)R 3D , or -SO 2 R 28 each of which may be substituted; R 6 is hydrogen, optionally substituted C 1 ~C 5 Alkyl (including methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl and pentyl), C 1 ~C 5 Haloalkyl (CHF 2 , C.H.F. 2 , C.F. 3 , C.H. 2 CF 3 and C.F. 2 CF 3 ), optionally substituted -(C 0 ~C 2 Alkyl) (C 3 ~C 6 cycloalkyl), optionally substituted -(C 0 ~C 2 alkyl) (heterocycle), optionally substituted -(C 0 ~C 2 alkyl) (aryl), optionally substituted -(C 0 ~C 2 alkyl)(heteroaryl), -C(O)R 3C (-C(O)CH 3 , -C(O)CH 2 CH 3 , -C(O)CH(CH 3 ) 2 , -C(O)OCH 3 , -C(O)OC 2 H 5 , -C(O)OC 3 H 7 , -C(O)OC 4 H 9 and -C(O)OC 5 H 11 including -C(S)R 3D , or -SO 2 R 28 and Or, R 5 and R 6 may form a heterocycle together with the nitrogen to which they are attached; R 12 is CH 3 , C.H. 2 F, C.H.F. 2 , C.F. 3 or ethynyl, R 22 is F, Cl, Br, CN, N 3 , C 1 ~C 6 Alkyl, C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, -(C 1 ~C 2 Alkyl) (C 3 ~C 6 Cycloalkyl), -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Heterocycle), -(C 0 ~C 2 alkyl) (aryl), -(C 0 ~C 2 alkyl)(heteroaryl), -ONHC(=O)OR 23 , -NHOR 24 , -OR 25 , -SR 25 , -NH(CH 2 ) 1~4 N (R 26 ) 2 , -NHNHR 26 , -N=NR 27 , -NHC(O)NHNHR 27 ,-NHC(S)NHNHR 27 , -C(O)NHNHR 27 , -NR 27 SO 2 R 28 , -SO 2 N.R. 27 R 29 , -C(O)NR 27 R 29 , -CO 2 R 29 , -SO 2 R 29 , 【Chemistry 6】 , -P(O)H(OR 29 ), -P(O)(OR 29 ) (OR 30 ), -P(O)(OR 29 ) (NR 29 R 30 ), or -NR 5 R 6 and R 23 is C 1 ~C 5 Alkyl, -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Cycloalkyl), -(C 0 ~C 2 alkyl)(heterocycle)-(C 0 ~ 2 alkyl) (aryl), or -(C 0 ~C 2 alkyl)(heteroaryl), each of which is optionally substituted; R 24 is hydrogen, C 1 ~C 6 Alkyl, -(C 1 ~C 2 Alkyl) (C 3 ~C 6 Cycloalkyl), -(C 1 ~C 2 Alkyl) (C 3 ~C 6 Heterocycle), -(C 0 ~C 2 alkyl) (aryl), or -(C 0 ~C 2 alkyl)(heteroaryl), each of which, except for hydrogen, is optionally substituted; R 25 is hydrogen, C 1 ~C 6 Alkyl, C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Cycloalkyl), -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Heterocycle), -(C 0 ~C 2 alkyl) (aryl), or -(C 0 ~C 2 alkyl)(heteroaryl), each of which, except for hydrogen, is optionally substituted; R 26 is hydrogen, C 1 ~C 6 Alkyl, -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Cycloalkyl), -(C 0 ~C 2 alkyl) (heterocycle), -(C 0 ~C 2 alkyl) (aryl), or -(C 0 ~C 2 alkyl) (heteroaryl), each of which, except for hydrogen, is optionally substituted; R 27 is hydrogen or optionally substituted C 1 ~C 6 is alkyl, R 28 is C 1 ~C 6 Alkyl, C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Cycloalkyl), -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Heterocycle), -(C 0 ~C 2 alkyl) (aryl), or -(C 0 ~C 2 alkyl)(heteroaryl), each of which is optionally substituted; R 29 is hydrogen, C 1 ~C 6 Alkyl, C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Cycloalkyl), -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Heterocycle), -(C 0 ~C 2 alkyl) (aryl), or -(C 0 ~C 2 alkyl)(heteroaryl), each of which, except for hydrogen, is optionally substituted; Or, R 27 and R 29 may form a heterocycle together with the nitrogen to which they are attached; R 30 is hydrogen, C 1 ~C 6 Alkyl, C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Cycloalkyl), -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Heterocycle), -(C 0 ~C 2 alkyl) (aryl), or -(C 0 ~C 2 alkyl)(heteroaryl), each of which, except for hydrogen, is optionally substituted; Or, R 29 and R 30 may be bonded together to form a heterocycle; x is 1, 2 or 3, or a pharma- ceutically acceptable salt thereof.
15. R 4 is a stabilized phosphate prodrug, R 12 CH 3 , C.H. 2 F, C.F. 2 H or CF 3 15. The compound of claim 14, wherein
16. R 4 is a phosphoramidate, R 12 CH 3 , C.H. 2 F, C.F. 2 H or CF 3 16. The compound of claim 15,
17. Y is NR 1 R 2 and R 1 is methyl, R 2 The compound of claim 15, wherein is hydrogen or methyl.
18. R 22 The compound of claim 15 , wherein is F.
19. R 22 OR 25 16. The compound of claim 15,
20. R 22 is NR 5 R 6 and R 6 The compound of claim 15 , wherein is hydrogen.
21. R 22 is NR 5 R 6 16. The compound of claim 15,
22. R 22 But Cl, Br, CN, N 3 , C 1 ~C 6 Alkyl, C 2 ~C 6 Alkenyl, C 2 ~C 6 Alkynyl, -(C 1 ~C 2 Alkyl) (C 3 ~C 6 Cycloalkyl), -(C 0 ~C 2 Alkyl) (C 3 ~C 6 Heterocycle), -(C 0 ~C 2 alkyl) (aryl), -(C 0 ~C 2 alkyl)(heteroaryl), -ONHC(=O)OR 23 , -NHOR 24 , -OR 25 and -SR 25 16. The compound of claim 15, selected from:
23. R 22 is NR 5 R 6 and R 5 and R 6 The compound of claim 15 , wherein is hydrogen.
24. The following formula III: 【Chemistry 7】 (In the formula, R 7 is hydrogen, C 1~6 Alkyl, C 3~7 cycloalkyl, heteroaryl, heterocyclic group or aryl, where phenyl or naphthyl is C 1~6 Alkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, C 1~6 Alkoxy, F, Cl, Br, I, Nitro, Cyano, C 1~6 Haloalkyl, -(CH 2 ) 1~6 COOH, -(CH 2 ) 1~6 COOC 1~6 Alkyl, -N(R 7’ ) 2 , C 1~6 Acylamino, NHSO 2 C 1~6 Alkyl, -SO 2 N (R 7’ ) 2 , C.O.R. 7’’ , and -SO 2 C 1~6 It may be substituted with alkyl (R 7’ are independently hydrogen or C 1~6 alkyl, R 7’’ Yes - OR 11 Or -N(R 7 ) 2 and R 8 is hydrogen, C 1~6 Alkyl, or R 9a Or R 9b and R 8 are joined together to form a cyclic ring containing the adjacent N atom and C atom (CH 2 ) n where n is 2 to 4; R 9a and R 9b teeth, (i) Hydrogen, C 1~6 Alkyl, cycloalkyl, -(CH 2 ) c (NR 9’ ) 2 , C 1~6 Hydroxyalkyl, --CH 2 SH, -(CH 2 ) 2 S(O)(Me, -(CH 2 ) 3 NHC (=NH)NH 2 , (1H-indol-3-yl)methyl, (1H-imidazol-4-yl)methyl, -(CH 2 ) c C.O.R. 9’’ , aryl and aryl (C 1~3 alkyl)-, and the aryl group is independently selected from hydroxyl, C 1~6 Alkyl, C 1~6 optionally substituted with a group selected from alkoxy, halogen, nitro, and cyano; (ii) R 9a and R 9b Both are C 1~6 is alkyl, (iii) R 9a and R 9b together form a spiro ring (CH 2 ) r and (iv) R 9a is hydrogen, R 9b and R 8 are joined together to form a cyclic ring containing the adjacent N atom and C atom (CH 2 ) n and (v) R 9b is hydrogen, R 9a and R 8 are joined together to form a cyclic ring containing the adjacent N atom and C atom (CH 2 ) n and where c is 1 to 6, n is 2 to 4, r is 2 to 5, and R 9’ are independently hydrogen or C 1~6 alkyl, R 9’’ Yes - OR 11 , or -N(R 11’ ) 2 ) and (vi) R 9a is hydrogen, R 9b is hydrogen, CH 3 , C.H. 2 CH 3 , CH(CH 3 ) 2 , C.H. 2 CH (CH 3 ) 2 , CH(CH 3 ) CH 2 CH 3 , C.H. 2 Ph, CH 2 -indol-3-yl, -CH 2 CH 2 SCH 3 , C.H. 2 CO 2 H, C.H. 2 C(O)NH 2 , C.H. 2 CH 2 COOH, CH 2 CH 2 C(O)NH 2 , C.H. 2 CH 2 CH 2 CH 2 N.H. 2 , -CH 2 CH 2 CH 2 NHC (NH) NH 2 , C.H. 2 -imidazol-4-yl, CH 2 OH, CH(OH)CH 3 , C.H. 2 ((4'-OH)-Ph), CH 2 SH, or lower cycloalkyl; Or, (vii) R 9a is CH 3 , C.H. 2 CH 3 , CH(CH 3 ) 2 , C.H. 2 CH (CH 3 ) 2 , CH(CH 3 ) CH 2 CH 3 , C.H. 2 Ph, CH 2 -indol-3-yl, -CH 2 CH 2 SCH 3 , C.H. 2 CO 2 H, C.H. 2 C(O)NH 2 , C.H. 2 CH 2 COO H, C.H. 2 CH 2 C(O)NH 2 , C.H. 2 CH 2 CH 2 CH 2 N.H. 2 , -CH 2 CH 2 CH 2 NHC (NH) NH 2 , C.H. 2 -imidazol-4-yl, CH 2 OH, CH(OH)CH 3 , C.H. 2 ((4'-OH)-Ph), CH 2 SH or lower cycloalkyl; R 9b is hydrogen, R 10 is a C optionally substituted with hydrogen, alkoxy, di(lower alkyl)-amino, or halogen. 1~6 Alkyl, C 1~6 Haloalkyl, C 3~7 cycloalkyl, heterocycloalkyl, aminoacyl, aryl such as phenyl, heteroaryl such as pyridinyl, substituted aryl, or substituted heteroaryl; R 11 is optionally substituted C 1~6 Alkyl, optionally substituted cycloalkyl, optionally substituted C 2~6 Alkynyl, optionally substituted C 2~6 alkenyl, or optionally substituted acyl, including but not limited to C(O)(C 1~6 alkyl), Here, Y and R 3 , R 12 and R 22 is defined in claim 14, or a pharma- ceutically acceptable salt thereof.
25. Y is NR 1 R 2 and R 1 is methyl, R 2 is hydrogen, R 12 CH 3 25. The compound of claim 24, wherein
26. Y is NR 1 R 2 and R 1 is methyl, R 2 is methyl, R 12 CH 3 25. The compound of claim 24, wherein
27. Y is NR 1 R 2 and R 1 is methyl, R 2 is cyclopropyl, R 3 is hydrogen, R 7 is phenyl, R 8 is hydrogen, R 9a is hydrogen, R 9b is methyl, R 10 is isopropyl, R 12 CH 3 25. The compound of claim 24, wherein
28. Y is NR 1 R 2 and R 1 CH 3 and R 12 CH 3 and R 22 The compound of claim 24, wherein is F.
29. Formula IV: 【Chemistry 8】 (Wherein, the variables Y, R 3 , R 7 , R 8 , R 9a , R 9b , R 10 and R 22 is defined in claim 24, or a pharma- ceutically acceptable salt thereof.
30. The following formula V: 【Chemistry 9】 (Wherein, the variables Y, R 3 , R 7 , R 8 , R 9a , R 9b , R 10 and R 22 is defined in claim 24, or a pharma- ceutically acceptable salt thereof.
31. The following formula VI: 【Chemistry 10】 (In the formula, Y, R 3 , R 4 and R 12 is defined in claim 24, R 41 is F, Cl, OR 3 , N 3 , N.H. 2 or CN, or a pharma- ceutically acceptable salt thereof.
32. Formula VII: 【Chemistry 11】 (In the formula, Y, R 3 , R 4 , R 12 , R 22 and R 41 is defined in claims 1, 24 and 31, or a pharma- ceutically acceptable salt thereof.
33. 13. A pharmaceutical composition comprising a compound of claim 1 in a pharma- ceutically acceptable carrier in an amount effective to treat HCV in a host.
34. 10. A pharmaceutical composition comprising an effective amount of a compound of claim 9 in a pharma- ceutically acceptable carrier to treat HCV in a host.
35. 17. A pharmaceutical composition comprising a compound of claim 14 in a pharma- ceutically acceptable carrier in an amount effective to treat HCV in a host.
36. A pharmaceutical composition comprising a compound according to claim 24 or any one of claims 29-32 in a pharma- ceutically acceptable carrier in an amount effective to treat HCV in a host.
37. 34. The pharmaceutical composition of claim 33, suitable for oral delivery.
38. 35. The pharmaceutical composition of claim 34, suitable for oral delivery.
39. 36. The pharmaceutical composition of claim 35, suitable for oral delivery.
40. 37. The pharmaceutical composition of claim 36, suitable for oral delivery.
41. A method for treating hepatitis C infection or a condition resulting from hepatitis C infection in a host in need of treatment, comprising administering an effective amount of a compound described in claim 1, optionally in a pharma- ceutical acceptable carrier.
42. A method for treating hepatitis C infection or a condition resulting from hepatitis C infection in a host in need of treatment, comprising administering an effective amount of a compound described in claim 9, optionally in a pharma- ceutical acceptable carrier.
43. A method for treating hepatitis C infection or a condition resulting from hepatitis C infection in a host in need of treatment, comprising administering an effective amount of a compound described in claim 14, optionally in a pharma- ceutical acceptable carrier.
44. 33. A method of treating Hepatitis C infection or a condition resulting from Hepatitis C infection in a host in need of such treatment, comprising administering an effective amount of a compound according to claim 24, or any one of claims 29 to 32, optionally in a pharma- ceutically acceptable carrier.
45. 42. The method of claim 41 , wherein the compound is administered transdermally.
46. 42. The method of claim 41, wherein the compound is administered by controlled release.
47. 42. The method of claim 41 , wherein the compound is administered intravenously.
48. 42. The method of claim 41, wherein the pathology resulting from hepatitis C infection is antibody-positive and antigen-positive states, chronic liver inflammation due to the virus, liver cancer, cirrhosis or fatigue due to severe hepatitis C.
49. 42. The method of claim 41, further comprising administering the compound in combination with another anti-HCV agent.
50. 50. The method of claim 49, wherein the additional anti-HCV agent is selected from the group consisting of a protease inhibitor, an NS5A inhibitor, an additional NS5B polymerase inhibitor, a non-substrate (allosteric) inhibitor, an interferon alpha-2a which may be pegylated, ribavirin, a helicase inhibitor, an antisense oligodeoxynucleotide (S-ODN), an aptamer, a nuclease resistant ribozyme, an iRNA, an antibody against HCV, a partial antibody against HCV, and a domain antibody against HCV.
51. 51. The method of claim 50, wherein the protease inhibitor is selected from the group consisting of telaprevir, boceprevir, simeprevir and paritaprevir.
52. The method of any one of claims 41 to 51, wherein the host is a human.
53. The following formula: 【Chemistry 12】 (In the formula, R 4 is a stabilized phosphate prodrug, or a pharma- ceutically acceptable salt thereof.
54. the below described: 【Chemistry 13】 (In the formula, R 4 is a stabilized phosphate prodrug), or a pharma- ceutically acceptable salt thereof.
55. The following formula: 【Chemistry 14】 (In the formula, R 4 is a stabilized phosphate prodrug, or a pharma- ceutically acceptable salt thereof.
56. the below described: 【Chemistry 15】 (In the formula, R 4 is a stabilized phosphate prodrug), or a pharma- ceutically acceptable salt thereof.
57. The following structure: 【Chemistry 16】 (In the formula, R 4 is a stabilized phosphate prodrug, or a pharma- ceutically acceptable salt thereof.
58. the below described: 【Chemistry 17】 (In the formula, R 4 is a stabilized phosphate prodrug), or a pharma- ceutically acceptable salt thereof.
59. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 18】 (In the formula, R 1 , R 2 , R 5 and R 6 is as defined in claim 14, or a pharma- ceutically acceptable salt thereof.
60. the below described: 【Chemistry 19】 (In the formula, R 1 and R 2 is as defined in claim 1, or a pharma- ceutically acceptable salt thereof.
61. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 20】 【change】 (In the formula, R 1 , R 2 , R 5 and R 6 is as defined in claim 14, or a pharma- ceutically acceptable salt thereof.
62. the below described: 【Chemistry 21】 (In the formula, R 1 , R 2 , R 5 , R 6 , R 7 and R 10 is as defined in claims 9 and 14), or a pharma- ceutically acceptable salt thereof.
63. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemical 22】 (In the formula, R 7 and R 10 10. A compound of the structure selected from the group consisting of:
64. the below described: 【Chemistry 23】 (In the formula, R 7 and R 10 10. A pharmaceutical composition comprising the structure:
65. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 24】 (In the formula, R 3C , R 7 and R 10 10. A compound of the structure selected from the group consisting of:
66. the below described: 【Chemistry 25】 (In the formula, R 3C , R 7 and R 10 10. A pharmaceutical composition comprising the structure:
67. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 26】 (In the formula, R 22 F and OR 25 is selected from R 7 and R 10 10. A compound of the structure selected from the group consisting of:
68. the below described: 【Chemical 27】 (In the formula, R 22 F and OR 25 is selected from R 7 and R 10 10. A pharmaceutical composition comprising a compound of the formula:
69. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 28】 【change】 (In the formula, R 7 and R 10 is defined in claims 1 and 9, R 3C is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 ) (heteroaryl), and -O-alkyl), or a pharma- ceutically acceptable salt thereof.
70. the below described: 【Chemical 29】 (In the formula, R 3C , R 7 and R 10 10. A pharmaceutical composition comprising a compound of the formula:
71. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 30】 (In the formula, R 22 is F, OR 25 , N 3 or CN, R 7 and R 10 10. A compound of the structure selected from the group consisting of:
72. the below described: 【Chemistry 31】 (In the formula, R 22 is F, OR 25 , N 3 or CN, R 7 and R 10 10. A pharmaceutical composition comprising a compound of the formula:
73. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 32】 (In the formula, R 3C , R 7 and R 10 10. A compound of the structure selected from the group consisting of:
74. the below described: 【Chemical 33】 (In the formula, R 3C , R 7 and R 10 10. A pharmaceutical composition comprising a compound of the formula:
75. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemical 34】 【change】 (In the formula, R 22 is F, OR 25 , N 3 or CN, R 7 and R 10 10. A compound of the structure selected from the group consisting of:
76. the below described: 【Chemistry 35】 (In the formula, R 22 is F, OR 25 , N 3 or CN, R 7 and R 10 10. A pharmaceutical composition comprising the structure:
77. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemical 36】 (In the formula, R 7 and R 10 is defined in claims 1 and 9, R 3C is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 ) (heteroaryl), -O-alkyl, alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 ) (heteroaryl), and -O-alkyl), or a pharma- ceutically acceptable salt thereof.
78. the below described: 【Chemical 37】 (In the formula, R 7 and R 10 is defined in claims 1 and 9, R 3C is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 ) (heteroaryl), and -O-alkyl), or a pharma- ceutically acceptable salt thereof.
79. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemical Formula 38】 (In the formula, R 22 F and OR 25 is selected from R 7 and R 10 10. A compound of the structure selected from the group consisting of:
80. the below described: 【Chemical Formula 39】 (In the formula, R 22 F and OR 25 is selected from R 7 and R 10 10. A pharmaceutical composition comprising a compound of the formula:
81. the below described: 【Chemistry 40】 【change】 (In the formula, R 7 and R 10 is defined in claim 1 and claim 9, R 3C is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 ) (heteroaryl), and -O-alkyl), or a pharma- ceutically acceptable salt thereof.
82. the below described: 【Chemistry 41】 (In the formula, R 7 and R 10 is defined in claims 1 and 9, R 3C is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 ) (heteroaryl), and -O-alkyl), or a pharma- ceutically acceptable salt thereof.
83. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 42】 (In the formula, R 22 F and OR 25 is selected from R 7 and R 10 10. A compound of the structure selected from the group consisting of:
84. the below described: 【Chemistry 43】 (In the formula, R 22 F and OR 25 is selected from R 7 and R 10 10. A pharmaceutical composition comprising a compound of the formula:
85. The isolated phosphorus S enantiomers are in the form: 【Chemistry 44】 【change】 (In the formula, R 3C , R 7 and R 10 A compound having a structure selected from the group consisting of:
86. the below described: 【Chemistry 45】 (In the formula, R 3C , R 7 and R 10 10. A pharmaceutical composition comprising a compound of the formula:
87. The isolated phosphorus S enantiomers are in the form: 【Chemistry 46】 (In the formula, R 22 is F, OR 25 , N 3 or CN, R 7 and R 10 10. A compound of the structure selected from the group consisting of:
88. the below described: 【Chemistry 47】 (In the formula, R 22 is F, OR 25 , N 3 or CN, R 7 and R 10 10. A pharmaceutical composition comprising the structure:
89. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 48】 【change】 (In the formula, R 7 and R 10 is defined in claims 1 and 9, R 3C is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 ) (heteroaryl), and -O-alkyl), or a pharma- ceutically acceptable salt thereof.
90. the below described: 【Chemistry 49】 (In the formula, R 7 and R 10 is defined in claims 1 and 9, R 3C or a pharma- ceutically acceptable salt thereof.
91. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 50】 (In the formula, R 22 F and OR 25 is selected from R 7 and R 10 10. A compound of the structure selected from the group consisting of:
92. the below described: 【Chemistry 51】 (In the formula, R 22 is F, OR 25 , N 3 or CN, R 7 and R 10 10. A pharmaceutical composition comprising the structure:
93. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 52】 【change】 (In the formula, R 7 and R 10 is defined in claims 1 and 9; R 3C or a pharma- ceutically acceptable salt thereof.
94. the below described: 【Chemistry 53】 (In the formula, R 7 and R 10 is defined in claims 1 and 9, R 3C is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 ) (heteroaryl), and -O-alkyl), or a pharma- ceutically acceptable salt thereof.
95. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemical 54】 (In the formula, R 22 is F, OR 25 , N 3 or CN, R 7 and R 10 10. A compound of the structure selected from the group consisting of:
96. the below described: 【Chemistry 55】 (In the formula, R 22 F and OR 25 is selected from R 7 and R 10 10. A pharmaceutical composition comprising a compound of the formula:
97. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 56】 【change】 (In the formula, R 7 and R 10 is defined in claims 1 and 9, R 3C is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 ) (heteroaryl), and -O-alkyl), or a pharma- ceutically acceptable salt thereof.
98. the below described: 【Chemistry 57】 (In the formula, R 7 and R 10 is defined in claims 1 and 9, R 3C is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 ) (heteroaryl), and -O-alkyl), or a pharma- ceutically acceptable salt thereof.
99. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 58】 (In the formula, R 22 F and OR 25 is selected from R 7 and R 10 10. A compound of the structure selected from the group consisting of:
100. the below described: 【Chemical 59】 (In the formula, R 22 F and OR 25 is selected from R 7 and R 10 10. A pharmaceutical composition comprising the structure:
101. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 60】 【change】 (In the formula, R 7 and R 10 is defined in claims 1 and 9, R 3C is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 ) (heteroaryl), and -O-alkyl), or a pharma- ceutically acceptable salt thereof.
102. the below described: 【Chemistry 61】 (In the formula, R 3C , R 7 and R 10 10. A pharmaceutical composition comprising the structure:
103. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 62】 (In the formula, R 22 is F, OR 25 , N 3 or CN, R 7 and R 10 10. A compound of the structure selected from the group consisting of:
104. the below described: 【Chemistry 63】 (In the formula, R 22 is F, OR 25 , N 3 or CN, R 7 and R 10 10. A pharmaceutical composition comprising the structure:
105. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 64】 【change】 (In the formula, R 3C , R 7 and R 10 10. A compound of the structure selected from the group consisting of:
106. the below described: 【Chemistry 65】 (In the formula, R 7 and R 10 is defined in claims 1 and 9, R 3C is an alkyl, alkenyl, alkynyl, -(C 0 ~C 2 ) (cycloalkyl), -(C 0 ~C 2 ) (heterocyclo), -(C 0 ~C 2 ) (aryl), -(C 0 ~C 2 ) (heteroaryl), and -O-alkyl), or a pharma- ceutically acceptable salt thereof.
107. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 66】 (In the formula, R 22 F and OR 25 is selected from R 7 and R 10 10. A compound of the structure selected from the group consisting of:
108. the below described: 【Chemistry 67】 (In the formula, R 22 F and OR 25 is selected from R 7 and R 10 10. A pharmaceutical composition comprising the structure:
109. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 68】 【change】 (In the formula, R 3C , R 7 and R 10 10. A compound of the structure selected from the group consisting of:
110. the below described: 【Chemistry 69】 (In the formula, R 3C , R 7 and R 10 10. A pharmaceutical composition comprising the structure:
111. 2. The following in the form of isolated phosphorus R or S enantiomers, or mixtures thereof, containing at least 90% of the designated enantiomer: 【Chemistry 70】 (In the formula, R 22 is F, OR 25 , N 3 or CN, R 7 and R 10 10. A compound of the structure selected from the group consisting of:
112. the below described: 【Chemistry 71】 (In the formula, R 22 is F, OR 25 , N 3 or CN, R 7 and R 10 10. A pharmaceutical composition comprising the structure:
113. R 3 The compound of any one of claims 1, 9, 14, 24, or 29-32, wherein
114. R 4 The compound of any one of claims 1, 9, 14, 24, or 29-32, wherein
115. R 4 33. The compound of any one of claims 1, 9, 14, 24, or 29-32, wherein is a monophosphate, diphosphate, or triphosphate.
116. 33. The compound of any one of claims 1, 9, 14, 24, or 29-32, wherein phosphorus is in the S configuration.
117. 33. The compound of any one of claims 1, 9, 14, 24, or 29-32, wherein phosphorus is in the R configuration.
118. 33. The compound of any one of claims 1, 9, 14, 24, or 29-32, wherein the amino acid has the D configuration.
119. 33. The compound of any one of claims 1, 9, 14, 24, or 29-32, wherein the amino acid has the L configuration.
120. R 22 are chloro, bromo, fluoro, cyano, azido, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, and n-pentyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, 1-methylbutyl, 1-ethylpropyl, vinyl, allyl, 1-butynyl, 2-butynyl, acetylenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -(CH 2 )-cyclopropyl, -(CH 2 )-cyclobutyl, -(CH 2 )-cyclopentyl, -(CH 2 )-cyclohexyl, aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, tetrahydrofuran, thiolane, pyrazolidine, piperidine, oxane, thiane, -(CH 2 )-aziridine, -(CH 2 )-oxirane, -(CH 2 )-thiirane, -(CH 2 )-azetidine, -(CH 2 )-oxetane, -(CH 2 )-thietane, -(CH 2 )-pyrrolidine, -(CH 2 )-tetrahydrofuran, -(CH 2 )-thiolane, -(CH 2 )-pyrazolidine, -(CH 2 )-piperidine, -(CH 2 )-oxane, -(CH 2 )-thiane, phenyl, pyridyl, -ONHC(=O)OCH 3 , -ONHC(=O)OCH 2 CH 3 , -NHOH,NHOCH 3 , -OCH 3 , O.C. 2 H 5 , -OPh, OCH 2 Ph, -SCH 3 , -SC 2 H 5 , -SPh, SCH 2 Ph, -NH(CH 2 ) 2 NH 2 、-NH(CH 2 ) 2 N(CH 3 ) 2 -NHNH 2 -NHNHCH 3 -N=NH, -N=NCH 3 、-N=NCH 2 CH 3 -NHC(O)NHNH 2 -NHC(S)NHNH 2 (O)NHNH 2 -NHSO 2 CH 3 -NHSO 2 CH 2 CH 3 、-SO 2 P.O. 3 、-SO 2 N(CH 3 ) 2 、-C(O)NH 2 、-C(O)NHCH 3 、-C(O)N(CH 3 ) 2 、-CO 2 CH 3 、-CO 2 CH 2 CH 3 、-CO 2 Ph、-CO 2 CH 2 Ph、-SO 2 CH 3 、-SO 2 CH 2 CH 3 、-SO 2 Ph、-SO 2 CH 2 Ph、 【Chemical 72】 、-P(O)H(OH),--P(O)H(OCH 3 ),-P(O)(OH)(OH),--P(O)(OH)(OCH 3 ),-P(O)(OCH 3 )(OCH 3 ),-P(O)(OH)(NH 2 ),-P(O)(OH)(NXCH 3 ),-P (O)(OH)N (CH 3 ) 2 、-NHC(O)CH 3 、-NHC(O)CH 2 CH 3 、-NHC(O)CH (CH 3 ) 2 、-NHC(O)OCH 3 、-NHC(O)OCH 2 CH 3 、-NHC(O)OCH (CH 3 ) 2 , -NHC(O)OCH 2 CH 2 CH 3 , -NHC(O)OCH 2 CH 2 CH 2 CH 3 or -NHC(O)OCH 2 CH 2 CH 2 CH 2 CH 3 33. The compound according to any one of claims 14, 24, 29, 30 or 32, selected from:
121. R 41 The compound of claim 31 , wherein is fluoro.
122. R 41 The compound of claim 31 , wherein is chloro.
123. R 41 is hydroxyl.
124. R 41 The compound of claim 32, wherein is fluoro.
125. R 41 The compound of claim 32, wherein is chloro.
126. R 41 is hydroxyl.
127. 36. A compound according to any one of claims 1, 9, 14, 24 or 29 to 32, and pharma- ceutically acceptable salts and prodrugs thereof, for use in the treatment or prevention of Hepatitis C viral infection.
128. 36. Use of a compound according to any one of claims 1, 9, 14, 24 or 29-32, and pharma- ceutically acceptable salts and prodrugs thereof, in the manufacture of a medicament for the treatment of Hepatitis C viral infection.
129. A method for the manufacture of a medicament intended for therapeutic use for the treatment of Hepatitis C virus infection, characterized in that in said manufacture a compound according to any one of claims 1, 9, 14, 24 or 29 to 32 is used.
130. 36. A pharmaceutical formulation comprising a compound according to any one of claims 1, 9, 14, 24 or 29-32, or a pharma- ceutically acceptable salt or prodrug thereof, in an amount effective to treat a host, together with a pharma- ceutically acceptable carrier or diluent.
131. the below described: 【Chemical Formula 73】 【change】 【change】 【change】 (In the formula, R 7 , R 10 , R 22 and R 41 is as defined in claims 9, 14 and 31.
132. The following formula: 【Chemical 74】 (In the formula, R 4 is a stabilized phosphate prodrug, R 1 , R 2 , R 22 and R 41 are as defined in claims 1, 9, 14 and 31) or a pharma- ceutically acceptable salt thereof.
133. the below described: 【Chemistry 75】 (In the formula, R 4 is a stabilized phosphate prodrug, R 1 , R 2 , R 22 and R 41 is as defined in claims 1, 9, 14 and 31, or a pharma- ceutically acceptable salt thereof.
Citation Information
Patent Citations
2'-fluoro-2'-(fluoromethyl)-2'-deoxynucleoside compound and phosphate potential drug thereof
CN103980332A
Nucleoside phosphoramidate prodrugs
JP2010532747A
Nucleoside cyclic phosphate esters
JP2011524356A
Purine nucleoside monophosphate prodrugs for the treatment of cancer and viral infections
JP2012517443A
Compounds and pharmaceutical compositions for the treatment of viral infections
JP2013523765A
